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Abstract
The novel contribution of this research is the development of a super-
vised algorithm that extracts relevant attributes from The Health Im-
provement Network database to detect prescription side effects. Pre-
scription drug side effects are a common cause of morbidity through-
out the world. Methods that aim to detect side effects have his-
torically been limited due to the data available, but some of these
limitations may be overcome by incorporating longitudinal observa-
tional databases into pharmacovigilance. Existing side effect detect-
ing methods using longitudinal observational databases have shown
promise at becoming a fundamental component of post marketing
surveillance but unfortunately have high false positive rates. An extra
step is required to further analyse and filter the potential side effects
detected by existing methods due to their high false positive rates,
and this reduces their efficiency. In this thesis a novel methodology,
the supervised adverse drug reaction predictor (SAP) framework, is
presented that learns from known side effects, and identifies patterns
that can be utilised to detect unknown side effects. The Bradford-Hill
causality considerations are used to derive suitable attributes as in-
puts into a learning algorithm. Both supervised and semi-supervised
techniques are investigated due to the limited number of definitively
known side effects. The results showed that the SAP framework im-
plementing a random forest classifier outperformed the existing meth-
ods on The Health Improvement Network longitudinal observational
database, with AUCs ranging between 0.812-0.937, an overall MAP
of 0.667, precision values between 0.733-1 and a false positive rate
≤ 0.013. When applied to the standard reference the SAP frame-
work implementing a support vector machine obtained a MAP score
of 0.490, an average AUC of 0.703 and a false positive rate of 0.16.
The false positive rate is lower than that obtained by existing methods
on the standard reference.
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Chapter 1
Introduction
The occurrence of negative side effects due to prescribed medication is a health
issue that occurs worldwide. The early detection of side effects is imperative for
the prevention of unnecessary morbidities or mortalities. Two types of electronic
healthcare databases are frequently used to extract data for the detection of side
effects, the spontaneous reporting system (SRS) databases and the longitudinal
observational databases (LODs). Many methods have been developed for the SRS
databases but these databases have a limited perspective and do not contain the
data required to detect all side effects. This has prompted the focus towards using
the LODs, but the proposed methods tend to be unsupervised. In this thesis,
supervised and semi-supervised techniques capable of detecting side effects by
utilising the data contained in LODs are investigated. The first part of this
chapter focuses on the research background and motivation, this is followed by
the aims and objectives. The chapter concludes with the thesis organisation that
provides the outline of each chapter.
1
1.1 Background & Motivation
All prescribed drugs have side effects under certain conditions [170]. A negative
effect following the ingestion of a drug is referred to as an Adverse Drug Event
(ADE) and is defined as ‘any untoward medical occurrence that may present
during treatment with a medicine but which does not necessarily have a causal
relationship with the treatment’ [206]. When an ADE has been linked to a spe-
cific drug it becomes an Adverse Drug Reaction (ADR). An ADR is defined by
the World Health Organization as a response to a medicine which is noxious and
unintended, and which occurs at doses normally used in humans from the pro-
phylaxis, diagnosis or therapy of disease, or for the modification of physiological
function [182].
As ADRs can lead to patient morbidity or mortality, their early discovery
is essential. As a consequence, the safety of a new drug is extensively analysed
throughout its development. Unfortunately, the ability to analyse a drug’s toxi-
city is limited by the clinical study designs. The pre-clinical studies of a drug’s
development, involving animal testing, are done to initially assess a drug’s toxi-
city [25], however, the ability to infer ADRs is limited by the inability of animal
testing to be completely informative for effects on humans [133]. If a drug passes
the initial toxicity analysis, it is then tested on humans during phases i–iii, with
the trial population size increasing incrementally after each phase. Phase i will
often involve testing the drug by giving it to healthy individuals under unrealistic
conditions (i.e., the individuals cannot smoke, drink alcohol, exercise excessively
and may have food limitations enforced) [38]. It is also widely known that clini-
cal trials can be biased towards certain demographics, for example the majority
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of individuals tested during phase i trails are white males [38]. Clinical trials
involve testing the drug on a limited population size, with the largest population
size used during phase iii, but this generally only contains up to 3000 individuals
[38]. Due to numerous reasons, including the limited trial population size and
the unrealistic conditions of the trials, many ADRs are undetectable during phase
i-iii studies and can only be identified after the drug is marketed [11]. It is also
clear that ADRs that result from polypharmacy (i.e., when multiple drugs are
prescribed at the same time) will be difficult to detect. The reason is, due to the
limited population being tested, it is impossible to investigate all the different
drug combinations.
Studies investigating the prevalence of ADRs have provided evidence that
many ADRs are not discovered prior to marketing. The results indicate that up
to 6.5% of UK hospital admissions are due to ADRs [135] with similar rates also
being observed in the US hospitals (6.7%) [103]. Another study found a similar
prevalence within a UK paediatric hospital (4%) [62]. Research suggests ADRs
are more common in geriatric patients (older than sixty five), in females and in
patients taking more than one drug [17]. It has also been highlighted that the lack
of efficient means to detect ADRs causes a burden in terms of cost and quality of
life. Furthermore, this burden appears to be getting worse. It has been reported
that ADRs could cost the UK £637 million each year [43], with £466 million
being due to ADR hospital admissions and £171 million being due to ADRs
during hospitalisation. These estimates do not take into consideration additional
medical costs or loss of earning while in hospital due to an ADR. A study by Wu
et al. (2010) compared the frequency of ADRs as the cause of hospital admission
over 1999 to 2009 and showed the number of people admitted to hospital due to
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ADRs has increased over the ten years at a greater rate than the rate of hospital
admission [207]. Further, they found 26,399 people died in hospital in the UK over
the ten years as a result of an ADR [207]. This corresponded to a probability of
almost one in twenty ADRs resulting in death. One explanation for the increase
in the number of ADRs over the years is due to polypharmacy [112].
This highlights the importance of continuous post-marketing surveillance of
drugs and motivates the requirement of new methods that can identifying ADRs
efficiently. When a new potential ADR association is detected, the potential
ADR is referred to as being signalled. The majority of current post-marketing
surveillance techniques make use of the SRS databases. These databases contain
records of suspected ADRs, that were originally restricted to submissions made
by medical practitioners and coroners, but it is becoming increasingly common
for them to enable the general public to submit reports. The SRS databases
have many limitations that prevent them signalling ADRs efficiently and they
cannot be used to quantify ADR risks [57], nor can they be used to consistently
identify risk factors. It is widely known that the majority of ADRs signalled
by the existing methods applied to SRS databases do not correspond to ADRs
[172]. Retrospective studies have confirmed their inability to efficiently signal
all ADRs, as the methods applied to SRS databases were unable to signal some
ADRs before they were discovered by other means [3]. This has prompted the
demand for better surveillance techniques [43] [207] and to use other forms of
data to complement drug safety using SRS.
An alternative approach for signalling ADRs, that has recently surfaced, is to
use data contained within LODs. The LODs are not restricted to a specific period
of time around the drug prescription and can contain patient medical histories
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spanning decades. These databases may present to opportunity to efficiently
discover new ADRs [198] and enable ADR risks to be quantified. Their impor-
tance for future post-marking surveillance has been expressed [203]. The existing
methods proposed for the LODs are unsupervised and many are derived from
the SRS methods [216] but new methods have been presented that are based on
epidemiology techniques [156]. Unfortunately, these methods have been shown to
have a high false positive rate [156], due to the difficulty distinguishing between
association and causation, and this may reduce their signalling efficiency. The
majority have been developed for a common data model [115; 131] (the integra-
tion of multiple LODs into a general database) rather than specific databases.
Not all data can be converted into the common model [214], so information may
be lost. Therefore, it is of interest to also develop methods that are specific to
a single database, as new information may be revealed. It may be possible to
develop a method with a low false positive rate by considering the Bradford-
Hill causality consideration [19], as these are often used within extensive post
marketing investigations to confirm causality .
The Health Improvement Network (THIN) database is an example of a LOD
that contains approximately 6% of the general practice records within the UK.
The THIN database contains complete medical records and prescription records
(while the patient is registered) for all registered patients at participating prac-
tices. The THIN database contains heterogeneous data and has hierarchal struc-
tures embedded within it. An example of one of the hierarchal structures con-
tained in the database is the recording of the medical events (i.e., administrative
events, illnesses, symptoms, laboratory tests/results and medical history). The
medical events are recorded via READ codes, these codes have five levels of
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specificity and follow a tree structure. Little work to date has focused on using
the THIN database for general postmarking surveillance and no ADR signalling
method has been specifically developed. Research has suggested that the THIN
database potentially holds a wealth of information [105]. If its complex struc-
ture can be dealt with, then its integration into post-marketing surveillance may
enable ADRs to be signalled efficiently.
1.2 Aims & Objectives
As this research is interdisciplinary it has both a clinical and technical aim. The
overall clinical aim of this project is to develop a data-mining algorithm for a
specific LOD, the THIN database, that can detect ADRs and discover new in-
formation to improve current post marketing drug surveillance. The technical
aim is to develop an algorithm that can classify a pair consisting of a drug and
medical event (drug-medical event pair) as a causal relationship or non-causal
relationship. The algorithm must have a low false positive rate and a sufficiently
high true positive rate. This algorithm has multiple applications as it can iden-
tify causation in databases containing discrete information. One such example
is using databases containing customer shopping histories to identify items that
when purchased influence a different item being purchased in the future. Another
useful implementation of the algorithm using market data could be to identify the
impact of promotions and find what purchases are caused by the promotion. The
advantage over sequential pattern mining is that the algorithm does not require
the events to be common.
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1.2.1 Hypotheses
The THIN database potentially contains a wealth of information but this is hidden
within a magnitude of heterogeneous data containing many underlying hierarchal
structures. The abilities of the existing ADR signalling methods developed for
LODs are likely to be impacted by the structure of the THIN database and also by
their inability to distinguish between association and causation. These limiting
factors may prevent the extraction of all the information that is potential avail-
able by mining the THIN database. To extract all the possible information and
utilise the full potential of the THIN database, novel supervised/semi-supervised
methods may need to be developed. It is therefore hypothesised that,
H1 Current ADR signalling algorithms developed for LODs are not suitable for
ADR detection when they are implemented on the THIN database.
H2 Novel ADR signalling algorithms applied to the THIN database will be able
to consistently perform better than existing LOD ADR signalling algorithms
if they 1) deal with the hierarchal structures within the THIN database, 2)
incorporate new attributes essential for determining causality and 3) use
known ADR knowledge.
H3 Novel ADR signalling algorithms applied to the THIN database will outcom-
pete existing methods developed for the Observational Medical Outcomes
Partnership (OMOP) common model when considering the specified drug
and health outcomes of interest [141].
H4 Novel ADR signalling algorithms applied to the THIN database will be able
to generate new ADR signals.
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1.2.2 Objectives
To address the research hypotheses the following research objectives are proposed,
with the hypothesis they are linked to indicated in brackets.
1. Determine the benchmark for signalling ADRs using the THIN database
and identify limitations (H1).
2. Propose suitable attributes for each drug-medical event pair that may help
separate association from causation or that are specific to the THIN database
(H2.1-H2.2).
3. Develop a novel supervised/semi-supervised ADR signalling algorithm for
implementation on the THIN database that can accurately signal ADRs
(H2.3). The requirements are,
(a) A low false positive rate.
(b) To be efficient.
(c) To be robust.
4. Evaluate the novel algorithm on the THIN database.
(a) Compare the general signalling ability of the novel ADR signalling
algorithm and the existing methods applied to the THIN database
(H2).
(b) Evaluate the novel ADR signalling algorithm’s ability on the OMOP
specified drug and health outcomes of interest (H3).
(c) Generate new ADR signals (H4).
Chapters 3-6 focus on Objectives 1-4 respectively.
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1.3 Thesis Organisation
The continuation of this thesis is organised as follows. Chapter 2 presents the
literature review that is split into a pharmacovigilance section and a pattern
recognition section. The pharmacovigilance section presents an overview of the
current techniques and the recent advances. The Bradford-Hill causality consid-
erations are discussed, as ADRs represent a causal relationship and the criteria
may present the opportunity to distinguish ADRs from non-ADRs. The exist-
ing methods developed for different healthcare databases are summarised, with
their connection to the Bradford-Hill causality considerations evaluated. The
final part of the pharmacovigilance section focusses on the new initiatives cur-
rently taking place that aim to improve the way ADRs are signalled. The pattern
recognition part presents the statistical learning theory view of supervised and
semi-supervised learning. The main supervised and semi-supervised algorithms,
that are used during the later chapters of the thesis, are summarised.
In Chapter 3, the benchmark for the ADR signalling ability of the THIN
database is determined by applying a selection of the existing methods to the
THIN database. As there is no perfect gold standard for signalling ADRs, two
different comparisons were applied. The first comparison involved analysing all
the possible drug-medical event pairs for a set of specific drugs and consider-
ing only the drug-medical event pairs listened as known ADRs on the website
NetDoctor [176] to be ADRs and all other pairs to be non-ADRs. This enabled
the evaluation of the methods when there is a large number of non-ADRs, but
the comparison was limited due to the possibility of ADRs listed on NetDoctor
being incorrect and due to unknown ADRs. The second comparison, termed the
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specific comparison, only evaluated the drug-medical event pairs corresponding
to ADRs listed on drug packaging or definitively known non-ADRs. The specific
comparison enabled a more realistic evaluation and highlighted methods that are
non-consistent.
In Chapter 4, attributes that are suitable inputs for a learning algorithm to
distinguish ADRs and non-ADRs were proposed. The attributes included values
from existing method, novel attributes derived from the Bradford-Hill causality
criteria or novel attributes derived by considering the structure of the THIN
database. The technique for extracting and cleansing the data are described and
mathematical formula for calculating each attribute are presented.
In Chapter 5, the learning algorithm is developed and tentative results are
presented. The first part of the chapter proposes a novel supervised technique
that learns from a mixture of drugs and, once learned, can be applied to any
drug. In the second part, a novel semi-supervised technique is presented that
uses the limited number of known ADRs for a drug of interest to generate a
model that is specific to the drug. Both the supervised and semi-supervised
models are evaluated on a selection of drugs. The evaluation suggests that a
supervised model trained on multiple drugs will outperform a semi-supervised
model trained on a single drug. This is advantageous, as the supervised model
can be trained on drugs that have been marketed for years and can be applied to
newly marketed drugs that have limited toxicity knowledge.
In Chapter 6 the novel supervised algorithm is applied to more drugs and
compared with a selection of existing methods using the specific comparison
technique. The results showed that the novel supervised algorithm was often
significantly better and had a better mean average precision (MAP) score and
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lower false positive rate than existing methods. An additional evaluation was con-
ducted by investigating the novel supervised algorithm’s ability when considering
the health outcomes of interest (HOIs) and drugs of interest (DOIs) specified by
the OMOP. The evaluation showed that the novel supervised algorithm obtains
a lower false positive rate than existing methods (0.16) and is able to signal a
high proportion of definitively known ADRs. Therefore, the novel supervised al-
gorithm has the potential to extract new pharmacovigilance knowledge and may
help signal ADRs shortly after new drugs are marketed.
The final chapter of the thesis contains the conclusion that highlights the
key results of the research and answers the research questions proposed in the
introduction. Areas of future work are proposed, such as the modification of
the algorithm to return quantitative information about the risk of each ADR
signalled. The journal and conference contributions derived from this research
are presented at the end of Chapter 7.
1.4 Contribution to Knowledge
This research has presented the first supervised and semi-supervised methods for
signalling ADRs using LODs. New techniques for generating labels that are es-
sential for supervised/semi-supervised algorithms have been presented and novel
attributes that can distinguish between association and causation were proposed.
The research also highlighted the current limitations with evaluating the
methods, as restricting the evaluation to a small number of definitively known
drug-medical event pairs may prevent an accurate evaluation due to ignoring the
numerous drug-medical event pairs that are associated due to confounding but
11
including more pairs into the evaluation may introduce error due to unknown
ADRs.
This research has contributed to four journal papers (two published, one in
print and one under review) and four conference papers. A full list of the journal
and conference papers produced during this research is presented at the end of
Chapter 7.
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Chapter 2
Literature Review
‘Prevention is the next frontier for pharmacovigilance,
beyond simply generating alerts.’
N. Moore [121]
2.1 Current Pharmacovigilance
2.1.1 Introduction
In 1961 a link was discovered between pregnant mothers ingesting the drug
Thalidomide and then giving birth to infants with congenital malformations [167].
This widespread incident highlighted the importance of drug safety and prompted
the start of systematic approaches to monitor the safety of marketed medications
[29]. The research into medication safety is commonly referred to as pharma-
covigilance. This involves the detection, assessment and prevention of ADRs for
any marketed drug. The aim of pharmacovigilance is to identify ADRs, study
relevant data and then investigate each ADR to assess risk factors. This knowl-
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edge can then be used to help prevent ADRs that would otherwise lead to patient
morbidity or mortality; helping to improve healthcare.
The process of identifying new ADRs involves signalling sets consisting of one
or many drugs and an adverse event that may correspond to an ADR. There are
different definitions for the term ADR signal in the context of pharmacovigilance
but generally it means there is information to suggest a previously unknown causal
relationship between some medication and an adverse event. The World Health
Organization’s (WHO) definition of an ADR signal is ‘reported information on a
possible causal relationship between an adverse event and a drug, the relationship
being unknown or incompletely documented previously. Usually, more than a
single report is required to generate a signal, depending on the seriousness of the
event and quality of the information’ [53; 111]. Almenoff et al.(2005) interpret this
as being able to ‘view a signal as any information, qualitative or quantitative, that
prompts further investigation on the relationship between a drug and an event’
[1].
Once an ADR signal is generated, the medication and adverse event are stud-
ied further with more stringent statistical tests to confirm whether the signal is
true, meaning there is sufficient evidence to confirm a causal relationship between
the medication and the adverse event. Conversely, if there is not sufficient ev-
idence, then the signal is false. In effect, ADR signalling is a way of filtering
all the possible combinations of drug and adverse event pairs so that only the
combinations that are most likely to correspond to ADRs remain to be inves-
tigated further. This is important as it is not possible to efficiently investigate
the thousands or even millions of possible combinations of drugs and suspected
ADRs in fine detail.
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Overall, the process of identifying an ADR (a causal relationship between a
drug and medical event) requires three steps [136];
1. Signal generation/detection- this step involves analysing all drug-medical
event pairs representing a possible ADR and highlighting the ones that are
most suspicious.
2. Signal refinement- after signals are generated in step 1 for some drug-
medical events pairs these drug-medical event pairs are actively surveyed
to look for more evidence that they may correspond to an ADR.
3. Signal evaluation- this is when a single in depth investigation (formal epi-
demiological study) is performed to determine if there is causality between
a drug and a medical event that has been signalled in step 1 and refined in
step 2.
Early pharmacovigilance depended on professionals manually investigating
hard copies of reports detailing suspected ADRs. These professionals would then
identify commonly occurring suspected ADRs or highly noxious suspected ADRs
as signals [113; 145]. The limitations with this methodology was that collabora-
tion was difficult prior to the World Wide Web so the reports were only collected
from a segment of the population and less obvious ADRs may never have been
suspected and reported or may have been difficult to identify. With the advances
in technology enabling rapid communication between borders and helping pool
large quantities of data together, many of the original limitations are beginning
to disappear [198]. Using the large collections of electrically stored data, we are
now presented with the opportunity to apply data mining methods and gener-
ate ADR signals more efficiently [35], as less time is required before there is a
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sufficient number of ADR incidences reported to enable the signal generation
[158].
The majority of existing pharmacovigilance methods that use large databases
for ADR signal detection are applied to the SRS databases. The SRS databases
are readily available electronic databases that contain a collection of voluntary
reports of suspected ADRs, often containing millions of reports. This type of
database has been used to successfully signal many ADR signals, but the signals
cannot be considered definitive [119]. There are also well documented limitations
with using SRS databases for ADR signalling, due to these databases relying on
people recognising and reporting suspected ADRs [63; 79; 168]. It has been sug-
gested that these limitations may prevent the detection of rare ADRs [79] or lead
to delays in generating ADR signals [93]. The standard procedure for automating
the generation of ADR signals in SRS databases relies on calculating a measure of
disproportionality corresponding to how often the adverse event is reported after
a specific drug compared to a baseline determined by how often it is reported
after any drug within an SRS database [119]. As there is no gold standard for
ADR signal detection, each country tends to have a different preference for the
choice of disproportionality method applied to his SRS database. The main dis-
proportionality methods applied to the SRS databases and their limitations are
detailed in Chapter 2.1.3.
Recently the LODs have caught the attention of pharmacovigilance researches
as it offers a unique perspective for ADR signal generation and is starting to
become more readily available [180]. The LODs suitable for pharmacovigilance
contain timestamped medical records and timestamped prescription records for
patients over large periods of time. Rather than relying on people suspecting
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ADRs like the SRS databases, potential ADRs can be inferred using temporal
relationships between the medical and prescription records for a patient. This
may enable the detection of rare ADRs or ADRs with a high background rate
[180] that can not be identified by mining the SRS databases. Additionally, as
generating ADR signals by mining the LODs does not require people noticing
potential ADRs, it may be possible to generate ADR signals earlier than by
mining the SRS databases. In Chapter 2.1.4, the current ADR signalling methods
developed for the LODs are described, along with their limitations.
The continuation of the pharmacovigilance section of the literature review in-
cludes a section summarising causality, and the frequently applied Bradford-Hill
causality considerations [19]. This is followed by a description of the current
methodologies for detecting ADRs by mining the SRS databases and the new
advances into mining ADRs using LODs. The final section summarises the cur-
rent pharmacovigilance initiatives and highlights how this field of research may
change with the integration of multiple electronic healthcare databases.
2.1.2 Causality
The definition of a statistical association is ‘a relationship between two measured
quantities that renders them statistically dependent’ [183] . Whereas the term
causality is defined as ‘a relationship between two events, the cause (or incidence)
event and effect (or consequent) event, where the effect event is dependent on the
cause event’ [169]. Therefore a causal relationship is also an association but not all
associations are causal. It is clear that an ADR represents a causal relationship,
as the adverse event is a result of a patient ingesting a specific drug and would
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not have occurred if the patient did not have the drug. The first step in current
ADR discovery, namely signal generation, finds drug-medical event pairs that
are associated and the later two steps, signal refinement and evaluation, aim to
determine if the found association is also a causal relationship.
A common method to assess causality between an antecedent and consequence
is to use the Bradford-Hill causality considerations [19] that proposes nine factors
that need to be considered,
1. Strength- how much do the antecedent and consequence appear to be
associated? A high association would suggest causation however a low as-
sociation does not mean there is no causation.
2. Consistency- has the relationship been observed in different patients and
situations? (In the context of ADRs, has it been reported in multiple pa-
tients and databases?).
3. Specificity- is the relationship specific (e.g., there are few other associa-
tions containing the antecedent or consequence). This factor has limitations
as many ADRs are the result of multiple causes. An alternative interpreta-
tion is whether the population experiencing the relationship is specific (e.g.,
old, young or female).
4. Temporality- the order of the antecedent and consequence (e.g., did the
medical event make the patients more prone to the drug or did the drug
cause the medical event?).
5. Biological Gradient- is there an increasing monotonic relationship be-
tween the frequency/amount of the antecedent and the frequency of the
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consequence (e.g., does a higher dosage of the drug increase the medical
event frequency?).
6. Plausibility- does it make sense? However, this is not a necessary feature
as plausibility depends on current knowledge and even the improbable could
be true.
7. Coherence- does the relationship conflict with known facts? (e.g., Do we
know drug-medical events pairs that are definitely not ADRs?).
8. Experimentation- does changing the antecedent change the consequence?
(e.g., Does the medical event start when the drug starts and stop when it
stops?).
9. Analogy-are there similarities with known causal relationships (e.g., does
the ADR exist for a similar drug)?.
The more Bradford-Hill causality factors covered by a method, the more likely
it is to correctly identify causal relations and therefore identify ADRs. In Chap-
ters 2.1.3.2 and 2.1.4.3 the range of Bradford-Hill causality factors considered by
each of the existing ADR signalling methods are determined.
2.1.3 Spontaneous Reporting Databases
2.1.3.1 Overview
The SRS databases were one of the first resources to contain vast quantities of
pharmacovigilance data and enable an aggregated analysis [152]. Their presence
in the field of pharmacovigilance has aided the discovery of many ADRs [106],
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A : medical event A i : drug i
time(days)
lack of complete history
Report 1- Gender:♂; Age:? 2 A5
Report 2 - Gender:?; Age:? 6 d1
...
Report n - Gender:♀; Age:21 1 b1
Figure 2.1: Illustration of data contained in SRS databases.
but their application is limited [63; 172]. The databases contain linked drug
and medical event records. Each link represents that the drug was a suspected
cause of the medical event. In additional to the linked drug and medical records,
there are also details specifying information about the patient that experienced
the suspected ADR. An illustration of the data contained in SRS database is
presented in Figure 2.1, where drugs are represented by squares and medical
events are represented by circles. An example of the database design for an SRS
database can be seen in Figure 2.2. The records in the database are submitted
voluntarily by medical practitioners or the general public [118]. Two common
examples of SRS databases are the Food and Drug Administration (FDA) Adverse
Event Reporting System (AERS) [77; 184] in the USA and the Yellow Card
Scheme SRS [118] run by the Medicines and Healthcare products Regulatory
Agency (MHRA) and the Commission on Human Medicines (CHM) in the UK.
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Events 
¾ eventID 
¾ readID 
Figure 2.2: An example entity relationship diagram for an SRS database based
on the FAERS database.
The general process involved in reporting a suspected ADR into an SRS
database is for a patient or doctor to fill out a form detailing the drug/drugs
prescribed, the adverse event experienced, some information about the patient
and information about the person making the report. An example of a typical
SRS report submitted online via the yellow card scheme in the UK can be seen
in Figure 2.3. The majority of fields in the form are not required and the entries
are not validated during submission. This causes limitations as it is common
for SRS databases to contain missing or incorrect data [137]. It is also known
that SRS databases suffer for bias reporting [173], especially under reporting [79].
Another issue is underascertainment, when the ADRs is not noticed (e.g., ADRs
corresponding to medical events with a high background rate or rare ADRs may
never be suspected) [173].
The SRS methods determine the association strength between a drug-medical
event pair and pairs with a high association are signalled. The generated signals
require further analysis as association does not imply causation [1]. This has
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 Figure 2.3: The online form for submitting suspected ADRs via the Yellow Card
Scheme in the UK.
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prompted researches to state that the SRS methods are ‘initial filters’ for iden-
tifying ADR associations [8] and are not capable of generating definitive signals.
Once the SRS methods generate a signal, it is then refined and finally evaluated.
This means the causal relationship is not confirmed until much later in time than
when the original signal occurred.
The SRS databases generally have a fixed point in time perspective, as limited
past and present medical knowledge for each patient is known [12], the lack
of historical data is illustrated in Figure 2.1. The actual rate that a drug is
prescribed and the rate that a medical event occurs is unknown [172], as SRS
databases only contain data on the drug prescriptions that may have resulted
in an ADR. Consequently, the SRS methods estimate the baseline rate that a
medical event occurs by finding out how often the medical event is reported with
any drug in the database. Medical events that are reported disproportionally
more often with the drug of interest compared to all the other drugs in the
database are then ranked highly as suspected ADRs. The methods make use of a
contingency table, see Table 2.1, summarising the number of reports that contain
(or do not contain) the drug and event of interest. Each method estimates the
baseline rate differently, by using different combinations of the values in Table
2.1. Unfortunately, the estimation of the background rate, by using other drug
reports, can limit the signals that are generated [76] and prevent some ADRs
(e.g., those with a high background rate) being identified. In addition, both over-
reporting and under-reporting can lead to skewed estimates for the background
rates and influence the signalling ability.
Initially, the disproportionality methods relied on calculating measures linked
to standard epidemiology statistical values such as the Reporting Odds Ratio
23
Table 2.1: A sample contingency table used by the disproportionality methods
applied to the SRS databases.
Event Y Other Event Total
Drug X a b a+b
Other Drug c d c+d
Total a+c b+d a+b+c+d
Table 2.2: The different SRS methods and the measures they implement to cal-
culate the association between a drug-medical event pair. 1
Method Measure Probabilistic Interpretation [75] Approach
ROR a/b
c/d
P(AE|Drug)/P(notAE|Drug)
P(AE|notDrug)/P(notAE|notDrug)
F
PRR a/(a+b)
c/(c+d)
P(AE|Drug)
P(AE|notDrug)
F
NPRR a/(a+c)
b/(b+d)
P(Drug|AE)
P(Drug|notAE)
F
BPCNN (IC) log2(
a(a+b+c+d)
(a+c)(a+b)
) log2(
P(AE|Drug)
P(AE)
) B
EBGM (RR) a(a+b+c+d)
(a+c)(a+b)
P(AE|Drug)
P(AE)
B
(ROR) [9] and Proportional Reporting Ratio (PRR) [185]. In [196] the authors
propose a novel PRR (NPRR) method, that takes a slightly different perspective,
and they suggested that both the PRR and NPRR should be used to generate a
signal. More recently, methods have been implemented that are based on artificial
neural networks, such as the Bayesian Propagation Confidence Neural Network
(BPCNN) [10], or Bayesian modelling, such as the Empirical Bayesian Geometric
Mean (EBGM) [50]. Table 2.2 summarises the different methods and displays
their probabilistic derivations. The SRS signal generation methods are split
between frequentist statistical approaches (ROR, PRR) and Bayesian statistical
approaches (EBGM, BPCNN). The frequentist statistical methods assume that
the parameters for a model are fixed and they consider that the data comes from
1In the approach column, F represents frequentist and B represents Bayesian.
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a repeatable random sample. These methods do not require prior knowledge of
a model and are computationally cheap. It follows that the advantage of fre-
quentist methods for signal detection is that they are fast, which is an important
factor due to the large quantities of data available. Conversely, the Bayesian sta-
tistical methods assume that the data are fixed and the parameters are unknown
but described by a probabilistic distribution. These methods require some prior
knowledge and can be computationally costly. The advantage of using Bayesian
methods for signal detection is that, due to the parameters being non-fixed, they
can adapt over time when changes in the drug prescription habits may differ,
such as when doctors change the prescription rates of drugs or prescribe drugs to
patients for a non-standard indication.
The methods all have signalling criteria, see Table 2.3. The frequentist meth-
ods generate a signal for a drug-medical event pair when there are three or more
case reports and the lower 95% confidence interval is greater than one. Their stan-
dard errors, displayed in Table 2.4, are estimated using the woolf logit method
[205], a method that approximates the distribution of the ln(ROR) and ln(PRR)
as being normal. The EBGM generates a signal for a drug-medical event pair
when the lower bound of the 90% credibility interval, EB05, is greater than two.
The BPCNN signals a drug-medical event pair when its IC value minus two
standard deviations changes from negative to positive.
2.1.3.2 Causality
The SRS methods all work out the association strength between a drug and
medical event based on the disproportionality measure. As the SRS databases
sometimes contain the patient details such as age and gender it is possible for
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Table 2.3: The signalling criteria for the different SRS methods [50; 185] .
Method Signal Criteria Shrinkage
ROR exp[ln(ROR)− 1.96SE(ln(ROR))] > 1 No
PRR exp[ln(PRR)− 1.96SE(ln(PRR))] > 1 No
NPRR exp[ln(NPRR)− 1.96SE(ln(NPRR))] > 1 No
EBGM EB05 ≥ 2 Yes
BPCNN IC − 2SD > 0 Yes
Table 2.4: The standard errors for the frequentist methods [185; 196].
Method Standard Errors
ROR SE(ln(ROR)) =
√
1
a
+ 1
b
+ 1
c
+ 1
d
PRR SE(ln(PRR)) =
√
1
a
− 1
a+b
+ 1
c
− 1
c+d
NPRR SE(ln(NPRR)) =
√
1
a
− 1
a+c
+ 1
b
− 1
b+d
the SRS algorithms to deal with the specificity criteria, but none of the existing
methods does and the problem of missing values may make this difficult. The
methods do not cover the consistency criteria when they are only applied to one
SRS database and they do not deal with the biological gradient as they do not
take into consideration the dosage of the drug. The SRS methods estimate the
background risk of a medical event based on all other drugs rather than restrict-
ing themselves to estimating the risk of the medical event based on similar drugs,
therefore they do not consider the analogy criterion. Due to their restricted per-
spective, they cannot cover the experimentation factor as this requires observing
what happens when the drug stops and starts. The temporality, plausibility and
coherence criteria are indirectly covered as people should only submit a report
when a drug is suspected to have caused an ADR, and any suspected ADR would
have occurred after the drug is taken and must be plausible and coherent oth-
erwise it would not be suspected. However, people may make mistakes when
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Table 2.5: The Bradford-Hill causality considerations covered by each method. 1
Criteria ROR PRR EBGM BPCNN
Strength 4 4 4 4
Consistency 5 5 5 5
Specificity 5 5 5 5
Temporality • • • •
Biological Gradient 5 5 5 5
Plausibility • • • •
Coherence • • • •
Experimentation 5 5 5 5
Analogy 5 5 5 5
reporting a suspected ADRs or may not know information that would otherwise
make them reconsider that the medical event is a suspected ADR.
The criteria that could be covered by SRS methods, but are not currently,
are the consistency, analogy and possibly the specificity. The consistency criteria
could be covered by using other SRS databases as a cross reference to see if there
is evidence in other databases for the signals generated by the SRS methods. The
analogy could be covered by comparing a drug of interest against drugs in the
same family and using knowledge about existing ADRs for similar drugs and the
specificity could be covered by comparing the drug and event disproportionali-
ties between different groups of the population, such as the old or young. This
information is summarised in Table 2.5.
2.1.3.3 Limitations
The main limitations with signal generation using the disproportionality methods
applied to SRS databases are due to database issues. The databases are known to
contain missing or duplicated data and suffer from inconsistent reporting such as
1• represents indirectly covered.
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under-reporting or over-reporting for new drugs or more serious adverse events [9].
It is often common for the SRS databases to be plagued by inconstancies due to
changes in medical terminology over time or variance in the level of detail recorded
for the medical event depending on the person making the report [9]. Bate et al.
(2009) state that ‘disproportionality methods do not estimate reporting rates’,
as the reporting rate calculation requires the knowledge of drug usage and this is
not contained in the SRS databases [9]. The effect of this is that specific adverse
events will not be found, such as when a drug causes all events to increase or
when an adverse event is common for many drugs. The two major consequences
of the under-reporting are that there may be a large time lag between when a
rare ADR is first reported and when it is signalled, or it is possible that rare
ADRs may never be detected. One retrospective study found that 19.6% of
known ADRs were signalled by the PRR after other pharmacovigilance methods
and 26.9% of known ADRs had not been signalled during the study period [3].
The SRS methods cannot be used for signal refinement or evaluation due to the
limitation of not knowing the actual background rates that medical events occur
or drug are prescribed. Therefore, it is not possible to develop a method capable
of definitively identifying ADRs that only uses the SRS databases, instead, other
types of databases are required for the signal refinement and evaluation once
signals have been generated by mining the SRS databases.
2.1.3.4 Summary
Mining the SRS databases has aided new ADR discoveries, but the signals gen-
erated by mining the databases require further evaluation and the majority of
signals do not lead to ADR discovery [172]. A recent study provided evidence
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to suggest that limitations due to how the SRS data are collected may make it
difficult for the disproportionality methods to identify ADRs with a high back-
ground rate [70]. Furthermore, as a consequence of the the limited perspective
of the SRS databases, they cannot be used to quantify ADR risks [119], nor can
they be used to identify risk factors.
2.1.4 Longitudinal Observational Databases
2.1.4.1 Introduction
The LODs are databases containing temporal medical data [12] on thousands or
millions of patients, often spanning over many patient years. An example of an
LOD is The Health Improvement Network (THIN) database, see appendix A,
that is an electronic database containing the data stored in over 500 UK general
practices [65]. The data consists of patient details such as their year of birth,
gender, family links and timestamped medical and prescription records. It has
been found to be a suitable representation of the UK [15] and it is not common
to find duplicated or missing data due to validation procedures. Researchers
have assessed the validity of using the THIN database for pharmacovigilance
by investigating whether known associations can be found using the data and
concluded that its use is valid [105]. The database contains records of every
medical event for a patient that the doctor has been informed of, as the data
is extracted directly from the local GP databases and doctors must record all
the relevant medical details each time a patient visits [85]. Unfortunately under-
reporting is still possible in these types of databases, as some drugs can be bought
rather than being prescribed and patients may not inform their doctor of all the
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medical events that they experience. It is also possible for LODs such as the
THIN database to have inconsistencies in data recording between practices [78].
The THIN database also has issues with patients changing practices, as each
patient is given an anonymous ID within their practice but when they change
practices they will receive a new ID, and there are no links between the two IDs
to identify them as representing the same patient [104].
The LODs offer a unique perspective for discovering ADRs as, unlike the SRS
databases, they do not have direct links between drugs and medical events that
are potential ADRs [161] but potential ADRs can be inferred using the temporal
information. For example, if investigating ADRs that occur immediately after
taking a drug, all the medical events that occur within 30 days of taking the drug
can be flagged as potential ADRs. The advantage of generating ADR signals
using the LODs compared to the SRS databases are they contain patients’ medical
histories and include patients that did not experience adverse events after taking
a drug [71]. Therefore they contain the background rates that a drug is prescribed
or a medical event occurs [216] and are less prone to bias reporting due to not
relying on voluntary reports. As the LODs are not restricted to finding ADRs
that occur shortly after taking a drug, they could be used to find ADRs that are
not present till many years after taking a drug. Furthermore, the vast quantities
of data contained in LODs makes them more suitable for detecting drug-drug
interaction ADRs or child specific ADRs. Figure 2.4 illustrates the data contained
in LODs, and shows that the drug-medical event pairs that are potential ADRs
can be found by investigating the [t0, t1] period around each prescription. Another
advantage of the LODs is that they have frequently been used for signal refinement
and evaluation [31], so all three steps of detecting an ADR can be implemented
30
time (years)
pat1 (♂) :
(05/08/1994)
a1 d5 a3 1 g4 b3 b3
0 t0 t1
pat2 (♂) :
(05/12/1966)
d2 d4 14 d4 b2
0 t0 t1
...
patn (♀) :
(10/11/1984)
a2 b1 a3 g3 5 3 g5
0 t0 t1
0 t0 t1
Figure 2.4: Illustration of patients’ longitudinal data contained in the THIN
database.
on a single LOD, making it possible to develop an efficient algorithm capable
of definitively detecting ADRs. Although, there may be issues with performing
signal evaluation on the same data used to generate the signal.
Numerous approaches have been suggested to signal ADR using LODs [26;
83; 90; 128; 216], but there is currently no algorithm that has been developed
specifically for the THIN database . The methods tend to calculate a measure of
association between each medical event and drug. This is calculated by comparing
the risk of the medical event for the drug taking population within a defined time
interval after the drug is prescribed with the risk of the medical event in some
substituted population. These methods are based on the counterfactual theory
of causality, where the observed risk of the medical event in the drug taking
population is compared with the risk that would have been observed had the
patients not taken the drug [122]. Once the patients take the drug, the second
31
situation (i.e., patients not taking the drug) is counterfactual and unobservable,
so an observable substitution is use instead to approximate the second risk. If the
substitution does not match the counterfactual, then confounding is introduced
and the measure of association differs from the measure of causation [66].
An example of the counterfactual theory of causation is presented in Figure
2.5. It can be seen that the patient 1 given treatment 1 experienced medical event
A but would not have experienced it if treatment 0 was given, so medical event
A was caused by being given treatment 1 rather than treatment 0. However, it is
impossible to observe patient 1 taking only treatment 1 and only treatment 0 at
the same time, therefore an observable substitution is used to estimate causality.
Association is determined by observing patient 2 taking treatment 0 and compar-
ing the outcome with patient 1 taking treatment 1. Unfortunately, as the patients
are different, the observed outcome over [t0, t1] for patient 2 taking treatment 0
is different to what would have been observed for patient 1 given treatment 0
and the substitution comparison indicates that both medical event A and med-
ical event B are associated with treatment 1. However, only medical event A is
caused by treatment 1, the medical event B association is due to confounding
introduced by the substitution.
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A : medical event A i : treatment i
time
t0 t1
Patient 1 B D
0 B
1 A B
Patient 1 B D 1 A B
Patient 2
(substitute)
G D 0
Figure 2.5: Illustration of the counterfactual theory of causaltion.
2.1.4.2 Methods
Disproportionally Methods
The disproportionality methods, such as modified SRS [216] and Temporal pat-
tern Discovery (TPD) [128], compare the risk during the time interval [t0, t1]
centred around the drug of interest prescriptions with the risk during the time
interval [t0, t1] centred around all drug prescriptions, so the substituted popula-
tion is the patients taking any drug. This is illustrated in Figure 2.6. The TPD
also looks for temporal changes in the measure of association, as this reduces
the effect of confounding by indication (i.e., when differences arise between the
patients taking the drug and those not taking the drug), as illustrated in Figure
2.7. Justification for using all other drug reports as a substitution, but keeping
the same time interval of interest, is that medical events are not reported uni-
formly over time [128], and it is common for the majority of medical events to be
reported shortly after a prescription. By investigating the same period of time
relative to the prescription, the potential bias caused by non-uniform reporting
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time
30 days
2 B2 A5
2 D1
...
2 B1 B2
Calculate risk after drug
time
30 days
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3 A1
...
1 D4 A1
Estimate background risk ( risk after other drug)
Figure 2.6: Illustration of the disproportionality methods.
is removed.
To apply the standard SRS methods, described in Chapter 2.1.3, the contin-
gency tables need to be determined using the LOD data. In [216], the authors
presented three different proposals for calculating the contingency tables for a spe-
cific drug x and medical event y using LODs. The spontaneous reporting system
(SRS) and modified-spontaneous reporting system (modified-SRS) approaches
performed similarly and both outperformed the distinct patient approach. Re-
ferring to the set time period after the drug of interest is prescribed as the drug
hazard period, the SRS approach calculates the a-d values in Table 2.1 as, a is
the number of distinct times event y occurs during any x hazard period, b is the
number of distinct times any non–y event occurs during any x hazard period, c
is the number of distinct times event y occurs in any non–x hazard period and d
is the number of distinct times any non–y event occurs within any non–x hazard
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u=[1,30] day intervalv
B2 2 B2 A5
A4 2 D1
...
2 B1 B2
Find temporal changes in risk
time
u=[1,30] day intervalv
A1A3 9 G1
3 A1
...
A1 1 D4 A1
Estimate background temporal risk change
(by calculating risk change for other drugs)
Figure 2.7: Illustration of the TPD method.
period. The modified-SRS approach is similar but considers the prescriptions
that do not have medical events recorded. Therefore, b becomes the number of
distinct times any non–y event occurs during any x hazard period plus the num-
ber of x hazard periods that have no medical event recorded and d becomes the
number of distinct times any non–y event occurs within a non–x hazard period
plus the number of non–x hazard periods that have no medical event recorded
plus the number of distinct times non–y events are reported outside of a hazard
period.
The TPD method [128] compares the amount of patients that have the first
prescription of drug x in thirteen months followed by event y within a set time t
relative to the expected number of patients if drug x and event y were indepen-
dent. The background rates that a medical event occurs is calculated based on
how often it occurs within the hazard period for any drug. Letting,
nt.y denote the number of patients that are prescribed any drug for the first time
in 13 months and have event y within time t.
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ntx. denote the number of patients that have drug x for the first time in 13 months
and are registered for any period over time t
nt.. denote the number of patients that have any other drug for the first time in
13 months and are registered for some period over time t.
ntxy denotes the number of patients that have drug x for the first time in 13
months and event y occurs within time t after.
The expected number of patients that have drug x and then event y in a time
period t is then,
Etxy = n
t
x.
nt.y
nt..
(2.1)
If for a given drug, the event occurs more than expected, the ratio between the
observed and expected will be greater than one. By taking the log2 of the ratio,
a positive values suggests an interesting association between a drug and event.
Modifying the equation to prevent the problem of rare events or drugs resulting
in a small expectation that can cause volatility, a statistical shrinkage method is
applied.
IC = log2
ntxy + 1/2
Etxy + 1/2
(2.2)
The shrinkage adds a bias for the IC towards zero when an event or drug is rare.
The credibility intervals for the IC are the logarithm of the solution to equation
2.3 with q = 0.025 and q = 0.975.
∫ µq
0
(Etxy + 1/2)
ntxy+1/2
Γ(ntxy + 1/2)
u(n
t
xy+1/2)−1e−(n
t
xy+1/2)du = q (2.3)
The above can find possible drug and event associations of interest for a given
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t, however, the authors suggest that general temporal patterns can be found by
comparing the IC of two different time periods. The follow-up period of primary
interest is denoted by u and the control time period by v. This removes event
and drug relationships that just happen to occur more in certain sub-populations.
The different between the IC for both time periods is,
log2
nuxy
Euxy
− log2
nvxy
Evxy
(2.4)
re-arranging and adding a shrinkage term gives,
IC∆ = log2
nuxy + 1/2
Eu∗xy + 1/2
(2.5)
where
Eu∗xy =
nvxy
Evxy
.Euxy (2.6)
As it was observed that medical events related to the cause of the drug are often
assigned a high IC value after the prescription but also prior to the time the drug
is prescribed, the TPD algorithm includes a filter thats ignores medical events
that have a higher IC value on the day of prescription or a month before the
prescription relative to the month after the prescription.
Methods that calculate association tend to suffer from confounding as associ-
ation does not imply causation, so many of the medical events signalled due to a
high association value may not be ADRs. One method that has been presented to
counteract the problem of confounding is the ROR Regression (RORR) method
[72]. The RORR effectively filters the drugs that are signalled as ADRs by the
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ROR by determining whether the association may be due to confounding. The
method applies two regression models, the first model does not consider the effect
of covariates, letting y represent the medical event, and x1 represent the drug,
then the log odds of medical event y is,
log(
P (y|x1)
1− P (D|x1)
) = b0 + b1x1 (2.7)
where b0 is the background log odds ratio of medical event y. The second model
considers the effects of the covariates, xi, i > 1, and the log odds of y is calculated
as,
log(
P (y|x1, x2, ..., xk)
1− P (D|x1, x2, ..., xk)
) = b0 +
k∑
i=1
bixi (2.8)
For each drug with a high ROR, the regression model only considering the drug,
equation (2.7), and the regression model considering all the covariates, equation
(2.8), are both applied and drugs that have similar b1 values for both models
are considered to be causes of medical event y. Unfortunately, its application on
the THIN database is currently limited due to the requirement of choosing the
appropriate covariates for each signal. This requires manual expert input for each
signal, which would be time consuming.
Sequential Pattern Methods
Methods based on sequential pattern mining include Mining Unexpected Tem-
poral Association Rules given the Antecedent (MUTARA) [91] and Highlighting
UTARs Negating TARs (HUNT) [90]. These methods calculate the standard se-
quential patterning mining measure known as leverage [134] that subtracts the
expected proportion of all sequences that contain the drug followed by the medical
event within a defined time interval from the observed proportion. The expecta-
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tion is derived by calculating the risk within a randomly selected time interval for
the population of patients never prescribed the drug. In effect, this is similar to a
retrospective cohort study as the cohorts are the patients exposed or non-exposed
to the drug.
The authors of MUTARA and HUNT refer to the patients prescribed the drug
as users and patients never prescribed the drug as non-users. Both methods first
restrict their attention to subsequences of the user and non-user sequences. For
each user sequence, the Th constrained subsequence of interest is the subsequence
of length Th days starting from the day the drug is first prescribed. The value of
Th differs between users depending on whether the user has a repeat prescription
within Te days after the first prescription. If the user does not have a repeat
prescription within Te days of the first prescription then Th = Te, whereas if the
second prescription of the drug occurs s days after the first prescription where
s ≤ Te then Th = s + Te. For each non-user, the Tc constrained subsequence
of interest is a subsequence of length Tc days that is randomly chosen from the
non-user’s sequence. An illustration of this can be seen in Figure 2.8.
Defining tot as the number of users and non-users, the supp(x
T
→ y) is defined
as the number of user Th constrained subsequences containing the medical event y
divided by tot, the supp(x
T
→) is the number of users divided by tot and supp(
T
→ y)
is the number of user Th constrained subsequences that contain the medical event
y divided by tot plus the number of non-user Tc constrained subsequences that
contain the medical event y divided by tot. The leverage is calculated as,
Leverage = supp(x
T
→ y)− supp(x
T
→)× supp(
T
→ y) (2.9)
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Figure 2.8: Illustration of the MUTARA and HUNT methods.
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In addition to calculating the standard leverage, a new measure called unexpected-
leverage is also calculated. The unexpected-leverage (unexlev) makes use of a
user’s history to filter repeated medical events from the users’s Th constrained
subsequence as these are ‘predictable’ and unlikely to be ADRs. This is done by
investigating a reference period prior to the first prescription within the user’s
sequence and filtering medical events from the user’s Th subsequence if they oc-
curred during the reference period. Defining supp(x
T
→֒ y) as the number of users
who’s Th constrained subsequence contains medical event y but who do not have
medical event y within the reference period divided by tot and supp(
T
→֒ y) as the
total of the number of users whose Th constrained subsequence contains medical
event y but who do not have medical event y within the reference period plus the
number of non-user Tc constrained subsequences that contain the medical event
y all divided by tot, the unexpected leverage is calculated as,
unexlev = supp(x
T
→֒ y)− supp(x
T
→).supp(
T
→֒ y) (2.10)
MUTARA returns medical events ordered by unexlev and HUNT returns med-
ical events in descending order of the ratio between the leverage rank and the
unexpected-leverage rank,
RankRatio =
medical event rank based on leverage
medical event rank based on unexpected-leverage
(2.11)
Other Methods
Other methods for signalling ADRs using LODs that have been proposed include
fuzzy logic methods [89], calculating the log likelihood over time [26], applying a
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Table 2.6: The different LOD ADR signalling algorithms and the causality criteria
each of them covers. 1
Criteria MUTARA HUNT TPD Modified SRS RORR
Strength 4 4 4 4 4
Consistency 5 5 5 5 5
Specificity 5 5 5 5 ∗
Temporality 4 4 4 5 5
Biological Gradient 5 5 5 5 ∗
Plausibility 5 5 5 5 4
Coherence 5 5 5 5 5
Experimentation 5 5 5 5 5
Analogy 5 5 5 5 5
sequential version of the self controlled case series [83] or adapted epidemiology
based approaches, see Chapter 2.1.5. These methods tend to suffer from con-
founding effects and are likely to have a high false positive rate. However, it is
worth noting that the self controlled case series is resilient to any fixed in time
confounding. Very few of these methods have been implemented on a range of
LODs, so their robustness is unexplored.
2.1.4.3 Causality
The LOD ADR signalling algorithms all cover the strength criteria as they cal-
culated the dependancy of the occurrence of a medical event on the occurrence
of a drug being prescribed. The filtering in the MUTARA/HUNT and the TPD
algorithms means they cover the temporality criteria as medical events that occur
before the drug are generally filtered. The modified SRS and RORR algorithms
do not apply a filter, so they do not cover the temporality criteria. In effect, the
RORR covers plausibility by filtering out drug-medical event pairs that are asso-
1∗ means that the factor could be incorporated but is currently not.
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ciated due to other causes, so the remaining drug-medical event pairs are more
plausible ADRs. Additionally, it would be possible to include dosage and per-
sonal attributes into the regression model used by the RORR, so the specificity
and biological gradient could be included. The other causality criteria are not
covered by the LOD algorithms. This is likely to be the reason why the existing
LOD algorithms frequently signal medical events linked to the cause of taking
the drug or medical events that are just common in the drug taking population.
2.1.4.4 Limitations
The LOD databases have presented the opportunity to signal ADRs without the
limitations associated with the SRS databases, but research has shown they have
their own limitations [100; 131]. The main limitation is the effect of confounding
factors[198], as many drug-medical event pairs that are associated do not corre-
spond to ADRs. The existing methods that signal drug-medical event pairs based
on association do not consider the eight other Bradford-Hill factors, but some of
these could be integrated by utilising the data available in the LODs. The RORR
method has the potential to cover the most Bradford-Hill causality factors, but
it is a signal refinement method rather than a signal generating method, as it
requires a signal generating method such as the ROR to identify which drug-
medical event pairs to apply the regression models on. Therefore, the RROR is
limited by any limitations with the signal generating method it incorporates.
2.1.4.5 Summary
The LOD algorithms show promise at becoming an integral part of pharmacovig-
ilance in the future due to the wealth of information they potentially hold [198].
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Although numerous methods have been developed for generating ADR signals
using LODs, they have not been robustly analysed. Their theoretical founda-
tions would suggest that they are likely to signal many non-ADRs due to the
reliance on association. The RORR method, presented to identify confounding,
requires initial drug-medical event pair signals to be generated, so it is a signal
refinement method. There has been no method that combines signal generating
and refinement into one, but such a method could signal drug-medical event pairs
more efficiently and obtain a lower rate of signalling non-causal relationships.
2.1.5 Combining Multiple Databases
2.1.5.1 Overview
There has been a recent initiative to integrate multiple electronic healthcare data
sources into one. Examples include the Mini-Sentinel [136], that will eventu-
ally become Sentinel, a US Congress mandated pharmacovigilance system that
contains medical data for more that 125 million Americans [124], the Exploring
and Understanding Adverse Drug Reactions (EU-ADR) project [34], a European
initiative set up in 2008 that contains data on over 30 million patients and the
Observational Medical Outcomes Partnership (OMOP) that has a network of
databases containing over 200 million patients. Numerous researchers have ex-
pressed the significance of large pharmacovigilance sources in aiding the ability
to discover ADRs efficiently [144]. The initiatives may bridge gaps in the current
pharmacovigilance, such as lack of knowledge concerning drug safety for minority
groups [34].
The OMOP was formed to analyse the methodologies for pharmacovigilance
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using longitudinal data. The partnership have developed a common data model
that enables the combination of different databases by transforming them into
a general format [115; 131]. The OMOP have presented a magnitude of differ-
ent techniques specifically for signalling ADRs using longitudinal data, including
cohort studies [107], disproportionality methods [216], case series methods [71],
case control methods [71], case crossover methods [160] and propensity score based
methods [159]. To enable an analysis of the methods, an approximate gold stan-
dard consisting of 53 ‘ground truth’ drug-medical event pairs (i.e., drug-medical
event pairs that are known to be ADRs or non-ADRs) have been identified [141].
The ability of the methods to generate correct signals for these ‘ground truths’,
at their natural threshold, has been investigated [156].
The standardised ‘ground truths’ only consider a selection of medical events,
referred to as Health Outcomes of Interest (HOI) and a small subset of drugs
known as Drugs Of Interest (DOI). Tables 2.7-2.8 display the OMOP’s proposed
HOIs and DOIs. Unfortunately, there are few studies investigating the methods
abilities in generating signals when a large number of drug-medical event pairs
are studied, however this is more realistic [143].
The OMOP methods tend to be based on standard epidemiological studies
that aim to identify associations between drugs and medical events by finding
medical event that have a greater incidence after a drug compared to the medical
event’s estimated background incidence. Many methods have been presented
and the seven that have been extensively investigated as described below. The
first method, the High–throughput Screening by Indiana University (HSIU), is
1READ codes do not exist for the exact medical event, so GI ulcer READ codes are given.
2READ codes do not exist for the exact medical event, so mortality due to cardiac or patient
died READ codes are given.
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Table 2.7: The Heath Outcomes of Interest defined by the OMOP [80] and their
corresponding THIN READ codes.
Medical event THIN READ code
Angioedema SN51.
Aplastic anemia D20.., D2011, D201., D2012, D2012, D204., D202.,
Dyu2.
Acute liver injury J6000, J6357
Bleeding J68.., J68z., J68z0, J68z1, J68z2, J68zz
GI ulcer hospitalization 1 J11.., J110’s
Hip fracture S30.., S30y.
Hospitalization 8H2.., 8H2z., 8H7a., 8Hd.., 8HJ.., 9144.
Acute myocardial infrac-
tion
G30.., G30’s
Mortality after myocar-
dial infarction 2
G5751, 22J..
Acute renal failure K04.., K04y., K04z., Kyu20, K043.
a cohort approach [80]. A cohort study follows a group of patients that have a
common attribute or event (such as a drug prescription) and assesses outcome risk
factors [178]. The Observation Screening method [155] calculates the screening
rate within the drug population (the frequency of a outcome divided by the total
risk time) and normalises this by dividing it by an estimate for the background
screening rate. This is either the screening rate in a non-risk period (frequency
in a pre-exposure period divided by the total pre-exposure time period) or the
screening rate in a control group. The third method, the Disproportionality
Analysis (DP) [216], identifies associations by comparing the rate that a medical
event occurs within the drug population relative to the rate it occurs within some
other population, similar to the SRS methods in Chapter 2.1.3.
The Univariate Self-control Case Series (USCCS), based on the method devel-
oped in [54], can be considered a cohort based study but where the exposed and
non-exposed patients are the same. The approach partitions the cases’ timelines
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Table 2.8: The Drugs of Interest defined by the OMOP, table from [80].
DOI Drug Name DOI Description
OMOP ACE Inhibitor ACE inhibitors: benazepril, captopril, enalapril, fosino-
pril, lisinopril, quinapril, and ramipril; restricted to oral
form
OMOP Amphotericin B parenteral Amphotericin B
OMOP Antibiotics:
erythromycins, sulfon-
amides, and thetracy-
clines
Antibiotics: erythromycins, sulfonamides, and tetracy-
clines; restricted to oral and injectable
OMOP Antiepilep-
tics: carbamazepine,
phenytoin
Antiepiletics: carbamasepine, phenytoin: restricted to
oral and injectable
OMOP Benzodiazepines Benzodiazepines: alprazolam, chlordiazepoxide, clon-
azepam, clorazepate, diazepam, estazolam, flurazepam,
halazepam, lorazepam, oxazepam, prazepam, quazepam,
temazepam, or triazolam
OMOP Beta blockers Beta blockers: propanolol, metoprolol, atenolol; re-
stricted to oral form
OMOP Bisphospho-
nates
Bisphosphonates: alendronate
OMOP Tricyclic antide-
pressants
Tricyclic antidepressants: restricted to oral and in-
jectable
OMOP Typical antipsy-
chotics
Typical antipsychotics: Chlorpromazine, chlorprothix-
ene, levomepromazine, flupentixol, Fluphenazine de-
canoate, Fluphenazine enanthate, Fluphenazine hcl,
Haloperidol, Haloperidol decanoate, Loxapine hcl,
Loxapine succinate, melperon, Mesoridazine, Molindone,
Perphenazine, amitriptyline hcl/perphenazine, Pimozide,
pipamperone, promazine, Prochlorperazine edisylate,
periciazine, Prochlorperazine maleate, Promazine, Propi-
omazine, Thioridazine, Thiothixene, Trifluoperazine, zu-
clopenthixol
OMOP Warfarin Warfarin
47
into hazard and non-harard periods and compares the incidence in the hazard
periods with the incidence in the non-hazard periods [200]. Fixed in time con-
founding is overcome within the USCCS by using the same patients as the exposed
and non-exposed. The Multi-Set Case Control Estimation (MSCCE) method is
a case control approach that selects cases based on the occurrence of a speci-
fied condition and selects control that do not have the condition and are active
over the required observation period (i.e., have events reported before and after
the period) [217]. The Bayesian Logistic Regression (BLR) [87] method applies
a logistic regression approach using prior knowledge to initialise the coefficients
that determine the weight that each covariate has on the final output. The final
method is the Information Component Temporal Pattern Discovery (ICTPD),
summarised in Chapter 2.1.4.2.
The seven methods only cover the Bradford-Hill association strength consid-
eration and some incorporate filters to cover the temporality. Consistency is
indirectly incorporated due to the combination of multiple data sources. Some of
the methods, such as the BLR, remove confounding by adjusting for covariates
or apply stratification to reduce confounding by age and gender.
The seven OMOP methods described above were applied in the Non-Specific
Association (NSA) experiment, whereby the ten DOIs were paired with all possi-
ble outcomes and the signals generated by each method at their natural thresholds
were determined [80]. The majority of methods have many parameters that de-
termine their performance and the study applied the methods over a range of
parameter values to identify the optimal performance. This shows that addi-
tional work is required to tune these existing methods depending on the database
being used. The performance of the seven OMOP methods during the NSA ex-
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Table 2.9: The OMOP methods NSA experiment results.
Method
Optimal Scores over the NSA experiment
AUC MAP P(10) FPR
HSIU 0.7342 0.1408 0.42 0.2658
OS 0.7138 0.0942 0.22 0.2862
DP 0.6741 0.0622 0.23 0.3259
USCCS 0.7342 0.1408 0.4200 0.2658
MSCCE 0.603 0.032 0.05 0.397
BLR 0.6329 0.0316 0.03 0.3671
ICTPD 0.6695 0.0591 0.1 0.3305
periment is presented in Table 2.9. It can be observed that all seven methods
had False Positive Rates (FPRs) greater than 0.25 and Mean Average precision
(MAP) scores less than 0.015. The AUC values ranged from 0.6 − 0.735, as the
AUC corresponds to the probability that an ADR is ranked above a non-ADR
(rank 1 being the highest) [20], there is still approximately 30%-40% chance than
a non-ADR will be ranked higher than an ADR.
A recent study investigated potential loss from mapping the raw THIN data
into the common data model [214]. A few existing methods were applied to both
the raw THIN database and the THIN database mapped to the common data
model. The results of the study suggested that the existing methods performed
equally well on the raw and mapped data when considering the signals generated
for the 53 ground truths. However, the study showed that 55% of drug codes and
25% of medical events codes could not be mapped from THIN into the common
model [214], and this is likely to have detrimental effects when more than the
53 ground truths are considered. This highlights the important of developing
database specific methods, in additional to the common model methods, that
can utilise all the data available and present an alternative perspective for ADR
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discovery. When improvements in the mapping to the common data model are
developed, then any method developed for THIN could also be modified for im-
plementation on the THIN mapped to the common data model (or any other
common data model mapped database).
2.1.5.2 Summary
Combining the databases means that it may be possible to generate signals ef-
ficiently [3]. However, the combination requires the data to be transformed and
normalised and this has the potential to lose information and can negatively im-
pact the efficiency of signalling ADRs. It was demonstrated in [214] that many
of the raw THIN data cannot be incorporated into the common data model,
motivating the development of methods that are specific to certain databases.
Comparisons of existing OMOP methods have shown that they perform mod-
erately on the common data model [156] and there is no optimal method. In
addition, the methods had a high false positive rate, even when the number of
drug-medical event pairs being investigated is controlled. It is likely that the
methods will be further hindered when applied to determine a drug’s complete
set of side effects as there will be a surplus number of drug-medical event pairs
corresponding to non-ADRs.
2.1.6 Pharmacovigilance Summary
Adverse drug reactions are becoming an increasing burden on the NHS [166].
Existing post-marketing surveillance of drugs is limited by underlying issues as-
sociated with SRS databases [79]. Many ADRs are only being found years after
the drugs are marketed and as a result, many patients suffer serious health issues
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that could be avoided with improved ADR knowledge. Rare ADRs that are hard
to identify, ADRs corresponding to medical events with a high background rate
or less serious ADRs may never be detected by data-mining algorithms applied
to SRS databases [173]. As a result there has been a recent demand for improved
post-marketing surveillance [129; 190].
One recent solution has been to develop data-mining algorithms for LODs or to
combine multiple electronic healthcare databases as a resource for ADR detection.
Unfortunately the current methods developed for LODs have a high false positive
rate [156] and have not been extensively investigated due to a lack of a complete
‘gold standard’ [33]. The high false positive rate is probably due to confounding
caused by the countless number of possible covariates. Integrating the Bradford-
Hill causality considerations into a signalling method is one possible consideration
to reduce the negative impact of confounding factors and therefore reduce the
number of false positive signals. The Bradford-Hill causality considerations have
been used to help distinguish between associations that are causal, and those
that are not. As confounding causes the associations that are non-causal, the
Bradford-Hill causality considerations must be able to indirectly identify some
confounding. The majority of existing methods only cover a few of the Bradford-
Hill causality considerations, however, there is potential to extract data from the
LODs to enable novel methods that cover more of the criteria. This could then
reduce the number of false positives.
The THIN database is a LOD that contain medical data for over 10 million
patents, often spanning decades of years per patient. The general benchmark for
the THIN database is unknown, as only a few methods have been investigated by
considering the signals generated for a small set of 54 ‘ground truth’ drug-medical
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event pairs [214]. A specific method to signal ADR using the THIN database may
generate novel signals that cannot be generated using the common data model
nor the SRS databases. There are inconsistencies in the recording of data into
the THIN database [78], but this may be overcome by developing a novel method
that takes this into account.
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2.2 Pattern Recognition
In the previous part of the literature review the existing pharmacovigilance tech-
niques that tend to signal ADRs by calculating an estimate for the relative risk of
each drug-medical event pair were summarised. The medical events with a large
estimated relative risk are then signalled, or alternatively ‘classified’, as poten-
tial ADRs. These methods can be considered unsupervised learning algorithms,
algorithms that infer hidden structure without being taught [2], as they do not
use knowledge of existing ADRs to learn intrinsic differences between ADRs and
non-ADRs. Rather, they use a single attribute such as the relative risk estimate
to distinguish between ADRs and non-ADRs. The limitation with relying on
a single attribute, such as the relative risk, is that confounding can occur and
cause many non-ADRs to have a high relative risk estimate. This results in the
techniques having high false positive rates and reduces the efficiency in detecting
ADRs.
There has been no research to date that extracts attributes for drug-medical
event pairs from LODs and then uses known ADRs as a means to learn the un-
known ADRs based on their attributes, although in [113] the authors use chemical
knowledge and learn from known ADRs. This type of learning is called supervised
learning [74]. During the training stage, supervised learning requires attributes
that describe each data-point and knowledge of the ‘classes’ that the data-points
belong to. In the context of ADR signalling each drug-medical event pair would
represent a data-point and their attributes would correspond to values that could
be used to distinguish between ADRs and non-ADRs. Examples of suitable at-
tributes include the risk of the medical event within a defined time period after
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taking the drug or the average age of the patients experiencing the medical event
after the drug. Labels need to be assigned to each data-point (i.e., each drug-
medical event pair) to define their class, for example the pair ciprofloxacin and
tendon rupture would be in the class ADR whereas the pair ciprofloxacin and
normal menopause are in the class non-ADR. In the pharmacovigilance field this
has been unexplored in general due to the uncertainty with knowing what med-
ical events are definitely ADRs or non-ADRs of a drug . If a sufficient number
of labelled data-points could be generated then a supervised algorithm could be
trained. This would enable classification of any drug-medical event pair whose
ADR status is unknown, as an ADR or non-ADR. If suitable attributes were
chosen so that it was possible to distinguish between medical events linked to
drugs due to confounding factors and true ADRs, then a supervised algorithm
could offer significant improvement over existing ADR signalling methods .
In the following section the theory behind supervised learning and the main al-
gorithms applied are described. This is followed by a summary on semi-supervised
learning, the technique developed to deal with the situation of having labels that
are difficult to generate [30]. Due to the conundrum that applying supervised
learning for signalling ADRs imposes, requiring knowledge of ADRs to extract
knowledge of ADRs, it may be impossible to generate the required number of
labeled data-points and a semi-supervised algorithm may be more appropriate.
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2.2.1 Supervised Learning
2.2.1.1 Introduction
Supervised learning is the process of learning from examples to infer the rela-
tionship between inputs and outputs. A training set consisting of inputs (also
known as attributes) and their corresponding outputs are used to ‘supervise’ the
training of a function that is capable of generalising the mapping between input
and output. The trained function can then be used to predict the output of
any unseen input coming from the same distribution as the training set inputs.
When the outputs are discrete they are referred to as classes or labels and the
supervised learning is known as classification. Alternatively, when the output is
continuous the supervised learning is known as regression [37]. For example, if
the odds ratio (OR) and risk difference (RD) attributes are known for a thou-
sand different drug-medical event pairs and for each pair their class (ADR or
non-ADR ) is also known, then supervised learning could be applied to partition
the attribute space into areas likely to correspond to ADRs and areas likely to
correspond to non-ADRs, see Fig 2.9 illustrating the ideal situation where ADRs
and non-ADRs are separable in the space determined by the OR and RD.
Formalising the previous statement, the training set An is a collection of inputs
xi ∈ X and corresponding outputs yi ∈ Y pairs,
An = {(x1, y1), (x2, y2), ..., (xn, yn)} (2.12)
Where each pair (xi, yi) are assumed to be independent identically distributed
samples from an unknown joint probability distribution P . In general, X ⊂ Rm
55

 


	



		
	



		

 

Figure 2.9: Illustration of a classifier partitioning the attribute space. Using the
training data (blue dots are labelled as ADR and red as non-ADR) a function
is trained to partition the space into ADR sections and non-ADR sections. This
can then be used to predict whether a new data-point is an ADR or non-ADR
based on where the data point lies in the attribute space.
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and Y ⊂ R for regression or Y = {−1, 1} for binary classification. The task of
supervised learning is to find a function f : X → Y , where f ∈ H (a class of
functions).
As the training data is considered to consist of n independently identically
distributed samples from an unknown joint probability distribution P (x, y), then
the task of supervised learning is to develop a function f that models the de-
pendency within the joint distribution. There are two different approaches for
producing machine learning models, the discriminative model and the generative
model. The discriminative model aims to determine the conditional distribution
of the class label given the input, P (y|x) , by using a parametric model and
determining the model’s parameter values with the aid of the training set [102].
The generative method calculates the joint probability distribution, P (x, y), and
makes use of this distribution to predict the conditional distribution [102]. In gen-
eral, if the training set is sufficiently large (depending on the complexity of the
model), discriminative models have been shown to perform better [92], however,
generative models have the advantage of being able to incorporate unlabelled
data [102]. This is advantageous when generating labels becomes costly.
To find the optimal function f ∈ H for mapping the inputs to their outputs
it is necessary to evaluate each functions performance. This is calculated by a
non-negative loss function,L : Y × Y → R+, that determines a measure of error
between the predicted output f(xi) and the real output yi. Various loss functions
have been proposed, examples for binary classification [150] include,
• Square Loss: L(f(x), y) = (1− f(x)y)2
• Hinge Loss: L(f(x), y) = |1− f(x)y)|+
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• Logistic Loss: L(f(x), y) = (ln2)−1ln(1 + e−f(x)y)
The choice of the loss function that is implemented should be chosen based on
the specific classification problem [4]. The integral of the model’s loss function
over the joint probability distribution gives the generalisation error, or risk,
R(f) =
∫
L(f(x), y)dP (x, y) (2.13)
The Bayes estimator, g∗, is the function that minimises the risk,
R(g∗) = inf
f
R(f) (2.14)
The goal of a discriminative learning algorithm is to find the function within a
class of possible functions, f ∗ ∈ H, that minimises the risk, f ∗ = argminf∈H R(f).
Unfortunately it is often the case that the Bayes estimator does not belong to
the class of possible functions. Methods that aim to determine the function that
minimises the risk include empirical risk minimisation [123], structural risk min-
imisation [187], regularisation [18] and normalised regularisation [18].
Empirical risk minimisation is a simple and generally efficient means to deter-
mine a suitable function. The empirical risk measures the difference between the
predicted output values and the true output values by calculating the average of
the loss function over each data-point in the training set,
Remp(f, An) =
1
n
n∑
i=1
L(f(xi), yi) (2.15)
The empirical risk minimisation method then identifies the function f from a
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model of possible functions H that minimises the empirical risk,
f ∗ = argmin
f∈H
Remp(f)
It is clear that the choice of model that determines the possible functions has a
direct impact on the results returned by the empirical risk minimisation method.
The idea behind the structural risk minimisation is to pick a sequence of
models, {Hs|s ∈ N} , than increase in size and find the argument that minimises
a trade off between the empirical risk and a penalty that penalises large models
(models with a large capacity),
f ∗ = arg min
f∈Hs,s∈N
Remp(f) + pen(s, n) (2.16)
where n is the size of the training data. As the empirical risk only estimates the
actual risk, it is of interest to find bounds on the difference between the actual
and empirical risk, as this gives an indication into the predictive suitability of
any functions that are determined using a supervised learning model. Extensive
analysis by [187] managed to show that the actual risk is bounded by the empirical
risk and an additional term than corresponds to the complexity of the model.
With probability 1− η the following holds,
R(f) ≤ Remp(f) +
√
h(log(2n/h)− log(η/4))
n
(2.17)
where h is the VC dimension of the class of functions H, this is a measure of their
complexity. The VC dimension of a class of functions is the maximum number
of points that can be separated in every possible way by those functions over a
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Figure 2.10: Illustration of the maximum number of points separable in every
possible way by a linear classifier.
defined space [189]. A visual example demonstrating that a linear classifier has a
VC dimension of 3 can be seen in Figure 2.10. It can be seen that 3 non-collinear
points can be separated by a line in every possible way, but this is not the case
for 4 points, as the far right graph shows two lines are required.
In general the bound can be represented as,
Test error ≤ Training error + Complexity of set of models (2.18)
Training a highly complex model may lead to overfitting, where the training error
is minimised but the model is not generalised and performs poorly on the testing
data. On the other hand, a less complex model is likely to have a high training
error. Therefore, the perfect model determines a function that has a low training
error but is also as simple as possible.
The complexity of the model depends on H, the class of functions, and this
is determined by the classifier being applied. The most widely applied classifiers
are the Decision Tree [81], Naive Bayes [101], Logistic Regression [84], Support
Vector Machine [39] and K-Nearest Neighbours (KNN) [56]. Each of these have
different model assumptions and are briefly summarised in the following section.
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RR
OR
non-ADR
≤ 3
ADR> 3
< 4
RD
non-ADR
≤ 2
ADR> 2
≥ 4
Figure 2.11: Example of a decision tree to classify drug-medical event pairs as
ADRs or non-ADRs.
2.2.1.2 Classifiers
Decision Tree
The decision tree classifier is a directed tree that recursively partitions the at-
tribute space into sub-spaces. An illustration of a hypothetical decision tree can
be seen in Figure 2.11. A decision tree is non-parametric [116], self explanatory
[116] and has the advantage of being unaffected by heterogeneous data or differ-
ent features that have varied ranges. This means that the data does not need
to be extensively processed before applying the classifier. Unfortunately, it has
been described as ’greedy’ as noise or irrelevant attributes in the training set can
greatly impede its performance [139].
The decision tree can be constructed with a bottom-up [95] or top-down [149]
approach. Generally speaking, the algorithm uses a splitting measure to calculate
how well an available partitioning of the space separates the classes. During each
iteration in the top-down approach, the optimal partitioning is applied to the
current subspace, or the subspace stops being partitioned when the splitting
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measures shows there is no possible partition that can lead to a sufficient gain or
the stopping criterion is satisfied. In general, the splitting criteria is only based
on a single attribute during each iteration. This is known as univariate splitting
[116] and the measures are often based on impurity based criteria such as the
Gini index [21] or information gain [138].
The information gain takes its origin from information theory and measures
the change in the entropy value that is caused by partitioning the space. The
entropy value corresponds to the uncertainty within a set. Considering the binary
classification problem where there are two class, let p1 and p2 represent the pro-
portion of the data-points within the set S that are in class 1 or −1 respectively,
then the entropy is,
E(S) = −
2∑
i=1
pilog2pi (2.19)
If the data-points in a set are all from one class, without loss of generality, assume
they are from class 1, then p1 = 1 (log2p1 = 0) and p2 = 0 so E = 0, the lowest
possible value. If the data-points in a set are spread equally between the two
classes, p1 = p2 = 0.5, then the entropy is the highest possible value E = 1. It
is clear that choosing a partitioning with the highest information gain minimises
the entropy and leads to a final partitioning of the space into numerous subspaces
that are dense in a single class. The main limitations of using information gain as
the splitting measure for a decision tree classifier is that there is a bias towards
partitioning based on attributes with large ranges [201] that can lead to over-
fitting and it is common for the space to be fragmented into a surplus number of
small subspaces.
The Gini index is another splitting measure frequently implemented. The
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Gini index is calculated for a set S by,
Gini(S) = 1−
2∑
i=1
p2i (2.20)
The Gini index is minimised when the majority of the data-points within set S
belong to one class. In this case, one of the pi values will be close to one and
the others will be small. The square term in the Gini index calculation puts
more emphasis on larger values. Squaring the pi value close to one has little
effect, whereas the closer a pi value is to zero, the more it becomes reduced when
squared. So a set S containing data-points spread between different classes will
have a small value for
∑2
i=1 p
2
i and therefore a Gini index close to 1.
The average Gini index is the weighted average of the Gini index based on
partitioning the set S into subsets Si using the values of a single attribute A,
where |S| corresponds to the number of elements in the set S,
Gini(S,A) =
∑
i
|Si|
|S|
Gini(Si) (2.21)
The decision tree is generated by finding the partitions that minimise the average
Gini index. Research comparing the different univariate splitting measures has
often concluded that the choice has little effect on the decision tree as there does
not appear to be an overall superior measure [116].
Naive Bayes
The Naive Bayes classifier uses the training set to determine the distribution of
the class label, P (Y ), and the conditional distribution of the input attributes
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given the class label, P (Xi|Y ) for i ∈ [1, n], and then use these combined with
Bayes rules and a conditional independence assumption to find the most probable
class for any future inputs. The conditional independence assumption is used to
simplify the number of parameters required by the model and enables an efficient
calculation of the distribution P (Y |X).
Consider three random variables, X, Y and Z. It is defined that X is condi-
tionally independent of Y given Z if, P (X|Y, Z) = P (X|Z). Assuming that the
input features are conditionally independent given the class label, then,
P (X1, X2, ..., Xn|Y ) = P (X1|X2, ..., Xn, Y )P (X2|X3, ..., XN , Y )...P (Xn|Y )
= P (X1|Y )P (X2|Y )...P (Xn|Y )
=
n∏
i=1
P (Xi|Y )
Using Bayes rule,
P (Y = yk|X1, ..., Xn) =
P (Y = yk)P (X1, ..., Xn|Y = yk)∑
j P (Y = yj)P (X1, ..., Xn|Y = yj)
(2.22)
and using the conditional independence the expression for the conditional prob-
ability of the class label given the input data is,
P (Y = yk|X1, ..., Xn) =
P (Y = yk)
∏
i P (Xi|Y = yk)∑
j P (Y = yj)
∏
i P (Xi|Y = yj)
(2.23)
As the denominator in equation (2.23) is independent of the choice of class label,
it can be ignored. The classifier simply determines the most probable class label
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for an input by,
Y = argmax
yk
P (Y = yk)
∏
i
P (Xi|Y = yk) (2.24)
The classifier, although limited by its unrealistic assumption of conditional inde-
pendence, has performed well for some real life classification problems [47]. In
[146] the authors state that a known limitation of the Naive Bayes classifier is
that it does not perform optimally when the classes are non-linearly separable.
Logistic Regression
Logistic regression is a discriminative model so it assumes a distribution for
P (Y |X) and uses the training data to determine the parameter values. Logistic
regression is applied when the classification is binary and does not required the
inputs to be normally distributed, have equal variance within each class nor be
linearly related [27]. The main disadvantage with the classifier is that it uses
maximum likelihood to determine the parameter values and this requires larger
training sizes than for linear regression. It is suggested that a minimum of 50
cases per predictor are used [27].
The logistic regression model is based on the assumption that the log odds
of a data-point belonging to a class given its n attributes can be expressed as a
linear combination of the data-points attributes. Under this assumption the log
odds is expressed as,
ln(P (Y |X)/(1− P (Y |X))) = w0 +
n∑
i=1
wiXi
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by taking the exponential and re-arranging, the conditional model used by logistic
regression for the two class problem is,
P (Y = 0|X) =
exp(w0 +
∑n
i=1wiXi)
1 + exp(w0 +
∑n
i=1wiXi)
P (Y = 1|X) = 1− P (Y = 0|X)
=
1
1 + exp(w0 +
∑n
i=1wiXi)
As the classifier assigns the class for an input x based on argmaxyk P (Y = yk|X =
x), it is clear that class 0 is assigned when 1 < exp(w0+
∑
iwiXi) (or equivalently
0 < w0 +
∑
iwiXi) and class 1 is assigned otherwise.
Support Vector Machine
The Support vector machine (SVM) classifier is a parametric model that aims
to find the hyperplane that separates the classes while maximising the distance
between the data-points and the hyperplane, see Figure 2.12. For the two class
problem, the SVM works by finding two parallel hyperplanes such that they
separate the two classes and there are no points between the two hyperplanes.
The equations of two hyperplanes are w.xi + b = 1 and w.xi + b = −1. The bit
in-between the hyperplanes is referred to as the ‘margin’. This is what needs to
be maximised to ensure the classes are separated as much as possible. As the
distances between the two hyperplanes is 2/||w||, by minimising ||w|| we can find
the maximum separation between the classes. Previously in Chapter 2.2.1.1 it
was shown that the actual risk of a classifier is bounded by the empirical risk and
a term that depends on the capacity/complexity of the set of decision functions
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Figure 2.12: Illustration of the support vector machine classifier. The hyperplane
separating the classes is positioned such that the distance between the hyperplane
and the closest data points from either class is maximised.
defined by the classifier. The decision functions used by the SVM classifier are
the hyperplanes w.x + b. It has been proven that for the set of hyperplanes
(w.x) = 0 such that mini |w.xi| = 1 for xi ∈ X the set of decision functions
fw(x) : X → {−1, 0, 1}; fw(x) = sgn(w.x) satisfying ||w|| < A has a bounded
VC dimension [188],
h ≤ R2A2 (2.25)
where R is the radius of the smallest ball centred at the origin that covers the
set X. This defines an upper bound on the capacity/complexity of the SVM
classifier. In the separable case this motivates finding the parameters w and b
such that ||w||2 is minimised and,
(w.xi + b) ≥ 1 if yi = 1;
(w.xi + b) ≤ −1 if yi = −1.
(2.26)
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as this results in a zero empirical risk and minimises the capacity of the model.
When the data is non-separable (i.e. there is no hyperpane that can cleanly split
the classes), slack variables are introduced to enable the misclassification of some
data-points. The aim is to maximise the margin while minimising the degree of
misclassification. The optimisation problem becomes minimise:
||w||2 + C
m∑
i=1
σi
subject to:
yi(w.xi + b) ≥ 1− σi, σi ≥ 0
An addition to the optimisation problem includes incorporating kernel functions
that map the data-points into a space where they are separable [125].
K-Nearest Neighbour
The K-nearest neighbour (KNN) classifier is non-parametric, this means it does
not assume the data come from a specific distribution. The classifier is described
as a lazy algorithm as it does not use the training data to generalise (generate
a probabilistic distribution) [199], this makes the training state highly efficient,
but can cause the testing step to become costly.
The classifier requires the data to come from a metric space, but the measure of
distance can be any suitable metric. The classifier works by taking the majority
vote of the k nearest neighbours, where distance is determined by the defined
metric. If the set Nk(x) is the set of indices corresponding to the K nearest
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neighbours of x, then,
fKNN(x) =


1 if
∑
i∈Nk(x)
yi ≥ 0;
−1 if
∑
i∈Nk(x)
yi < 0.
For example, if k = 7, and for an input x three of its neighbours are class −1
and four are class 1 then the input would be assigned the class 1. The algorithm
can be modified to use the distance of the neighbours as weights so that closer
neighbours have more influence [49].
2.2.1.3 Ensemble Methods
An ensemble classifier considers the outputs from multiple trained classifier to
determine the class of a data-point [130]. In general, the method combines multi-
ple diverse ‘weak learners’ to produce a ‘strong learner’. The motivation behind
an ensemble classifier is to reduce the bias that can occur when considering single
classifiers and to reduce the variance than can occur due to the choice of data
used during training [23].
There exists a magnitude of options for generating diverse classifiers including
building models from different samples of the data [22], using different models
[51] or building models that use different subsets of attributes [82]. There are
also different ways to combine the predictions from the classifiers, such as deter-
mining the class by voting that returns the modal class or weighted voting that
incorporates the confidence of the classifiers or error estimations as weights to
produce a weighted sum of the votes. Another method, known as stacking, is to
use the outputs of the classifiers as inputs into a new meta classifier that does
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the final classification [177].
The most widely implemented ensemble methods that use sampling of the
training data set are known as bagging [22] and boosting [60]. Bagging involves
iteratively generating classifiers that are built on different training sets and re-
turning the class with the highest number of votes based on these classifiers. The
different training subsets are produced by drawing with replacement from the
whole training set. Bagging has a statistical basis and can be considered similar
to averaging as it reduces the classifier’s variance [23; 130]. The advantage of
bagging is that is it resistant to noise, however, experiments have shown that
with a little noise present it is not as accurate as other methods such as boosting
[46].
Boosting has its foundations in learning theory and the general aim is to pro-
duce a sequence of classifiers that are used to generate a weighted vote for the
overall class. The misclassifications of the previous classifiers in the sequence have
an influence on the weights assigned during classification in the later sequence
classifiers. The most widely used boosting classifier is the AdaBoost classifier
developed by Freund and Schapire [61] that generates a sequence of simple clas-
sifiers (hm ∈ H, where H is a class of simple classifiers) and weights (λm ∈ R) by
giving more importance to data-points that were misclassified by the simple clas-
sifiers earlier in the sequence. The final classification makes use of the weighted
majority vote sgn(
∑M
m=1 λmhm(x)). Considering (Xi, Yi), i ∈ [1, n] to be i.i.d.
samples where Yi ∈ {−1, 1} and Xi ∈ x then the sequence is determined by,
0. Let c1 = c2 = ... = cn = 1, and set m = 1.
1. Find hm = argmaxh∈H
∑n
i=1 cih(Xi)Yi. Set
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λm =
1
2
log(
∑n
i=1 ci +
∑n
i=1 cihm(Xi)Yi∑n
i=1 ci −
∑n
i=1 cihm(Xi)Yi
) =
1
2
log(
∑
hm(Xi)=Yi
ci∑
hm(Xi) 6=Yi
ci
) (2.27)
2. Set ci ← ciexp(−λmhm(Xi)Yi), and m← m+ 1, If m ≤M , return to step 1.
In step 1 the algorithm finds the simple classifier in H that has the smallest
weighted misclassification and then calculates the corresponding lambda based
on the ratio of correct classifications to misclassifications. The weights that de-
termine the importance of correctly classifying each datapoint are then updated
in step 2. If the simple classifier misclassified datapoint i then −λmhm(Xi)Yi will
be positive and therefore the weight given to it will increase, alternatively if the
classifier was correct the weight will decrease. Boosting has been shown to often
work well but it has been hypothesised that results by boosting may be impeded
when there is noise present in the training set [46; 59].
The random forest is a non-parametric ensemble classifier that produces a
‘forest’ containing multiple decision trees and determines the class based on ma-
jority voting whereby each tree in the forest is given one vote [24]. Each decision
tree is built on a different random sample of the training set, where sampling is
done with replacement.
Let the training set Dn = {(X1, Y1), (X2, Y2), ..., (Xn, Yn)} consists of n i.i.d.
pairs of random variables sampled from the joint distribution (X, Y ) whereX = R
and Y = {0, 1}. We represent the marginal distribution of X by µ(x) = P{X =
x} and the posteriori probability by η(x) = P{Y = 1|X = x}. The probability
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of a classifier gn misclassifying is,
L(gn) = P{gn(X,Dn) 6= Y }
It has been shown that the Bayes classifier, g∗(x) = 1{η(x)≥1/2} , minimises the
probability of error [45] and this probability of error for the Bayes classifier L(g∗)
is referred to as the Bayes risk. A sequence of classifiers ({gn}) is consistent for
the distribution (X, Y ) if ∀ǫ > 0 ∃N ∈ N s.t. ∀n ≥ N |L(g∗)− L(gn)| < ǫ.
A randomised classifier gn(X, θ,Dn) uses a random variable θ to determine its
prediction, where θ takes its values from some measurable space. The probability
of error for the randomised classifier can be calculated as,
L(gn) = P{gn(X, θ,Dn) 6= Y |Dn}
Givenm identically distributed draws from the random variable θ, θm = (θ1, ..., θm)
where each of the θis are considered independent conditionally on X, Y and Dn,
the random forest classifier is constructed such that it takes the majority vote of
m decision trees by,
g(m)n (x, θ
m, Dn) =


1 if 1
m
∑m
j=1 gn(X, θj, Dn) ≥
1
2
0 else
(2.28)
In [13], they prove that if the sequence of random classifiers is consistent then
so is the voting classifier. This result implies that if the sequence of random
decision trees generated by the random forest is consistent then the probability
of error of the random forest tends to the Bayes risk as the number of random
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trees increases. One example of the randomisation procedure used to generate
the random classifiers by the random forest is to use bagging. In this case each
decision trees is built on a random sample of the training data. Another common
method is to randomly sample from the attributes available in the training data
and train each tree on a difference set of attributes. Some random forest classifiers
incorporate the randomness by generating decision trees that interactively pick
a random attribute to partition the attribute space until each partition only
contains a single data-point from the training set, and then the class returned
for a new data-point is the class of the training data-point corresponding the the
subspace that the new data-point is in [24]. This method has been shown to have
similarities with the nearest neighbour classifier [110].
2.2.1.4 Supervised Learning Summary
In this section the statistical learning theory undermining supervised learning
was summarised and the main supervised classifiers currently implemented were
presented. It is clear that given sufficient historical data it is possible to learn
underlying patterns within the data that can be used to form future predictions.
As the THIN database contains a large quantity of historical data, supervised
learning techniques can be applied with the aim of inferring medical information
that can help improve current healthcare. In the later parts of this section the
ensemble classifiers, that make use of multiple classifiers with the aim of improving
the classifying accuracy on average, were discussed. In particular, the focus was
aimed towards the random forest as this classifier can be applied to heterogeneous
data and by incorporating bagging it can be more resilience to noise. These are
the two key issues associated with the THIN database, suggesting the random
73
forest may have excellent performance when applied to classify ADRs using the
THIN database.
The majority of existing algorithms for signalling ADRs using electronic health-
care databases are unsupervised as they do not include known ADR labels when
detecting patterns and instead find general structures of interest within the data.
The reason few supervised algorithms exist is due to the lack of known ADRs pre-
venting the ability to have sufficient quantities of labelled data. However, if these
labels can be discovered then a supervised algorithm, with appropriate attributes,
may significantly outperform its unsupervised counterpart. Due to clinical tri-
als and knowledge gained over the time that a drug is actively prescribed, some
ADRs are definitively known and could be used as labels. If there are some labels
but not enough, then an alternative method would be to apply semi-supervised
learning. Semi-supervised learning is a mixture of supervised and unsupervised
learning techniques. In involves the inclusion of unlabelled data-points into the
training stage of an algorithm when there is a small number of labelled data-
points [30]. It is often observed that including unlabelled data-points during
training can lead to an improvement in performance of the algorithm [30]. This
is discussed further in the next section.
2.2.2 Semi-Supervised Learning
2.2.2.1 Introduction
Supervised classification was previously introduced, where the aim is to find a
function that approximates the joint distribution between the random variables
X and Y when given n random i.i.d. samples. Unfortunately, it is not always
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possible to observe both X and Y together a sufficient number of times as the
label Y can be scarce or costly to determine [30]. When the number of labelled
samples in the training set is low, any classifier trained on the data is likely to
perform poorly [140].
When the number of labelled data-points are scarce but unlabelled data-points
are readily observable, under certain assumptions, knowledge of the marginal dis-
tribution can result in an improvement in the function that approximates the joint
distribution. Semi-supervised learning algorithms make use of unlabelled data-
points to learn the marginal distribution and incorporate this in addition to the
labelled data-points when inferring the joint distribution. Formally, given both
labelled ({(Xi, Y )}
l
i=1) and unlabelled ({Xi}
l+u
i=l+1) data the aim of the supervised
learner is to infer the joint probability distribution P (X, Y ) where the labelled
data-points are i.i.d. samples from the joint distribution and the unlabelled data-
points are i.i.d. from the marginal distribution P (X). In general there are more
unlabelled data-points, l << u
In the remainder of this introduction, the main semi-supervised techniques
are summarised and the limitations associated to the assumptions they make to
enable the incorporation of unlabelled data are discussed.
Self-training Algorithm
The self-training algorithm [40] trains a classifier on the labelled data and then
applies the trained classifier on the unlabelled data to predict their class. The
algorithm then assumes that some of the predicted classes of the unlabelled data-
points are true and moves these from the unlabelled dataset into the labelled
dataset. The algorithm continues until the unlabelled dataset is empty. Gener-
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ally the algorithm considers the model predictions for the unlabelled data-points
with the greatest prediction confidences to be true, however, this is not always
the case when the classes are non-separable [215]. Consequently, the self-training
algorithm can perform poorly when the classes are non-separable. Early mistakes
can have huge impacts as misclassifications will be incorporated into the training
of the classifiers in future iterations, potentially leading to further misclassifica-
tions.
Probability Generating Models
The aim of each classifier is to identify the most probable class given the in-
put, argmaxY p(Y |X), and this can be determined using a generative model.
The generative model makes use of Bayes rule to show that argmaxY p(Y |X) =
argmaxY p(X|Y )p(Y ) and this implies that the class can be determined when
the conditional distribution p(X|Y ) and marginal distribution p(Y ) are known.
If the conditional distribution and marginal distributions are assumed to come
from a specified model then given the training data D, the most likely parameter
value θ is,
θˆ = argmax
θ
p(D|θ) = argmax
θ
logp(D|θ) (2.29)
and
logp(D|θ) = log(
l∏
i=1
p(Xi, Yi|θ)
l+u∏
l+1
p(Xi|θ))
=
l∑
i=1
logp(Yi|θ)p(Xi|Yi, θ) +
l+u∑
l+1
logp(Xi|θ)
The Expectation Maximisation (EM) algorithm [120] can find the value of θ that
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locally maximises p(D|θ). The limitations with the probability generating models
are that the probabilistic model needs to be defined and an incorrect model will
lead to inaccurate results [215]. It can be difficult to determine the conditional
distribution if the number of labelled data-points is small [215]. This technique
is more appropriate if there is additional knowledge about the data (e.g., the
distribution the data come from is known).
Co-training
The semi-supervised method of co-training [16] is when two different classifiers
are trained, in a similar style to self-training except they learn from each other
and unlabelled data is iteratively added to each classifier’s labeled data based
on the predictions of the other classifier. The process of co-training at learning
speed k is,
1. Initially let the training sample be L1 = L2 = {(X1, Y1), ..., (Xl, Yl)}.
2. Repeat until unlabelled data is used up:
1. Training a view-1 classifier f (1) from L1 and a view-2 classifier f
(2)
from L2.
2. Classify the remaining unlabelled data with f (1) and f (2) separately.
3. Add f (1)’s top k most-confident predictions (X,f (1)(X)) to L2.
Add f (2)’s top k most-confident predictions (X, f (2)(X)) to L1.
Remove these from the unlabelled data.
In effect, the algorithm forces the two classifiers, using different views, to agree
on the prediction of the unlabelled data, and the chance of overfitting is reduced.
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The co-training algorithm assumes that the data can be partitioned into two
different views but how this is done is not always obvious. One limitation of this
algorithm is that it requires the two views to be conditionally independent given
the class [41],
P (X(1)|Y,X(2)) = P (X(1)|Y )
P (X(2)|Y,X(1)) = P (X(2)|Y )
Although in [6] the authors argue that the conditional independance can be re-
laxed. They suggested that co-training can be applied as long as the two views
are not highly correlated. However, many situations are likely to violate this
assumption. For example, in the context of classifying a drug-medical event pair
as a side effect, if one view uses the knowledge of when the drug occurs relative
to the medical event and the other view uses association strength, these views
are likely to be highly correlated. If the drug is only observed before the medical
event occurs and not after then this will probably mean there is also a strong
association between the drug and medical event.
In Chapter 2.2.1.1, the error of a classifier was shown to be bounded by the
training error and the term that corresponds to the complexity of the model. It is
known that a complex model that minimises the training error may not generalise
well to unseen data as it may over-fit. Co-training aims to reduce the complexity
of a model by restricting the function space, and therefore reduces the error [215].
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2.2.2.2 Semi-Supervised Clustering
When there are no labelled data available, unsupervised techniques such as clus-
tering are applied to find intrinsic patterns within the data [88] without learning
from labelled data. Examples include the k-means clustering that initially assigns
each data-point into a random cluster and then iteratively moves each data-point
into the cluster that is closest [73]. The distance between the data-point and each
cluster is based on the cluster centre, the average of the data-points within that
cluster. Recent semi-supervised techniques have involved the incorporated of a
small number of labelled data to bias the clustering [7]. For example, in [7] the
authors use the labelled data to determine the initial centres in the k-means clus-
tering algorithms and fix the labelled data-points into one cluster. Alternative
approaches to improving clustering with additional knowledge has involved using
must or cannot be in the same cluster constraints [191] or interactive clustering
[32], where the semi-supervised clustering algorithm adapts based on feedback.
If the labels are given, the seed-constrained K-means clustering algorithms,
developed in [7] improves the unsupervised k-means algorithm by using the labels
data to determine the initial cluster centres and then applies the k-means algo-
rithm while fixing the labelled data to their known cluster. The set of data-points
input into the seed-constrained K-means algorithm is the set {x1,x2, ...,xn}, the
value of K input is k (the maximum number of classes in the labelled data) and
the initial seeds are Sl = {xi : xi is labelled as class l}. The seed-constrained
k-means algorithm is described in Algorithm 1.
As there will be labels rather than constrains for the ADR detection problem,
the seed-constrained K-means algorithm presents a simple and efficient solution
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Input : Set of data-points X = {x1,x2, ...,xn}, xi ∈ R
d, number of
clusters K, the set S = ∪Kl=1Sl of initial seeds.
Output: Disjoint K partitioning {Xl}
k
l=1 of X such that the KMeans
objective function is optimised.
Initialization: µ
(0)
h ←
1
|Sh|
∑
x∈Sh
x, for h = 1, ..., K; t← 0
repeat
For x ∈ S, if x ∈ Sh assign x to the cluster h (i.e., set X
t+1
h ). For x 6∈ S,
assign x to the cluster h∗ (i.e., set X t+1h∗ ), for h
∗ = argmin
h
‖x− µ
(t)
h ‖
2
µ
(t+1)
h ←
1
|X
(t+1)
h |
∑
x∈X
(t+1)
h
x
t← (t+ 1)
until convergence;
Algorithm 1: The seed-constrained K-means algorithm developed in [7]
if the number of labelled data are low. A common problem with clustering is
that the measure of distance this is most suitable for a given problem is generally
unknown [210]. The Euclidean distance metric is the standard one implemented,
but this treats each attribute equally and assumes the attributes are independent
[208]. For many clustering problems these assumptions are unrealistic. This has
prompted researchers to develop methods that use the limited number of labelled
data available for semi-supervised learning to learn the optimal metric space. By
learning the suitable metric space, clustering techniques can be improved [208].
2.2.2.3 Metric Learning
An area of recent research is using additional knowledge to determine the optimal
metric, see [99] for a summary. As clustering looks for closely connected com-
munities within the data, the measure of ‘closeness’ will impact the results, and
the standard Euclidean distance may not be most suitable [208]. In [211] the au-
thors proposed learning the metric prior to clustering, whereas in [14] the metric
learning is embedded into the clustering and gets applied during each iteration.
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In [211], the authors proposed a metric learning algorithm that uses knowledge
of constraints (i.e. labelled data-points that are in the same cluster as must-link
and data-points that are in different clusters as cannot-link) to learn a mapping
from the original attribute space into a new space that maximises the distance
between data-points in different clusters while adding a constraint to the maxi-
mum distance that data-points in the same cluster can be apart. The algorithm
applies eigenvalue optimisation and is highly efficient.
The known constraints are used to determine S, representing the set of all
index pairs for data-points that are similar (e.g., (1, 3) ∈ S means that data-point
1 and data-point 3 are known to be in the same cluster), and D, representing
the set of index pairs for data-points that are different (e.g., (1, 5) ∈ S means
that data-point 1 and data-point 5 are known to be in different clusters). The
inner product of two d × n real valued matrices, A,B ∈ Rd×n, is denoted by
〈A,B〉 :=Tr(ATB), where Tr(A) means the trace of the matrix A and the cone
of positive semidefinite matrices is denoted by Sd+.
Given a pair of data-points xi,xj ∈ X
Di
L , the matrix Xij = (xi−xj)(xi−xj)
T .
If τ = (i, j) is an index pair, then Xτ ≡ Xij. The matrix XS is defined
by XS =
∑
(i,j)∈S Xij and
∼
Xτ = X
−1/2
S XτX
−1/2
S . The authors calculated that
∇fµ(S
µ
t ) =
∑
τ∈D e
−〈
∼
Xτ ,S〉/µ
∼
Xτ
∑
τ∈D e
−〈
∼
Xτ ,S〉/µ
. The metric learning process, that uses these matri-
ces, is presented in Algorithm 2.
The must-link and cannot-link constrains can be determined when some la-
belled drug-medical event pairs are known. The must-link pairs are all combina-
tion consisting of any two of the known ADRs pairs or all combinations consisting
of any two of the known non-ADRs pairs. The cannot-link pairs are all the possi-
ble combinations consisting of one of the known ADR pairs and one of the known
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Input :
• smoothing parameter µ > 0 (e.g., 10−5)
• tolerance value tol (e.g., 10−5)
• step sized {αt ∈ (0, 1) : t ∈ N}
Output: d× d matrix Sµt ∈ S
d
+
Initialization: Sµ1 ∈ S
d
+ with Tr(S
µ
1 )= 1
for t = 1, 2, 3, ... do
Zµt =argmax{fµ(S
µ
t ) + 〈Z,∇fµ(S
µ
t )〉 : Z ∈ S
d
+, Tr(Z)=1 }, that is,
Zµt = νν
T where ν is the maximal eigenvector of the matrix ∇fµ(S
µ
t )
Sµt+1 = (1− αt)S
µ
t + αtZ
µ
t
if |fµ(S
µ
t+1)− fµ(S
µ
t )| < tol then break
end
Algorithm 2: The distance metric learning algorithm from [211]
non-ADR pairs. It is then possible to apply the metric learning described by
Algorithm 2 to efficiently learn the optimal metric space.
2.2.2.4 Semi-Supervised Learning Summary
In this section the frequently applied semi-supervised techniques have been sum-
marised. The semi-supervised techniques can, under certain assumptions, im-
prove classification/clustering by incorporating the unlabelled data when the
number of labelled data are scarce [30]. Out of the semi-supervised classification
techniques discussed (i.e, self-training, co-training and probability generating),
the self-training algorithm is most applicable for classifying ADRs due to the
probability generating algorithm requiring prior knowledge of the distributions
[215], of which is unknown, and the difficulty with determining the non-correlated
views required by the co-training algorithm.
Alternatively, the most suitable semi-supervised clustering technique is the
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seed-constrained k-means [7] algorithm as this is efficient and takes advantage of
the labelled data available. However, as discussed previously, clustering can be
improved by applying metric learning [208]. As the ADR classification/clustering
is required to be efficient, a suitable metric learning algorithm to apply to im-
prove the clustering and ensure efficiency is the one presented in [211]. The
choice of semi-supervised classification or semi-supervised clustering will need to
be determined.
2.2.3 Pattern Recognition Summary
Statistical learning theory is a field of research that aims to learn or identify
intrinsic patterns within data. These patterns can then be applied to make future
predictions, and in the medical context, they can be used to aid decision making
such as what drug to prescribe to a patient. When there are a sufficient number
of labelled data, supervised learning can be applied whereby a general function is
learned that accurately maps the input into the output. Numerous methods have
been proposed that can produce a function that has a minimal training error but
will also perform well on future data [39; 56; 81; 84; 101]. Ensemble methods have
been presented that are able to combine multiple classifiers to reduce the variance
and can improve the classification accuracy. Unfortunately, issues arise when
using real life data. Such examples include the introduction of noise, difficulties
generating labels or the presence of missing data. Ongoing research aims to
develop methods that can produce an accurate function when there are issues
present. In the case of insufficient labels, semi-supervised techniques have been
proposed that make use of unlabelled data [215]. However, there is no guarantee
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that semi-supervised algorithms will outperform their supervised counterpart [30].
Nonetheless, semi-supervised techniques have been successfully implemented on
real life problems [108] and may be suitable for determining ADRs when there is
a lack of known ADRs.
2.3 Literature Review Summary
The first section of the literature review focussed on the current techniques being
applied by the pharmacovigilance community. The literature is full of techniques
for signalling ADRs using LODs, but no method has been presented that was de-
veloped specifically for the THIN database and few studies have applied a range
of methods on the THIN database. Therefore, there has been no extensive analy-
sis of applying ADR signalling methods on the THIN database and a benchmark
is unknown. The current research does highlight the inherent difficulties in accu-
rately determining current benchmarks for ADR signalling techniques, and this
will need to be addressed in order to find the THIN benchmark.
The majority of existing methods for signalling ADRs using LODs rely on
measures of association strength or temporality and do not cover the seven other
Bradford-Hill causality considerations [19]. Furthermore, they do not take into
consideration attributes specific to the database being used, but database specific
attributes may offer a unique insight into causality. As a consequence, the existing
ADR signalling methods tend to be affected by confounding and this causes
them to generate many false positives [156]. It may be possible to reduce the
negative effects of confounding by generating attributes for each drug-medical
event pair based on the remaining seven Bradford-Hill causality considerations
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or by generating attributes specific to the database. The justification is that the
Bradford-Hill causality considerations help distinguish between association and
causation, something that is currently lacking within the existing methods. This
may then result in a low false positive rate.
The existing ADR signalling techniques developed for LODs are unsuper-
vised, as they do not learn from drug-medical event pairs that are known ADRs
or non-ADRs. The reasoning being that it is difficult to obtain a large number of
drug-medical event pairs with definitive ADR or non-ADR labels. However, if a
sufficient number of ADR and non-ADR pairs were determined, then supervised
or semi-supervised techniques could be applied, using suitable attributes, to iden-
tify new ADRs. The semi-supervised techniques may be advantageous when the
number of labelled drug-medical event pairs are limited, for example in the case
when a drug is rarely prescribed, then its ADRs may be generally unknown and
the number of labelled data will be small.
A supervised or semi-supervised technique that uses attributes based on the
Bradford-Hill causality considerations or specific to the THIN database may be
able to reduce the negative effects of confounding by identifying and utilising
patterns linked to ADRs or non-ADRs. The random forest ensemble algorithm
is a suitable classifier to apply when there is a sufficient number of labelled data
due to its ability to handle heterogeneous data and its resilience to noise. When
the number of labelled data is low, a self-training algorithm or a semi-supervised
clustering algorithm may yield improved results. If such an algorithm signalled
ADRs with a low false positive rate, then a larger number of drug-medical event
pairs likely to correspond to ADRs could be evaluated extensively by rigorous
epidemiological studies, and this is likely to result in new ADRs being discovered
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efficiently. In addition, the supervised/semi-supervised technique that considers
more than just the association strength and temporality factors of the Bradford-
Hill causality considerations (and may reduce the effects of confounding) is likely
to outperform the existing ADR signalling methods on the THIN database and
on the OMOP standard reference.
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Chapter 3
Existing Methods Comparison
‘One result from the DOI-HOI experiment was a number of
reproducibly high false positive rates across methods and
data sources.’
Dubey et al. [48]
3.1 Introduction
So far in this thesis, the research hypotheses and aims have been defined and the
current research within the field has been summarised. Numerous ADR signalling
methods, specific for LODs, have been proposed, but few have been applied
directly on the THIN database. As there has been no extensive application of
existing methods applied on the THIN data, the general benchmark is unknown.
As the aim of this research is to developed a suitable ADR signalling algorithm
specifically for the THIN data, it is necessary to determine the current benchmark
(i.e., the suitability of the existing methods on the THIN database).
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3. Existing Methods Comparison
In this chapter, the motivation for choosing two different types of comparison
is given and followed by a description of the existing method implementations.
The methodology used to determine the ‘true’ labels for each drug-medical event
pair is proposed, as the signals generated by each method will be compared
with the ‘truth’. The various measures used to analyse each method’s signalling
ability are then presented and the comparisons are conducted. The chapter ends
with a summary of the key results of both comparisons and the ADR signalling
benchmark values for the THIN data are presented.
3.2 Motivation
ADRs are a consequence of multiple factors, for example, an ADR may only occur
when the patient is a certain age and gender, eats a specific diet or has certain
ongoing illnesses [94]. As a consequence, ADRs are difficult to identify and it is
common for many ADRs to be unknown [147]. This means there is no extensive
gold standard, as there is no complete list of definitive ADRs for any drug, and this
makes it difficult to accurately benchmark ADR signalling algorithms. Motivated
by the lack of gold standard, in [179], the authors developed a list of drug-medical
event pairs known to represent ADRs or non-ADRs, but, although the list it
expanding over time [70], it initially only considered four medical events. Further
research has focused on producing a larger reference standard [33] containing
drug-medical event pairs with definitive labels, but the number of drug-medical
pairs is still often less than a hundred.
In previous studies, on non-THIN data, the authors have used the HOI-DOI
reference standard containing 53 drug-medical event pairs with definitive labels,
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and applied the existing methods to these pairs to determine how they compare
and set an approximate benchmark [156]. In [156] the TPD and ROR05 signalled
16 drug-medical event pairs out a possible 53, with 6 and 4 known ADRs being
signalled respectively. The benchmarks, over a range of electronic healthcare
databases, for the TPD were an AUC of 0.73 and AP of 0.41 and for ROR05
an AUC of 0.68 and an AP of 0.2. The study also concluded that the existing
methods obtain a similar performance and the existing methods have a high false
positive rate, this was also evident in [162]. In the later study, the benchmark
AUC obtained was 0.83.
A previous study determined the benchmark for the signalling ability of exist-
ing methods on the THIN database using the HOI-DOI reference standard [214].
The paper applied three existing methods, including the PRR and USCCS, to
the THIN database mapped into the common data model and the raw THIN
database. The results of the study, on the HOI-DOI reference standard, showed
that the PRR and USCCS returned sensitivity values of 0.67 and 78 respectively
and specificity values of 0.68 and 59 respectively on the mapped THIN database.
Similar values were obtained by applying the PRR on the raw THIN data. Un-
fortunately, as the HOI-DOI reference standard restricts the analysis to a small
subset of drug-medical event pairs, the impact of false positives is likely to be
reduced (as there are less pairs to generate false positive on). This comparison
may also add bias due to the choice of HOIs and DOIs included in the analysis.
For example, the known ADRs included in the HOI-DOI reference standard have
generally been signalled by numerous sources and may be easier to signal. Unfor-
tunately, there has been no analysis of existing methods on the THIN database
that includes a larger set of drug-medical event pairs, but this may be a more
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realistic analysis.
To enable an extensive analysis of the signalling ability of the existing meth-
ods on the THIN database, additional comparisons with different perspectives
and bias are required. The first perspective, referred to as the general compari-
son, generates signals using the existing methods for all the drug-medical event
pairs satisfying the condition that the medical event occurs for at least one patient
during the month after the drug. The true label for each drug-medical event pair
is determined using current knowledge of ADRs, where only drug-medical event
pairs currently known to be ADRs are considered true ADRs. Unfortunately,
the known ADR status of each drug-medical event pair is not definitive, as some
ADRs may be unknown, so this introduces error into the general comparison. The
second perspective, referred to as the specific comparison, is similar to compar-
isons previously conducted [156], as it only analyses drug-medical event pairs that
are either definitively non-ADRs or listed on drug packages as ADRs. However,
the specific comparison considers a larger number of drug-medical event pairs
than the HOI-DOI reference standard, so there may be less bias. The specific
comparison is less affected by a lack of ADR knowledge than the general com-
parison, but may have errors due to drug package listed ADRs being potentially
incorrect, due to the difficulty in determining causality.
In summary, as there is no gold standard, numerous comparisons need to be
conducted to determine an extensive benchmark for the existing methods sig-
nalling ability on the THIN database. The HOI-DOI reference standard bench-
mark has been determined but this benchmark is limited due to potential bias
caused by non-randomly selecting drug-medical event pairs. The general com-
parison will evaluate the methods without the selection bias, but will introduce
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bias due to a lack of ADR knowledge. Finally, the specific comparison is a trade
off between the previous comparisons and potentially contains bias from both
non-random selection and a lack of ADR knowledge, but both types of bias are
relatively reduced.
3.3 Existing Methods
To enable a fair comparison the TPD, MUTARA, HUNT and modified ROR
methods, described in Chapter 2.1.4.2 were applied to investigate the one to
thirty day period after the drug is prescribed (i.e., the month after). If each
method used a different time period, the comparison would be biased.
3.3.1 TPD
In this study the TPD was implemented as described in [128], with IC value
over the time period corresponding to the 30 days after the first prescription
in 13 months (u = [0, 30]) contrasted with the IC value over the time period
corresponding to the 27 to 21 months prior to prescription (v = [−822,−639]),
but two different filters were investigated:
• The TPD is applied and medical events with an IC value the month prior
to prescription or an IC value on the prescription day greater than the IC
value during the month after the prescription are filtered (TPD 1).
• The TPD is applied and medical events with an IC value the month prior
to prescription greater than the IC value during the month after the pre-
scription are filtered (TPD 2).
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The justification for choosing two filters is due to the possibility that ADRs can
occur and be reported to doctors on the same day as the prescription, so filtering
events with an IC value on the day of prescription greater than the IC value
during the month after the prescription may prevent detection of some ADRs.
3.3.2 MUTARA & HUNT
Two different lengths for the reference period were investigated as the length
of the reference period determines the per patient filter stringency and the op-
timal stringency is unknown for the THIN database. The reference period for
MUTARA60 and HUNT60 is set to be the time period starting from two months
prior to the prescription and ending the day before the prescription. The reference
period for MUTARA180 and HUNT180 is set to be the time period starting from
six months prior to the prescription and ending the day before the prescription.
The reference periods are chosen to end the day before the prescribed as this gave
better preliminary results. The other parameter values used are: Tc = Te = 30,
as this corresponds to the time period of a month after the drug prescription.
3.3.3 ROR
The ‘Spontaneous reporting system’ style transformation [216] is applied, where
SRS style reports consisting of a patient, drug prescription and possible ADR are
inferred from the LOD by discovering all the medical events that occur within 30
days of a drug prescription. Signals are only generated for medical events that
have been reported with the drug of interest a minimum of 3 times.
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3.4 Determining Labels
3.4.1 ADR Labels
The drug-medical event pair (α, β), consisting of a drug α and a medical event
β, that correspond to an ADR were found using the online medical website Net-
Doctor [176] or using SIDER [98], a side effect resource containing side effects
mined from drug packaging.
3.4.1.1 Online
The online medical website, NetDoctor, lists known ADRs for the majority of
drugs available. The ADR strings for a general drug α were mined from the
website. A string match was then applied to find the corresponding READ codes
( e.g, SELECT READcode FROM Drugcodes WHERE description like ’%ADR
string%’), and each of the READ codes (βis) that matched the NetDoctor listed
ADRs were paired to the drug α and added to the set ΨAˆ,
ΨAˆ = {(α, β)|β is listed as an ADR to α on NetDoctor }
3.4.1.2 SIDER
The SIDER side effect resource contains information on drugs’ ADRs and indi-
cations that were obtained by applying text mining to drug packaging. In total,
the resource contains 996 drugs, 4192 ADRs and 99423 drug-medical event pairs
corresponding to ADRs. The drug-medical event pairs, (α, β), corresponding to
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ADRs were extracted from SIDER to generate the set ΨA,
ΨA = {(α, β)|β is listed as an ADR to α in SIDER}
3.4.2 Noise Labels
The noise labels were manually extracted by examining the THIN READ code
tree. READ codes corresponding to irrelevant events such as ‘Family history’,
‘Nationality’, ‘Job type’, ‘Chronic illnesses’ (as this research is focusing on acute
immediately occurring ADRs) or ‘administrative events’ were extracted and paired
with all the drugs in the THIN database to generate the set ΨN ,
ΨN = {(α, β)|β is irrelevant , α ∈ THIN}
3.5 Measures
For each drug, α, and medical event, β, the existing algorithms determine a
measure of association between α and β. The TPD uses the IC∆05(α, β), MU-
TARA uses unexlev(α, β), HUNT uses the rank ratio, rank in descending order of
lev(α, β) divided by rank in descending order of unexlev(α, β), and the modified
SRS used the ROR05(α, β) (reporting odds ratio lower 95% confidence interval).
This measure of association is referred to as the rank score in the remained of
this chapter.
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Table 3.1: The signalling criteria of the existing methods
Method Rank Score Signal Criteria
TPD IC∆05 IC∆05 > 0
MUTARA unexlev unexlev > 0
HUNT Ranklev/Rankunexlev -
modified SRS ROR05 ROR05 > 1
Table 3.2: A worked example of comparing the existing methods signals and the
known truth.
Known Truth
ADR Non-ADR
Signalled
Yes
True Positive False Positive
(TP ) = 10 (FP ) = 200
No
False Negative True Negative
(FN) = 12 (TN) = 500
3.5.1 Natural Thresholds
The existing methods generate signals at their natural threshold, indicated in
Table 3.1. The methods performances at their natural thresholds are generally
uninformative as the natural threshold is an arbitrary cut off. However, in this
thesis I will present the methods performances at their natural thresholds to en-
able comparison with existing work that has used these thresholds. To determine
the method’s ability to signal ADRs, the signals at the natural threshold are com-
pared with the known truth. If a signalled drug-medical event pair is a true ADR
then it’s a True Positive, else it’s a False Positive, conversely, if a non-signalled
drug-medical event pair is a true ADR then it’s a False Negative, else it’s a True
Negative, as summarised in Table 3.2. The measures of interest for the natural
threshold can then be calculated as;
Sensitivity = TP/(TP + FN) (3.1)
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Table 3.3: An example of the medical event list associated to a specific drug and
ordered by an existing method’ rank score.
Medical Event Rank Score Known ADR y(i)
Event 1 2.34 No y(1) = 0
Event 5 2.12 Yes y(2) = 1 P (2) = 1/2
Event 4 1.75 Yes y(3) = 1 P (3) = 2/3
Event 2 1.74 No y(4) = 0
Event 3 0.68 No y(5) = 0
Specificity = TN/(TN + FP ) (3.2)
So, using the example in Table 3.2, the Sensitivity is 10/(10 + 12) and the speci-
ficity is 500/(500 + 200).
3.5.2 Ranking Ability
To determine the general ranking ability, each existing method is applied and
returns a ranked list of the drug-medical event pairs being investigated in de-
scending order of the rank score. Table 3.3 shows an example of the output of a
method when considering the ranking of the medical events paired to the same
drug. The function yi, known as the truth, is 1 if the i
th ranked medical event
is a known ADR and 0 otherwise. The precision of each method at cutoff K,
denoted P (K), is defined as the fraction of known ADRs that occur in the top
K events of the list returned by each method for a specific drug, see Eq. (3.3).
P (K) =
∑K
i=1 y(i)
K
(3.3)
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Table 3.4: An example of the medical event list for all the drugs and ordered by
one of the algorithms.
Drug Medical Event Rank Score Known ADR y(i)
Drug 10 Event 7 2.34 No y(1) = 0
Drug 10 Event 5 2.12 Yes y(2) = 1
Drug 2 Event 56 1.75 Yes y(3) = 1
Drug 9 Event 7 1.74 No y(4) = 0
Drug 2 Event 16 0.68 No y(5) = 0
The average precision (AP) is a measure that can be used to determine how well
a method generally ranks the medical events associated to a drug. This measure
has previously been applied to compare methods implemented on the common
data model [156]. The AP is calculated by finding the average P (K) for each K
corresponding to a known ADR,
AP =
∑
K:y(K)=1
P (K)∑
i y(i)
(3.4)
Using Table 3.3 as an example, as there are two known ADRs returned (
∑
i y(i) =
2) and the known ADRs in the table are ranked second and third we have {K :
y(K) = 1} = {2, 3}, so the AP score is,
AP =
P (2) + P (3)
2
=
1/2 + 2/3
2
=
7
12
(3.5)
To give a general measure of the ranking ability of each algorithm over all
the drugs investigated, the receiver operating characteristic (ROC) curves are
computed. The ROC plots were generated by combining all the results for each
method, as illustrated in Table 3.4. The ROC curves are formed by plotting the
sensitivity against (1−specificity). The Area Under the Curve (AUC) [28], was
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approximated using the trapezoidal rule for a range of specificity values (AUC[a,b]
corresponds to the partial AUC [193] when only considering the specificity within
the interval [a, b]). To compare the AUCs of various methods DeLongs test at a
5% signifiance level is implemented [44].
3.6 General Comparison
3.6.1 Method
For the general comparison the method was as follows.
Step 1: Find the set of drug-medical event pairs such that the medical event
is recorded within a [1, 30] day time period after the drug for any patient.
G = {(α, β)|β occurs within the [1, 30] day time interval centred around the
day of the prescription of drug α for any patient }.
Step 2: Determine the ground truth for each drug-medical event pair ((α, β) ∈
G),
Truth(α, β) =


ADR, if (α, β) ∈ ΨAˆ
non-ADR, otherwise
(3.6)
Step 3: For each drug-medical event pair ((α, β) ∈ G), calculate the method’s
rank score.
Step 4: • Natural threshold- Determine signals using rank score and signal
criteria. If (α, β) is signalled and Truth(α, β) is ADR then this is
a TP, otherwise it is a FP. Conversely, if (α, β) is not signalled and
Truth(α, β) is ADR then this is a FN, otherwise it is a TN.
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Table 3.5: The specificity and sensitivity at the natural thresholds for the different
algorithms (3dp).
Algorithm Signals Sens Spec Precision
HUNT60 7785 0.179 0.903 0.0541
HUNT180 7785 0.193 0.903 0.058
MUTARA60 67624 0.933 0.109 0.032
MUTARA180 65435 0.914 0.136 0.032
TPD 1 1893 0.090 0.953 0.057
TPD 2 3557 0.107 0.926 0.043
ROR05 37729 0.312 0.726 0.031
• General Ranking - Plot the ROC curves and calculate the AUCs using
the rank scores and Truth for each drug-medical event pair. The AP
is also calculated on the list of medical events for each drug that are
ordered in descending order of the assigned rank score, see Table 3.3.
The existing methods were applied to 27 drugs for 6 drug families, for information
about the drugs investigated, see Appendix B.
3.6.2 Results
Table 3.5 shows the specificity and sensitivity for the different methods at their
natural thresholds and the number of signals generated. As HUNT does not
have a natural threshold, the top 10% of medical events were considered to be
signalled.
The AUC[0,1] ranged between 0.546 (ROR05) to 0.597 (MUTARA180), the
AUC[0.7,1] ranged between 0.048 (ROR05) to 0.076 (MUTARA60) and the AUC[0.9,1]
ranged between 0.005 (ROR05) to 0.011 (HUNT180 and HUNT60), as presented in
Table 3.6. Figures 3.1a and 3.1b show the ROC plots for the different methods.
Figure 3.2a shows the AP scores for the different methods over the range
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(a) Whole specificity range
(b) Section of specificity greater than 0.7
Figure 3.1: The ROC plots for the different methods. The black line is the line
x=y.
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Table 3.6: The AUC results for the different algorithms (3dp).
Algorithm AUC[0,1] AUC[0.7,1] AUC[0.9,1]
HUNT60 0.566 0.072 0.011
HUNT180 0.570 0.071 0.011
MUTARA60 0.596 0.076 0.010
MUTARA180 0.597 0.069 0.010
TPD 1 0.570 0.065 0.009
TPD 2 0.557 0.060 0.007
ROR05 0.546 0.048 0.005
of drugs investigated. The family of drugs that the methods perform worse on
overall were the sulphonylureas with AP scores ranging from 0.0088−0.0687. The
algorithms all performed well on the calcium channel blockers, with AP scores
ranging from 0.0236−0.1988, but the ROR05 performed worse for all the calcium
channel blockers investigated. The methods also performed well for the tricyclic
antidepressants with AP scores ranging between 0.0499− 0.1670. It can be seen
in Figure 3.2a that generally the methods perform similarly between the same
drugs of the same class, apart from the methods performing much better for
benzylpenicillin sodium compared to the other penicillin drugs.
The box plots of the AP scores for the different methods seen in Figure 3.2b
show overall the TPDs, MUTARAs and HUNTs perform equally and outperform
the ROR05. The MUTARA algorithm has the highest median AP score over
all the drugs and is more consistent, whereas the performance of the TPD and
HUNT varies more between the drugs.
3.6.3 Discussion
The results show that the methods’ natural thresholds operate at different strin-
gencies. The most stringent method was the TPD 1 that returned 1893 signals,
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(a) Bar chart of the AP scores for each drugs.
(b) Box plot showing the median, quartiles and minimum/maximum AP scores.
Figure 3.2: AP results for each method applied for each drugs.
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the lowest out of all the methods, with a high specificity of 0.953 and low sensi-
tivity of 0.09, whereas the less stringent was the MUTARA60 that returned 67624
signals with a high sensitivity of 0.933 and a low specificity of 0.109. This was
not unexpected as the TPD threshold used the lower confidence interval value
rather than the actual IC∆ value and the TPD applied a statistical shrinkage.
The results also show that none of the methods was able to signal the known
ADRs without being swamped by false positives signals.
The AUC results show that the methods perform similarly and no method
had a higher partial AUC for all three restricted specificity intervals studied
(AUC[0,1],AUC[0.7,1] and AUC[0.9,1]). Overall no method consistently outperformed
the others over all the drugs investigated in this study, however, either the TPD
1 or HUNT had the highest AP score for the majority of the drugs studied. The
ROR05 generally performed the worse, but still had a higher AP score than the
other methods for the drug phenoxymethylpenicillin.
The results obtained in this study were consistent with previous results as
the P (10) for MUTARA and HUNT averaged 0.065 and 0.122 respectively in
this study and were 0.1 and 0.1− 0.3 respectively in previous work [91][90]. The
P (10) for the TPD method applied to Nifedipine in this study was 0.7, the same
as on the UK IMS Disease Analyzer database [128]. However, there was deviation
between the AP score of the ROR05 in this study (0.01− 0.06) and in the study
by Zorych et al. [216] (0.1-0.15), this is probably due to this study using real
data with redundant READ codes and Zorych et al. using simulated data. The
general comparison also demonstrated that the existing methods generate a large
number of false positive signals.
The main limitation of this comparative study was the assumption that if
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a drug pair (α, β) is not in the set of known ADRs, ΨA1 , then it is a non-
ADR. This is not true, as some pairs may be unknown ADRs, as there is no
definitive complete list of ADRs for any drug. The consequence of this is that the
true sensitivity, specificity and AP scores may be different to that the values
obtained. However, the methods should be able to correctly rank the known
ADRs and these are likely to be more common and obvious than the unknown
ones. Therefore, if the method is unable to correctly rank the known ADRs above
other events (and obtain a low AP in this study) then it is unlikely to identify the
unknown ADRs, so the AP scores determined in this study still give insight into
the methods abilities to detect ADRs. Another limitation was the READ code
redundancy. The negative effect of noise may get amplified due to the redundancy
causing there to be a larger number of noise READ codes. It may be the case
that the methods would have higher AP scores if there was a way to group READ
codes corresponding to the same medical event.
3.7 Specific Comparison
3.7.1 Method
Due to similar results being obtained in the general comparison by the MU-
TARA and HUNT methods implemented with different reference periods, only
the MUTARA180 and HUNT180 were applied for the specific comparison. The
method for the specific comparison is as follows.
Step 1: Find the definitive non-ADRs drug-medical event pairs corresponding
to the drug of interest α or the drug-medical event pairs listed as ADRs on
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α’s drug packaging, G = {(αˆ, β) ∈ ΨN
⋃
ΨA|αˆ = α}.
Step 2: Define the truth for each drug-medical event in G,
Truth(α, β) =


ADR, if (α, β) ∈ ΨA
non-ADR, if (α, β) ∈ ΨN
(3.7)
Step 3: For each drug-medical event pair ((α, β) ∈ G), calculate the method’s
rank score.
Step 4: • Natural threshold- Determine signals using rank score and signal
criteria. If (α, β) is signalled and Truth(α, β) is ADR then this is
a TP, otherwise it is a FP. Conversely, if (α, β) is not signalled and
Truth(α, β) is ADR then this is a FN, otherwise it is a TN.
• General Ranking - Plot the ROC curves and calculate the AUCs using
the rank scores and Truth for each drug-medical event pair. The AP
is also calculated on the list of medical events for each drug that are
ordered in descending order of the rank score assigned by the existing
method.
The existing methods were applied for five drugs, Nifedipine, Ciprofloxacin, Ibupro-
fen, Budesonide and Naproxen, see Appendix B.
3.7.2 Results and Discussion
For the specific comparison, MUTARA performed better at general ranking than
the other methods, with greater AUC, AUC[0.9,1] and AP values, see Table 3.7.
This result contradicts the general comparison results, that showed none of the
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Figure 3.3: The ROC plots for the specific comparison. The figure on the left
is the whole specificity range, the figure on the right is for the specificity within
the interval [0.9, 1]. The orange, red, yellow, green and blue curves correspond to
MUTARA180, HUNT180, TPD1, TPD2 and the ROR05 respectively.
106
3. Existing Methods Comparison
Table 3.7: The ranking ability of the existing methods obtained in the specific
comparison.
Method AUC AUC[0.9,1] AP
ROR05 0.5374 0.003 0.072
MUTARA180 0.770 0.032 0.315
HUNT180 0.678 0.023 0.222
TPD1 0.6149 0.007 0.095
TPD2 0.6197 0.006 0.094
Table 3.8: The signals returned by the existing methods at their natural thresh-
olds. The natural threshold used for HUNT was the rank ratio greater than
1.
Method TP FP FN TN Sensitivity Specificity Precision
ROR05 258 3197 429 4140 0.376 0.564 0.075
MUTARA180 614 4648 73 2689 0.894 0.366 0.117
HUNT180 466 4006 221 3331 0.678 0.454 0.104
TPD1 42 302 645 7035 0.061 0.959 0.122
TPD2 49 392 638 6945 0.071 0.947 0.111
existing methods outperforms any other when considering the overall ranking.
However, the TPD was the method that returned the least number of false pos-
itives and obtained the greatest precision, 0.122. In agreement to previously
obtained results, the specific comparison showed that the existing methods signal
many false positives at their natural thresholds, see Table 3.8.
To identify why the TPD’s ranking performance decreased relative to MU-
TARA for the specific comparison, the ranked list of drug-medical events pairs
returned by the TPD was manually investigated. Interestingly, the manual inves-
tigation showed that the READ code redundancy was to blame, as the TPD did
not assign a consistent IC∆05 for READ codes corresponding to the same medical
event, and the READ codes matching the SIDER ADR strings tended to have
lower IC∆05 values than other READ codes corresponding to known ADRs but
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not exactly matching the SIDER ADR string (e.g. If a SIDER ADR string was
‘vomiting’ , then the THIN READ code with a description ‘vomiting’ would be
labelled as an ADR, but ‘O:E vomiting’ or ‘[D] vomiting’ would not be labelled).
However, this does highlight that the TPD is not consistent and, although its
performance may improve if different labels were used, it still struggles to assign
a high IC∆05 to all READ codes corresponding to known ADR medical events .
Previous studies have also identified inconsistency with the TPD [80].
The specific comparison appears to be a better way to compare the methods
as the results are not limited by unknown ADRs. The potential bias introduced
by only considering a subset of drug-medical event pairs has the advantage of
highlighting methods that are not consistent. It can be argued that a perfect
method would assign a similar rank score to READ codes corresponding to the
same medical event, so methods unable to do this may be flawed.
3.8 Summary
In this chapter, four existing LOD ADR signalling methods were compared by
applying them to the THIN database for a range of drugs. The comparisons mea-
sured how well they ranked the known ADRs or signalled known ADRs at their
natural thresholds. As there is no golden standard, two different comparisons
were applied. The first comparison compared the methods on a wide range of
drug-medical event pairs but introduced bias by assuming there are no unknown
ADRs, whereas the second comparison removed the bias of assuming there are no
unknown ADRs but incorporated bias by only investigating a selection of drug-
medical events pairs and by assuming drug packaging listed ADRs are correct.
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The results highlight the issue of comparing existing methods without a golden
standard. If a golden standard existed (i.e., for one drug all the ADRs were
known), the methods could be applied to all the drug-medical event pairs for the
specific drug and accurate measures could be obtained. However, when there is
no gold standard, then bias is introduced and the results obtained may not be a
true reflection of the methods abilities.
Nonetheless, considering the results of both comparisons and previous studies,
the limitations of the existing methods were determined. The general comparison
showed that no method was superior over all the drugs considered, however the
specific comparison indicated that MUTATA is more consistently than the TPD.
The main conclusion is that, for both comparisons, the existing methods failed
to signal known ADRs without signalling a superfluous quantity of non-ADRs,
resulting in a low precision benchmark of 0.122 for the specific comparison and
0.058 for the general comparison. The general ranking benchmarks for the general
comparison are an AP of 0.2, an AUC of 0.597, an AUC[0.9,1] of 0.011 and an
AUC[0.7,1] of 0.076. The benchmarks for the specific comparison are an AP of
0.315, an AUC of 0.770 and an AUC[0.9,1] of 0.032. Future methods should aim
for higher scores.
Chapter 4
Incorporating Causation
‘The application of Austin Bradford-Hill’s criteria for
evaluation causal associations in pharmacovigilance and
pharmacoepidermiology is very useful.’
Saad A.W. Shakir [163]
4.1 Introduction
So far in this thesis, the current research focus was summarised and the existing
pharmacovigilance methodologies were presented. In the previous chapter the
benchmark measures were determined by applying the current ADR signalling
methods on the THIN database and it was concluded that they have a high
false positive rate. In this chapter the processes implemented to generate and
transform the data extracted from the THIN database are described. The main
focus is the proposal of suitable attributes that offer insight into causality. The
aim is to use these attributes as inputs into a learning algorithm that will be
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trained to signal ADRs with a low false positive rate.
4.2 Motivation
The main limitation of ADR signal detecting using LODs is the abundance of
confounding factors [68] [174]. The majority of medical events that occur after
a drug are related to pre-existing illnesses, but these are still strongly associated
to the drug. The existing methods can be considered unsupervised methods
that aim to approximate the measure of causation between a drug-medical event
pair. This is done by comparing the risk of the medical event after the drug
compared with a substitute, such as the risk in a control population [91] or the
risk when considering every other prescription [128]. Unfortunately, this only
measures association as the choice of substitute introduces confounding [117],
for example, as argued in [114], the choice of drug treatment may be influenced
by the patient’s medical history and the doctors preferences. To reduce the
number of signals corresponding to medical events that are related to the drug
cause, some authors have developed filters, such as ignoring medical events that
occur more often before the drug than after [128; 161]. The consistently high
false positive rate that occurs when the methods are applied to LODs suggests
that these filters are still unable to removed all the effects of confounding and
this hinders the effectiveness of the existing methods. The signals they generate
require further analysis [148] and rare ADRs may not be signalled [143].
To develop an improved ADR signalling algorithm, it is important to iden-
tify a way to distinguish between association and causation in observational data.
Such an algorithm would have a reduced false positive rate as it would be resilient
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against confounding effects. Causality is often determined using a randomised
controlled experiment [154], where treatments and controls are randomly assigned
to control confounding [153]. This cannot be implemented using observational
data, as there is no control over who is assigned a treatment. In [67], the authors
highlight the issues associated with using observational data for causal inference.
A common technique to identify causality using observational data is to apply
a supervised algorithm with additional knowledge that incorporates confounding
factors, such as fitting a regression model that incorporates parameters based
on confounding [58]. In [132] and [42] the authors manually investigated causal-
ity between a single drug and a single medical event by investigating suitable
measures of the Bradford-Hill causality considerations that can be derived from
pharmacovigilance data. The Bradford-Hill causality considerations are often
used when determining causation [164] and researchers have discussed the im-
portance of applying these considerations within pharmacovigilance [52]. In this
thesis, the idea is expanded by removing the requirement of a manual inspection.
Instead, an algorithm is implemented that learns to determine causality between
each drug-medical event pair based on Bradford-Hill causality derived attributes,
as this will increase efficiency and enable a wider search. The novel idea is to
train a supervised algorithm using attributes based on latent variables (not di-
rectly observed), derived from the Bradford-Hill causality considerations, rather
than observable variables. In this chapter, the attributes that add insight on
causality, derived from a selection of the Bradford-Hill causality considerations,
are proposed and explored.
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4.2.1 Data Cleansing
The THIN database contains validation fields indicating the integrity of each
record. Only records that are valid are extracted from the database and records
corresponding to patients with a missing date of birth or gender are deleted. Any
records containing an invalid age such as a negative number or greater than one
hundred and twenty years are also removed.
Patients whom are newly registered present a problem in the THIN database
as they often come to the practice with a magnitude of historical and existing
conditions that get recorded during their first few visits even when the condi-
tions initially occurred years previously. This is often referred to as ‘registration
event dropping’. Studies have shown that the probability of ‘registration event
dropping’ is significantly reduced after a patient has been registered at the same
practice for a year [104]. To prevent this biasing the results the medical records
that were recorded within the first year of each patient being registered are deleted
from the THIN database. The last month of prescription records for patients are
also ignored to prevent under-reporting, as implemented in [143].
4.2.2 Data Extraction
4.2.2.1 Formulation
Denoting the cleansed THIN data by Ω = {ΩP ,ΩE}, where ΩP is the set of
valid drug prescription reports and ΩE is the set of valid medical event reports
contained in the THIN database. Throughout this thesis, the ith element of the
vector x is represented by xi. Each prescription record, ω ∈ Ω
P ⊂ R8, is a vector
containing the details about the prescription, where ω ∈ R8 and,
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ω1 : is the corresponding record’s patient ID (who had the prescription).
ω2 : is the corresponding record’s prescribed drug.
ω3 : is the corresponding record’s gender (1 if male, 0 if female).
ω4 : is the corresponding record’s date of prescription (when the prescription was
issued).
ω5 : is the corresponding record’s patient’s age (time in days between the patients
date of birth and when the prescription was issued).
ω6 : is the corresponding record’s dosage (dosage of the drug issued).
ω7 : is the corresponding record’s British National Formulary (BNF) code (a
code specifying the general family of the drug).
ω8 : is the corresponding record’s noise value (the total number of drugs pre-
scribed within the [−30, 30] day time interval centred around the prescrip-
tion date).
Each medical event record in the complete THIN database, ψ ∈ ΩE ⊂ R5, is
a vector containing the medical event report details, where ψ ∈ R5 and,
ψ1 : is the corresponding record’s patient ID (who had the medical event).
ψ2 : is the corresponding record’s READ code (corresponding to medical event).
ψ3 : is the corresponding record’s date of recording (when the medical event was
reported).
ψ4 : is a binary value representing if a READ code with the same Level 3 READ
code parent as the record has been recorded for the patient before. If it is
the first time the value is 1, otherwise it is 0.
ψ5 : is a binary value representing if a READ code with the same Level 4 READ
code parent as the record has been recorded for the patient before. If it is
the first time the value is 1, otherwise it is 0.
114
4. Incorporating Causation
As it can be seen, each medical event is recorded via a READ code. The READ
codes have a tree structure with five levels of specificity, as described in Appendix
A. Therefore, the term drug-medical event pair is analogous to the term drug-
READ code pair. For clarity, the drug-medical event pair corresponding to drug
α and READ code β is denoted by (α, β). Unfortunately, the READ codes are
redundant, and multiple READ codes can correspond to the same medical event
but with slight variance in the description. For example, the READ code ‘91a..’
may represent ‘had a chat with patent’ and the READ code ‘91b..’ may represent
‘discussion with patient at his request’, both these READ codes correspond to
the medical event of talking to the patient, but differ slightly.
4.2.2.2 Extraction
For a given drug, α, it is possible to extract prescription records of interest in
three different ways. The first method extracts all the records containing the drug
α (where ω2 was previously denoted as the drug prescribed in therapy record ω),
ΩPα := {ω ∈ ΩP |ω2 = α} (4.1)
In the latter part of this chapter the prescription records in the set ΩPα are used
to find a rough measure of association, by investigating the medical events that
occur shortly before the drug compared with the medical events that occur shortly
after a drug. As there is no restriction on how far apart the prescription records
in the set ΩPα are for the same patient, some prescriptions, for the same patient,
may be recorded in short succession. This may cause bias when investigating the
medical events that occur shortly before one prescription, as they may be caused
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by the previous prescription.
To reduce this bias a second method to extract reports containing drug α is
proposed. For two therapy records, ω,
∗
ω ∈ ΩPα , the records correspond to the
same patient when both patient IDs are the same, ω1 =
∗
ω1, and correspond to
the same drug when ω2 =
∗
ω2. The second method only extracts reports if the
drug was not previously prescribed, to the same patient, within the previous 13
months,
ΩˆPα := {ω ∈ ΩPα | {
∗
ω ∈ ΩPα \ ω|ω1 =
∗
ω1, ω2 =
∗
ω2, tm(
∗
ω4, ω4) ∈ [0, 13]} = ∅}
Where the function tm(a, b) : Date×Date→ Z denotes the time in months from
date a to date b. As different drugs from the same family are often prescribed, due
to the first drug not being effective or the patient reacting badly, there can still be
bias when using ΩˆPα . To further reduce the bias, only prescription records where
there has been no previous prescription of a similar drug within the previous 13
months are considered,
Ω
Pα
:= {ω ∈ ΩPα | {
∗
ω ∈ ΩP \ ω|ω1 =
∗
ω1, ω7 =
∗
ω7, tm(
∗
ω4, ω4) ∈ [0, 13]} = ∅}
Figure 4.1 is a graphic representation of the different filtering that is imple-
mented to extract the data, where a drug is considered filtered if it is surrounded
by a red square. Each line represents the sequence of drug records ordered by
time, where drug 1 and 2 are from the same drug family (have the same BNF
code). The top line represents no filtering, so all drug records are included in the
analysis, the middle line represents filtering a drug if the same drug was recorded
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Key
i : unfiltered drug i i : filtered drug i
ΩP : 1
3 months
1
9 months
2
8 months
1
24 months
2
ΩˆP : 1 1 2 1 2
Ω
P
: 1 1 2 1 2
Figure 4.1: Illustration of filtering done during data extraction.
within 13 months previously, and the bottom line represents filtering a drug if a
drug in the same family was recorded within the 13 months previously. Using the
prescription record subsets for the drug α, it is possible to determine the ‘risk’
drug-READ code pairs that correspond to potential acutely occurring ADRs by
finding all the READ codes that occur within 30 days of any prescription of α,
see Equation 4.2. Figure 4.2 illustrates how the ‘risk’ drug-READ code pairs
corresponding to drug 1 are determined, where the medical events represented
by circles are paired with drug 1 if they occur between the square representing
drug 1 and the red line. A short time period is used as the focus of this research
is on discovering ADRs that occur immediately after ingesting a drug. It was
determined that investigating the 30 days after a drug is prescribed was the best
trade off between having a sufficiently large period of time after the prescription
to allow patients time to report the medical event while not having the time
period too large that many erroneous medical events will be reported.
RMEα = {ψ2|ψ ∈ Ω
E, ∃ω ∈ ΩPα where ω1 = ψ1, td(ω4, ψ3) ∈ [1, 30]} (4.2)
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Key
A : READ code A i : drug i
Pat 1: a1 1
30
1
30
f1
x6
a6 2 1
30
x6 2
Pat 2: h1 1
30
a1 x7
...
Pat n: f9 f4 h1 1
30
h1 4
Figure 4.2: Illustration of determining risk drug-medical event pairs.
where the function td(a, b) : Date × Date → Z represents the time in days from
date a to date b. One suitable approach to determine ADRs to drug α using LODs
is to combine medical event reports with prescription reports containing α when
the medical event report occurs within a set time frame around the prescription
report. Let Ω[u,v],Pα be a relationship between the prescription records of drug α
(ΩPα) and the medical event records (ΩE) defined by the records having the same
patient ID (ω1 = ψ1) and the medical event report occurring within the set time
period around the date of the prescription report (td(ω4, ψ3) ∈ [u, v]),
Ω[u,v],Pα = {(ω,ψ) ∈ ΩPα × ΩE|ω1 = ψ1, td(ω4, ψ3) ∈ [u, v]} (4.3)
As illustrated in Equation (4.3), each element in the set Ω[u,v],Pα contains the
combined prescription reports containing α and medical event reports of interest,
where the medical event report occurred with the [u, v] day interval around the
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prescription record. For each combined record, κ = (ω,ψ) ∈ Ω[u,v],Pα , the first
eight elements correspond to the prescription record (κi = ωi, i ∈ [1, 8]) and the
last five elements correspond to the medical event record (κi = ψi−8, i ∈ [9, 13]).
Similarly, the set of combined reports of interest can be calculated when only
considering the first time prescriptions in 13 months of drug α or the prescriptions
of drug α that have no similar drug prescribed within the previous 13 months by
substituting the set ΩPα with the set ΩˆPα or Ω
Pα
respectively,
Ωˆ[u,v],Pα = {(ω,ψ) ∈ ΩˆPα × ΩE|ω1 = ψ1, td(ω4, ψ3) ∈ [u, v]} (4.4)
Ω
[u,v],Pα
= {(ω,ψ) ∈ Ω
Pα
× ΩE|ω1 = ψ1, td(ω4, ψ3) ∈ [u, v]} (4.5)
The aim of this thesis is to develop a classifier such that, for each ‘risk’ drug-
READ code pair containing drug α, (α,β ∈ RMEα), the pair is classified as either
an ADR or non-ADR. To develop such a classifier requires generating suitable
attributes for each pair and learning from pairs that are known ADRs and non-
ADRs. In the next section the proposed attributes based on the Bradford-Hill
causality considerations and THIN structures are derived.
4.2.3 Data Derivation
After cleansing and extracting the data of interest, the data can now be trans-
formed into suitable attributes. The set of combined reports containing READ
code β that occur within the [u, v] time interval centred around the prescription
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Pat 1: a1 1
u
v
1
u
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f1
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a6 2 1
u
v
x6 2
Pat 2: h1 1
u
v
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Pat n: f9 f4 h1 1
u
v
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Figure 4.3: Illustration of combining drug records and medical event records.
of drug α is,
Ω[u,v],PαEβ = {κ ∈ Ω[u,v],Pα |κ10 = β} (4.6)
The equivalent sets when only considering the prescriptions of drug α for the
first time in 13 months or prescriptions of drug α when a similar family drug has
not been prescribed within the last 13 months are,
Ωˆ[u,v],PαEβ = {κ ∈ Ωˆ[u,v],Pα |κ10 = β} (4.7)
and
Ω
[u,v],PαEβ
= {κ ∈ Ω
[u,v],Pα
|κ10 = β} (4.8)
respectively.
This is graphically illustrated in Figure 4.3, where the medical event reports
are represented by circles and the drugs are represented by squares. For each
prescription of drug 1, the time interval [u, v] centred around the prescription
is investigated, and any medical event report occurring within the interval is
combined with the report to produce a new combined report.
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Table 4.1: Contingency table calculations for the epidemiological association mea-
sures.
READ code β not READ code β
Drug α |Ω[1,30],PαEβ | |Ω[1,30],Pα | − |Ω[1,30],PαEβ |⋃
γ 6=αDrugγ
∑
γ 6=α |Ω
[1,30],PγEβ |
∑
γ 6=α |Ω
[1,30],Pγ | −
∑
γ 6=α |Ω
[1,30],PγEβ |
4.2.3.1 Association Strength
‘Prospective inquiries into smoking have shown that the death rate
for cancer of the lung in cigarette smokers is nine to ten times the
rate in non-smokers’ - Bradford-Hill [19].
The association strength criterion concentrates on how associated the READ code
and drug are [19]. Previously implemented measures of association derived from
LODs are the IC∆ used by the TPD algorithm [128], see Chapter 2.1.4.2, or the
IC∆05. These values measure the association between the READ code and drug
during the ‘hazard’ period that occurs after the prescription relative to some
‘non-hazard’ time period.
xαβ1 = IC∆ (4.9)
xαβ2 = IC∆05 (4.10)
Alternative measures are the risk ratio (RR), odds ratio (OR) and risk dif-
ferent (RD) that are frequently used in epidemiological studies to measure the
association between an exposure and disease [194]. These measures contrast the
rate of disease in a population that is exposed to some risk with the rate of the
disease in a population not exposed. In [151] the author states that, if there are
other (non-drug) sufficient causes of a medical event, then the frequency of these
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has a greater impact on the medical event and drug’s risk ratio measure than
the risk difference measure. So the measures can generate varying strengths of
association for the same drug-READ code pair.
The RD investigates the additive difference between the risk of having the
READ code after the drug of interest is prescribed compared to the risk of having
the READ code after any other drug prescription [181]. Using Table 4.1 the RD
can be calculated by,
xαβ3 = (|Ω
[1,30],PαEβ |/|Ω[1,30],Pα |)− (
∑
γ 6=α
|Ω[1,30],PγEβ |/
∑
γ 6=α
|Ω[1,30],Pγ |)
xαβ4 = (|Ωˆ
[1,30],PαEβ |/|Ωˆ[1,30],Pα |)− (
∑
γ 6=α
|Ωˆ[1,30],PγEβ |/
∑
γ 6=α
|Ωˆ[1,30],Pγ |)
xαβ5 = (|Ω
[1,30],PαEβ |/|Ω
[1,30],Pα
|)− (
∑
γ 6=α
|Ω
[1,30],PγEβ |/
∑
γ 6=α
|Ω
[1,30],Pγ
|)
(4.11)
The RR estimates the risk of having the READ code in the month after the
drug of interest is prescribed divided by the risk of having the READ code in the
month after any other drug, the measure has been incorporated to signal ADRs
in SRS databases [9]:
xαβ6 = (|Ω
[1,30],PαEβ |/|Ω[1,30],Pα |)/(
∑
γ 6=α
|Ω[1,30],PγEβ |/
∑
γ 6=α
|Ω[1,30],Pγ |)
xαβ7 = (|Ωˆ
[1,30],PαEβ |/|Ωˆ[1,30],Pα |)/(
∑
γ 6=α
|Ωˆ[1,30],PγEβ |/
∑
γ 6=α
|Ωˆ[1,30],Pγ |)
xαβ8 = (|Ω
[1,30],PαEβ |/|Ω
[1,30],Pα
|)/(
∑
γ 6=α
|Ω
[1,30],PγEβ |/
∑
γ 6=α
|Ω
[1,30],Pγ
|)
(4.12)
The OR calculates the ratio between the odds that a READ code occurs in the
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drug of interest group and the odds that a READ code occurs in any other drug
group. There has been much debate into the usefulness of this measure, in [165]
the authors state that the OR should not be used in place of the RR although in
[194] they argue that the OR and RR are different measures and as long as the
OR is not considered on the same scale as the RR then it is worthwhile:
xαβ9 = (
|Ω[1,30],PαEβ |
[|Ω[1,30],Pα | − |Ω[1,30],PαEβ |]
)/(
∑
γ 6=α |Ω
[1,30],PγEβ |
[
∑
γ 6=α |Ω
[1,30],Pγ | −
∑
γ 6=α |Ω
[1,30],PγEβ |]
)
xαβ10 = (
|Ωˆ[1,30],PαEβ |
[|Ωˆ[1,30],Pα | − |Ωˆ[1,30],PαEβ |]
)/(
∑
γ 6=α |Ωˆ
[1,30],PγEβ |
[
∑
γ 6=α |Ωˆ
[1,30],Pγ | −
∑
γ 6=α |Ωˆ
[1,30],PγEβ |]
)
xαβ11 = (
|Ω
[1,30],PαEβ |
[|Ω
[1,30],Pα
| − |Ω
[1,30],PαEβ |]
)/(
∑
γ 6=α |Ω
[1,30],PγEβ |
[
∑
γ 6=α |Ω
[1,30],Pγ
| −
∑
γ 6=α |Ω
[1,30],PγEβ |]
)
(4.13)
4.2.3.2 Temporality
‘Does a particular diet lead to disease or do the early stages of the
disease lead to those peculiar dietetic habits?’ - Bradford-Hill [19].
The temporality criteria concerns itself with the direction of the relationship
between the READ code and drug. This is an important factor, and has been
highlighted in other criteria for causation [86]. It measures if the READ code
occurs after the drug, or the other way round. If the READ code and drug are
associated but the READ code frequently occurs before the drug, then this may
suggest the medical event corresponding to the READ code causes the drug and
not the other way round.
The first values of interest are the after and before ratios (AB ratios). The
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AB ratios calculate how many prescriptions of α have the READ code β recorded
between 1 and 30 days after the prescription divided by how many have the
READ code β recorded between 1 and 30 days before the prescription, this is a
basic implementation of the self controlled cross-over method.
xαβ12 = |Ω
[1,30],PαEβ |/|Ω[−30,−1],PαEβ |
xαβ13 = |Ωˆ
[1,30],PαEβ |/|Ωˆ[−30,−1],PαEβ |
xαβ14 = |Ω
[1,30],PαEβ |/|Ω
[−30,−1],PαEβ |
(4.14)
Other suitable attributes for the temporality criterion are the filters that have
been implemented by existing LOD ADR signalling algorithms, where xαβ15 and
xαβ16 correspond, respectively, to the TPD Filter 1 and the TDP Filter 2 , the
modified versions of the TPD filter applied initially in [128] and adapted in [143].
The final attribute, xαβ17 , is the output of the LEOPARD algorithm described in
[161].
4.2.3.3 Specificity
‘If the association is limited to specific workers and to particular sites
and types of disease and there is no association between the work and
other modes of dying, then clearly that is a strong argument in favour
of causation’ - Bradford-Hill [19].
The third Bradford-Hill consideration is how specific an association is. In gen-
eral, specificity is interpreted as the drug only causes a single, specific, ADR
[67]. Consequently, many researchers, including [151] and [67], argue this is not
very informative, as many drugs cause multiple ADRs . Other researchers have
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suggested modifying the interpretation of the specificity criteria [197]. Weiss ar-
gues that an association is specific when both the outcome and the exposure are
specific or when only specific people that are exposed have the outcome.
This prompts the novel specificity attributes proposed in this thesis. The first
considers how specific the READ code is, justification for this is that general
outcomes are likely to occur by chance as they probably have a high background
rate, but if a specific READ code occurs frequently after the drug of interest is
prescribed then this may give reason to suspect it as an ADR. The first specificity
attribute uses the READ code hierarchal level,
xαβ18 = i, where β corresponds to a level i READ code (4.15)
If the drug and READ code association is only found in a certain subpopulation
then this may also be suggestive of an ADRs. Therefore attributes are developed
based on the age and gender of the patients experiencing the READ code after
the drug compared to all the patients who are prescribed the drug. A suitable
method to measure if a specific age group experience β after α is to compare the
average age of the patients who experience β within 1 to 30 days after α with the
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average age of the patients prescribed α.
xαβ19 = (
∑
κ∈Ω
[1,30],PαEβ
κ5/|Ω
[1,30],PαEβ |)/(
∑
κ∈Ω[1,30],Pα
κ5/|Ω
[1,30],Pα |)
xαβ20 = (
∑
κ∈Ωˆ
[1,30],PαEβ
κ5/|Ωˆ
[1,30],PαEβ |)/(
∑
κ∈Ωˆ[1,30],Pα
κ5/|Ωˆ
[1,30],Pα |)
xαβ21 = (
∑
κ∈Ω
[1,30],PαEβ
κ5/|Ω
[1,30],PαEβ |)/(
∑
κ∈Ω
[1,30],Pα
κ5/|Ω
[1,30],Pα
|)
(4.16)
Justified by a similar argument, it is also useful to calculate a measure to compare
the ratio of patients that experience β within 1 and 30 days of α that are male
relative to the ratio of patients who are prescribed α and are male.
xαβ22 = (
∑
κ∈Ω
[1,30],PαEβ
κ3/|Ω
[1,30],PαEβ |)/(
∑
κ∈Ω[1,30],Pα
κ3/|Ω
[1,30],Pα |)
xαβ23 = (
∑
κ∈Ωˆ
[1,30],PαEβ
κ3/|Ωˆ
[1,30],PαEβ |)/(
∑
κ∈Ωˆ[1,30],Pα
κ3/|Ωˆ
[1,30],Pα |)
xαβ24 = (
∑
κ∈Ω
[1,30],PαEβ
κ3/|Ω
[1,30],PαEβ |)/(
∑
κ∈Ω
[1,30],Pα
κ3/|Ω
[1,30],Pα
|)
(4.17)
4.2.3.4 Biological Gradient
‘The fact that the death rate from cancer of the lung rises linearly
with the number of cigarettes smoked daily, adds a very great deal to
the simple evidence that cigarette smokers have a higher death rate
than non-smokers.’ - Bradford-Hill [19].
The biological gradient criterion in the context of ADR detection considers the
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dosage of the drug. Often, but not always the case, an ADR is more likely to occur
when the drug is ingested at a high dosage compared to a low dosage [36]. In [192]
the authors used the Pearson’s correlation and logistical regression to measure the
biological gradient. However, in [142], it was shown that the Pearson’s correlation
was difficult to calculate using data from the THIN database. Therefore different
measures are required.
The proposed novel biological attribute, calculated below, contrasts the aver-
age drug dosage for the patients that experience β within 1 to 30 days of α with
the average drug dosage for all the patients prescribed α,
xαβ25 = (
∑
κ∈Ω
[1,30],PαEβ
κ6/|Ω
[1,30],PαEβ |)/(
∑
κ∈Ω
[1,30],Pα
κ6/|Ω
[1,30],Pα
|) (4.18)
4.2.3.5 Experimentation
‘Because of an observed association some preventative action is taken,
Does it in fact prevent?’ - Bradford-Hill [19].
The final Bradford-Hill causality consideration investigated is experimentation.
There is deviation between the meaning behind experimentation, some authors
assume it relates to intervention (i.e. if the drug stops does the medical event,
if the drug restarts does the medical event follow?) [175], whereas others believe
it corresponds literally to experiments that have been conduced and their results
[64].
In this thesis we adopt the intervention interpretation and apply a retrospec-
tive investigation to find instances where a patient stopped taking the drug for a
while and then restarted, and refer to this as a retrospective intervention. Unfor-
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tunately, few patients experience retrospective interventions and this limits the
experimentation attribute’s usefulness. If a patient has two or more independent
prescriptions of the drug, it can be observed whether the medical event often
occurs shortly after the prescriptions but never shortly before. If this is the case,
then this is a very strong implication that the medical event is an ADR.
Equation 4.19 shows the calculation for the proposed novel attributes based
on the Bradford-Hill experimentation causality consideration. It is determined
by finding the number of patients that have READ code β within 1 to 30 days of
two or more independent prescriptions of α but never within 1 to 30 days before
any prescriptions of α divided by the number of patients that have two or more
independent prescriptions of α.
xαβ26 =
|{κ1|∃κ,
∗
κ ∈ Ω
[1,30],Pα,Eβ
, κ4 6=
∗
κ4, κ1 =
∗
κ1}
⋂
{κ1|κ 6∈ Ω
[−30,−1],Pα,Eβ}|
|{κ1|∃κ,
∗
κ ∈ Ω
[1,30],Pα
, κ4 6=
∗
κ4, κ1 =
∗
κ1}|
(4.19)
4.2.3.6 Other Criteria
The consistency, plausibility and coherence require additional resources for their
calculation and are not tackled in this thesis. The analogy factor is indirectly
incorporated by using a supervised algorithm, as attributes similarities for the
drug-READ code pairs corresponding to known ADRs are learned and used to
infer new ADRs.
4.2.3.7 THIN Specific
The attributes specific to the THIN database make use of the READ code struc-
ture and additional information available that might help distinguish between an
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ADR and non-ADR. The first attribute gives a measure of how much noise there
is present for the READ code β and drug α as it is harder to classify drug-READ
code pairs with a large measure of noise as the attribute values are likely to be
misleading. To determine the level of noise, the average number of prescriptions
that occur within the two month interval centred around the prescription of α is
calculated for all patients and compared with the average number of prescriptions
that occur within the two month time interval centred around the prescription of
drug α for the patients that also experienced READ code β within 1 to 30 days.
xαβ27 = (
∑
κ∈Ω
[−30,30],PαEβ
κ8/|Ω
[−30,30],PαEβ |)/(
∑
κ∈Ω
[−30,30],Pα
κ8/|Ω
[−30,30],Pα
|) (4.20)
The next attribute investigates whether, for each READ code β that occurs within
1 and 30 days of a prescription of α, the patient has previously experienced β (or
its level 3 parent). If many patients have previously experienced a more general
version of β but not β itself, then this is a sign that β is not an ADR to drug
α. The reason is that β is likely to have occurred due to an illness progression
rather than it being caused by the drug. This prompts,
xαβ28 = (
∑
κ∈Ω
[1,30],PαEβ
κ12)/(
∑
κ∈Ω
[1,30],Pα,Eβ
κ13) (4.21)
The final THIN specific attributes use the READ code structure to help distin-
guish between associations that are causal and associations that are due to illness
progressions. These attributes calculate the AB ratio when only considering the
more general versions of all the READ codes. Therefore, if the association has
occurred due to the illness progression, the AB ratio for the more general versions
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of the READ codes should be small, even if the AB ratio for the actual READ
code is large.
Letting Φβ3 denote the set of READ codes that have the same level 3 parent
as β, then the AB ratio is calculated on the transformed data,
xαβ29 = |
⋃
∗
β∈Φβ3
Ω
[1,30],Pα,E∗
β |/|
⋃
∗
β∈Φβ3
Ω
[−30,−1],Pα,E∗
β | (4.22)
Similarly, Φβ4 denotes the set of READ codes that have the same level 4 parent
as β and the AB ratio is calculated,
xαβ30 = |
⋃
∗
β∈Φβ4
Ω
[1,30],Pα,E∗
β |/|
⋃
∗
β∈Φβ4
Ω
[−30,−1],Pα,E∗
β | (4.23)
4.2.3.8 A Note on Dependency
Many of the attributes derived from the same Bradford-Hill causality consid-
erations may have some statistical dependency but also give slightly different
perspectives. The statistical dependency is unlikely to have any negative conse-
quences on the future classifiers as either feature selection is applied to remove
any redundancy or the methods are unaffected by statistical dependency. The
random forest is a decision tree based classifier; decision trees partition the at-
tribute space based on measures such as entropy. At each iteration the decision
tree will simply pick the partitioning of an attribute space based on how well it
separates the classes, dependency of two attributes will not have any negative
effect on this process. For the other classifier used throughout this research, fea-
ture selection will be performed prior to training. Feature selection will choose a
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subset of attributes to be used by the classifier that maximises its performance. If
two dependant attributes negatively affect the classifier then the optimal feature
subset will only contain a maximum of one of them.
4.2.4 Data Description
The attribute vector for a drug-READ code pair (α, β) is xˆαβ = (xαβ1 , x
αβ
2 , ..., x
αβ
30 ) ∈
R
30. The set Xˆα = {xˆαβi , βi ∈ RME
α} contains all the (α, βi) corresponding
Bradford-Hill causality consideration derived attribute vectors for the drug α and
each of its ‘risk’ READ codes βi (the READ codes recorded within 1 to 30 days
from any prescription of α).
4.2.5 Data Transformation
4.2.5.1 Continuous Attributes
The importance of processing the data has been stressed in [127], one vital stage
in processing is to ensure each attribute is treated equally by a classifier. This is
done by normalising the data. Normalisation scales the nominal attribute data
between two values [96], this ensures the optimal performance of some learning
algorithms [127]. The three frequently implemented normalisation techniques are,
N1 (z-score Normalisation, useful if data bounds are unknown)
f : X → X; fz−score(x) = (x− X¯)/(σX)
N2 (Min Max Normalisation, data are scale into the range [0, 1])
f : X → X; fMinMax(x) = (x−minX)/(maxX −minX)
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Table 4.2: The results of KNN with leave one out cross validation when the
different normalisations are applied to the data, k=8 (preliminary results showed
this was optimal).
Normalisation TP FP FN TN AUC
None 684 443 1080 7746 0.7885
N1 674 246 1090 7943 0.8055
N2 698 387 1066 7802 0.7567
N3 673 349 1091 7840 0.7561
N3 (Decimal Scaling Normalisation, data are scale into the range [−1, 1])
f : X → X; fdecimal(x) = x/10
j, j = min{j ∈ N|∀xi∈X |xi/10
j| < 1}
Table 4.2 shows the results when a KNN algorithm was applied with leave one
out cross validation on labelled data for 25 drugs with the data transformations
N1-N3 and no transformation. The optimal solution was obtained when the N1
transformation was applied, as the AUC was the greatest. Therefore, the N1
transformation will be used to transform any continuous attributes prior to any
learning algorithm in the remainder of this thesis.
4.2.5.2 Discrete Attributes
The discrete attributes, xαβ15 − x
αβ
18 are not normalised. The binary attributes do
not require any transformation, but the non-binary discrete attribute xαβ18 corre-
sponding to the READ code hierarchal level does. As described in [127], dummy
attributes (binary attributes corresponding to the each value of the discrete at-
tribute) are generated for xαβ18 , see Table 4.3 for an example. Due to the linear
dependancy between xαβ18 ’s dummy attributes, one can be discarded, so only four
of the dummy attributes are used. If we denote the z-score normalisation of the
continuous attributes and the creation of dummy attributes for the discrete at-
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Table 4.3: Example of how a discrete attribute is transformed into its dummy
attributes.
Orignal Dummy Attributes
READ code lv lv1 lv2 lv3 lv4 lv5
1 1 0 0 0 0
2 0 1 0 0 0
3 0 0 1 0 0
4 0 0 0 1 0
5 0 0 0 0 1
3 0 0 1 0 0
tributes by the mapping f : R30 → R33, then this leads to the transformed data
Xα = {f(x), x ∈ Xˆα}.
4.2.6 Feature Selection
In preliminary work I investigated the usefulness of different Bradford-Hill causal-
ity considerations based attributes for predicting ADRs. A multivariate filter
known as the Correlation-based Feature Selection (CFS) algorithm [69] was ap-
plied to a range of attributes. This feature selection technique aims to find a
subset of attributes such that each individual attribute in the subset is more cor-
related to the label/class than it is to other attributes in the subset. Therefore,
only attributes that offer new insight for predicting the label/class are included,
the others will be removed, as they are generally redundant. The paper detail-
ing this preliminary work can be found in appendix C. However, in the actual
framework proposed within this work, I will use wrapper feature selection prior to
the classification (except for random forest) as wrapper feature selection chooses
the attribute subset based on how well the classifier performs when trained using
only the subset of attributes, this is more useful than a multivariate filter as it
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considers the classifier performance rather than just relying on correlations.
A wrapper approach to feature selection implements a heuristic search through
the power set of the attributes. It aims to find the attribute subset that, when
used as input into a classifier, maximises the classifiers performance. For ex-
ample, consider the attribute set {x1, x2, x3}, the power set of these attributes
is {{}{x1}, {x2}, {x3}, {x1, x2}, {x1, x3}, {x2, x3}, {x1, x2, x3}}. A wrapper that
performs an exhaustive search will apply the classification using every possible
subset of attributes (all the power set) and choose the subset for which the clas-
sifier performed the best.
In general it is not suitable to perform an exhaustive search and a local optimal
subset (hopefully with a good performance) will be found instead. A forward
search starts with one attribute and iteratively investigates the addition of a single
attribute at a time until there is no further improvement possible. A backwards
search starts with all the attributes and iteratively investigates the removal of a
single attribute at a time until there is no further improvement possible. These
searchers described above are referred to as ‘greedy’ as the process of adding (or
removing) an attribute cannot be reversed once done. This leads to the searchers
finding local optimal subsets rather than global optimal ones.
In the future work I will implement a greedy backwards feature selection
algorithm named ’rfe‘ available in the R caret package. This algorithm requires
inputting the size of the attribute subset desired. It iteratively removes attributes
based on their ranking of importance by the naive Bayes classifier until the at-
tribute subset is reduced to the desired size. I will search for the subsets of size 5,
10, 15, 20, 25, 30 and 33. I will then select the subset out of these seven that max-
imises the classifier performance (prediction accuracy). Naive Bayes was chosen
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as this classifier assumes conditional independence, so it is more likely to be neg-
atively affected by attributes’ dependencies. Details about the chosen attributes
returned by wrapper feature selection throughout this research can be found in
appendix C.2.
4.3 Summary
In this chapter methods to generate thirty-three attributes for each drug-READ
code pair have been proposed. These attributes may help identify causal relation-
ships as they are derived from the Bradford-Hill causality considerations [19] that
has been used frequently to investigate causality between a single drug-medical
event pair. In addition, THIN specific attributes were presented with the aim
of preventing issues that arise due to the hierarchal READ code structure. The
attributes were explored and it was determined that z-score normalisation should
be applied to transform the continuous data and optimise the results of any learn-
ing algorithms applied. The foundations have been set to enable the development
of a novel framework for ADR signalling that incorporates causal knowledge and
the THIN data structure.
In Chapter 5, the attributes proposed in this chapter and their transformations
will be used as inputs into a learning algorithm which will be trained, using the
knowledge of known ADRs and non-ADRs, to distinguish between causal and
non-causal relationships.
135
Chapter 5
Developing The ADR Learning
Framework
‘Our evaluation showed that the phenotypic information
(when available) largely improved the performance of ADR
prediction models. ’
M. Liu [113]
5.1 Introduction
In the previous chapter suitable attributes based on the Bradford-Hill causality
considerations and specific to the THIN database were proposed, with the aim
of being used as inputs into a learning algorithm capable of identifying causality
and hence, able to signal ADRs. This was the first step toward testing the main
hypothesis being investigated in this thesis, that a framework that incorporates
attributes that give insight into causality and attributes specific to the THIN
database into a learning algorithm that uses knowledge of existing ADRs will
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signal ADRs without a high false positive rate. The second step is determining
which learning algorithm is optimal.
In this chapter the focus is on developing an algorithm for detecting ADRs
by applying supervised and semi-supervised techniques that utilised knowledge
of existing ADRs and non-ADRs. The sub question answered in this chapter is
what will yield a better ADR signalling algorithm, a supervised approach that is
trained on labelled data corresponding to a variety of drugs, or a semi-supervised
approach that uses the labelled and non-labelled data for a single drug?
5.2 Motivation
Generally ADR signalling methods using data contained in SRS databases and
LODs have been unsupervised, however, numerous supervised algorithms have
been presented to classify ADR using chemical structures and known ADRs.
One of the first algorithms that used chemical structures to infer ADRs was de-
veloped for a specific group of drugs known as the CEPT inhibitors [209]. This
idea was expanded to simultaneously identify multiple ADRs [5] where the authors
prosed two novel algorithms that incorporate knowledge of chemical structures
and known ADRs, extracted from SIDER [98], to infer new ADRs. The first algo-
rithm learns associations between drug attributes and known ADRs and uses this
knowledge to infer new ADRs. The second algorithm, based on a method of pre-
dicting disease-causing genes [186], uses a diffusion process that incorporates the
similarities between drugs and the similarities between ADRs. The overall mea-
sure of how likely a drug causes an ADR was calculated using a combination of the
values returned by the two algorithms. More recent methods have utilised target
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protein information in addition to chemical structure and ADR knowledge, and
used these to generate attributes that are fed into a predictive model [109; 212] or
included biological and phenotypic (e.g., indications and known ADRs) based at-
tributes [113]. In [113] the presented framework detected ADRs with a precision
of 66.17% and a recall of 63.06% and it was shown that including attributes based
on known ADRs improves the ability of the classifier and increases the recall and
precision. This is a key result, as it shows that incorporating knowledge of known
ADRs into an algorithm for signalling ADRs may decrease the false positive rate.
ADR signalling algorithms applied to LODs have exceptional potential to
identify new ADRs [204], but are currently limited by the high number of false
positives [156]. An ADR signalling algorithm that generates attributes based
on LODs, but also incorporates known ADR labels may reduce the number of
false positives and should outperform the existing unsupervised algorithms. As an
ADR represents a causal relationship, any attributes used by a learning algorithm
to distinguish between ADRs and non-ADRs need to contain information about
causality. In Chapter 4 suitable attributes for each drug-medical event pair based
on the strength, temporality, specificity, biological gradient and experimentation
factors of the Bradford-Hill causality considerations were investigated, as well as
attributes specific the to THIN database. These attributes are suitable inputs into
a causality learning algorithm as they are frequently implemented by researchers
to determine causal relations [42]. In Chapter 3.4, labels were extracted from the
SIDER resource for known ADRs, and noise medical events were extracted using
the READ code tree. Using the generated attributes and the known labels it
may be possible to learn areas of the attribute space that suggest a drug-medical
event pair represent an ADR. It is hypothesised that such an algorithm would
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reduce the time required to definitively identify ADRs and enable a wider search
for ADRs. Overall, this would improve current healthcare.
5.3 Algorithms
After the THIN data has been processed, as described in Chapter 4, for each drug
of interest α, we can assign class labels to some of the drug-READ code pairs
(class ADRs or class non-ADRs). Therefore, the set of Bradford-Hill causality
consideration attribute vectors Xα is partitioned into labelled data, (XαL , Y
α
L ) =
{(x, y)|x ∈ Xα and y is the known label}, and unlabelled data, XαU = {(x, y)|x ∈
Xα and the label is unknown}. The aim of the learning algorithms is to determine
a predictive function f : X → Y , using the labelled data and the unlabelled
data, that can then be applied to the attributes of a new drug-medical event
pair, (α∗, β∗), to predict the pair’s class.
5.3.1 Supervised ADR Predictor
Supervised methods only use the labelled data (XαL , Y
α
L ). The Supervised ADR
Predictor (SAP) framework signals ADRs by applying a classifier that is trained
on n drugs to a drug not used to train the classifier. Using a sufficiently large
value for n ensures that there is an adequate number of labels. In this study the
value of n used is 24 as this corresponded to approximately 10, 000 labelled data-
points. As the drug being investigated is not used in the training, no knowledge
of existing ADRs for that drug is required, so the SAP framework can be applied
to newly marketed drugs. The framework is illustrated in Figure 5.1.
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Ω
Input training
drugs: A =
{αi, i ∈ [1, n]}
Determine S =
{(α, β)|α ∈
A, β ∈ RMEα}
Extract training
data: (X, Y ) =
{(xαβ, Y αβ)|(α, β) ∈
S, Y αβ 6= 0}
Process data ρ :
X → X; ρ(X) = X∗
Train Classifier, sk :
X → Y ; sk(X
∗) = Y
Return sk(x)
Input drug of
interest: α∗
Generate Xα
∗
=
{xα
∗β|β ∈ RMEα
∗
}
Return sk(ρ(X
α∗))
Training
Predicting
Figure 5.1: The framework implemented to train the four different classifiers
using a variety of n drugs with known side effects. These general classifiers are
then used to predict the class for unlabelled data.
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5.3.1.1 Training Stage
Starting with the THIN data, Ω, and the set of training drugs, A = {αi, i ∈
[1, 24]}, the first step is determining the ‘risk’ drug-medical event pairs for each
of the training drugs. These are all the medical event and drugs pairs,(αi, β) ,
where the medical event β is observed to be recorded, for at least one patient,
within 30 days after a training drug αi was recorded. The set containing all these
‘risk’ drug-medical event pairs where the drug is a training set drug is denoted
by S.
Next, the Bradford-Hill causality consideration based attributes and the THIN
specific attributes are extracted for each pair in S with a corresponding label that
is ±1. The labels are determined (using the sets ΨA and ΨN defined in Chapter
3.4) by,
Y αβ =


1 if (α, β) ∈ ΨA;
−1 if (α, β) ∈ ΨN .
0 else.
(5.1)
So, the extracted labelled data is, (X, Y ) = {(xαβ, Y αβ)|(α, β) ∈ S, Y αβ 6= 0}.
Before the labelled data is used to train the classifier, it is processed according
to the chosen classifier being implemented. The processing step is represented
by the function ρ : X → X. For the random forest classifier, ρ is the z-score
normalisation function, ρ(x) = (x − µ)/σ, where µ is the mean of X and σ is
the standard deviation of X. For the SVM, Naive Bayes and Logistic Regression,
ρ represents z-score normalisation and wrapper feature selection (see appendix
C.2) [157].
The final step is using the processed labelled data to train and return the clas-
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sifier, sk : X → Y , using leave one out cross-validation. The classifier is trained
so that sk(x
ab) = 1 represents drug a causing medical event b and sk(x
ab) = −1
represents drug a not causing medical event b. The trained random forest clas-
sifier is represented by s1 : X → Y , the SVM is represented by s2 : X → Y , the
Logistic regression is represented by s3 : X → Y and the Naive Bayes classifier
is represented by s4 : X → Y .
5.3.1.2 Prediction Stage
Once the classifier, sk : X → Y , is trained, the SAP algorithm can then be
applied to any drug α∗ not used in training. The set of attribute vectors, Xα
∗
=
{xα
∗β|β ∈ RMEα
∗
}, corresponding to ‘risk’ drug-medical event pairs containing
the drug being investigated are extracted and processed. The trained classifier is
then applied to each of the data-points, xα
∗β ∈ Xα
∗
, to predict whether the drug
α∗ and medical event β correspond to an ADR. The final output for classifier k
is the set of medical events that correspond to the signalled drug-medical event
pairs containing drug α∗, {β|sk(x
α∗β) = 1,xα
∗β ∈ Xα
∗
}.
5.3.1.3 Results and Analysis
To analyse the SAP algorithm a set of 25 drugs were chosen, D = {αi, i ∈ [1, 25]}.
For each drug, αi ∈ D, the SAP algorithm was trained on the set of drugs in
D excluding αi and then validated by being applied to αi. The inputs into the
SAP framework were, A = {αj ∈ D|j 6= i} and α
∗ = αi. The predictions of
the classifiers on each labelled data-point (not used during training), sk(x
αiβ),
are then compared with the truth, Y αiβ, to measure the ability of the classifier.
Using the validation set, (Xαi , Y αi) = {(xαiβ, Y αiβ)|β ∈ RMEαi , Y αiβ 6= 0}, the
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Table 5.1: The results of the different classifiers at their natural thresholds for
three drugs, Nifedipine, Ciprofloxacin and Ibuprofen.
Drug Algorithm TP FN FP TN Sensitivity Specificity
Nifedipine RF 22 41 8 604 0.349 0.987
Ciprofloxacin RF 13 42 0 385 0.236 1
Ibuprofen RF 22 53 2 784 0.293 0.997
Nifedipine NB 14 49 6 606 0.222 0.990
Ciprofloxacin NB 6 49 5 380 0.109 0.987
Ibuprofen NB 9 66 16 770 0.120 0.980
Nifedipine SVM 25 38 9 603 0.397 0.985
Ciprofloxacin SVM 12 43 0 385 0.218 1
Ibuprofen SVM 24 51 9 777 0.32 0.989
Nifedipine LR 6 57 2 610 0.095 0.997
Ciprofloxacin LR 6 52 6 379 0.103 0.984
Ibuprofen LR 12 63 7 779 0.16 0.991
number of true positives (TP ), false positives (FP ), false negatives (FN) and
true negatives (TN), for each classifier sk, are calculate as,
• TP = |{sk(xj) = yj|(xj, yj) ∈ (X
αi , Y αi), yi = 1}|
• FP = |{sk(xj) = 1|(xj, yj) ∈ (X
αi , Y αi), yi = −1}|
• FN = |{sk(xj) = −1|(xj, yj) ∈ (X
αi , Y αi), yi = 1}|
• TN = |{sk(xj) = yj|(xj, yj) ∈ (X
αi , Y αi), yi = −1}|
Table 5.1 presents the results of the classifiers at their natural threshold and
Figure 5.2 presents the ROC plots and partial ROC plots of the classifiers, re-
spectively.
Bar charts of the AUC and AUC[0.9,1] values returned by the classifier for
the three drugs are displayed in Figure 5.3. The random forest classifier had
significantly greater AUC[0.9,1]s for all three drugs investigated at a 5% signifi-
cance level. However, the random forest’s AUC was only significantly greater for
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Figure 5.2: The ROC curves for the different classifiers used to predict the ADRs
of the drugs. The red curve represents the random forest classifier, the orange
curve represents the support vector machine classifier, the green curve represents
the logistic regression classifier and the blue curve represents the Naive Bayes
classifier.
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Figure 5.2: Continuation of the ROC plots.
Nifedipine (p-value: 0. 0002) and not for Ciprofloxacin nor Ibuprofen (p-values
0.164 and 0.052 respectively). The AUC for the random forest classifier was in
the range [0.823, 0.912], indicating excellent performance. The other classifiers
also performed well with the lowest AUC value of 0.730 obtained by the SVM for
Nifedipine.
The random forest and SMV were able to signal between 24% − 35% and
22%− 40% of the known ADR READ codes for the three drugs respectively. In-
terestingly, the classifiers all managed to keep the number of false positives low,
aggregating over the three drugs, 85%, 77%, 52% and 62% of the signals returned
by the random forest, SVM, Naive Bayes and logistic regression classifiers, re-
spectively, were known ADRs. Consequently, although only approximately 30%
of known ADRs were signalled by the random forest classifier at its natural thresh-
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Figure 5.3: The AUC and AUC[0.9,1] values for the SAP algorithm implementing
each of the classifiers when applied for the drugs Nifedipine, Ciprofloxacin and
Ibuprofen.
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old, the majority of signals were true, so no additional filtering would have been
required to further validate the signals. This is an improvement over the existing
methods (see Chapter 3).
When investigating the signal overlap between the classifiers, in general the
SVM returned the greatest number of unique signals (6 for Ibuprofen, 6 for
Nifedipine and 2 for Ciprofloxacin) although the random forest also had some
unique ones (4 for Ibuprofen, 2 for Nifedipine and 4 for Ciprofloxacin). This
suggests it may be of interest to investigate applying an ensemble technique that
integrates the results obtained from all four classifiers.
5.3.1.4 Summary
The classifiers that use the Bradford-Hill causality consideration based and THIN
specific attributes and additional knowledge of known ADRs and non-ADRs show
excellent promise at effectively signalling ADRs. These classifiers are trained on
drugs that are not investigated, so there is no requirement of known ADRs for
the drugs investigated and the classifiers had a high specificity and sensitivity.
Out of the four classifier investigated, the random forest returned significantly
better results and was also the classifier that required the least amount of pre-
processing, making it highly efficient. All four classifiers obtained a sufficiently
high specificity in addition to constraining the number of false positives. The
benchmark AUC for the supervised classifiers is set at 0.91 and the benchmark
AUC[0.9,1] are set at 0.048 for Ciprofloxacin, 0.059 for Ibuprofen and 0.053 for
Nifedipine.
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5.3.2 Semi-Supervised ADR Predictor
In the previous section a general classifier was proposed but the combinations of
attribute values that suggest a drug-medical event pair corresponds to an ADR
may vary for each drug, so information may be lost by combining the labelled data
for a variety of drugs. However, it is difficult to determine a specific classifier with
a high accuracy as the number of known ADRs per drug is generally less than
a hundred or so, but the number of ‘risk’ drug-medical event pairs are often in
the thousands. When there is only a small number of labelled data, but surplus
unlabelled data, it has been shown that semi-supervised techniques may yield
more accurate results [126]. In this section a novel semi-supervised framework is
proposed.
A frequently implemented example of a semi-supervised technique is the self-
training wrapper algorithm, summarised in Chapter 2.2.2.1. This algorithm trains
a classifier on labelled data and then gets the classifier to ‘teach’ itself by applying
the trained classifier on the unlabelled data and adding any unlabelled data-point
and its prediction to the labelled data, if the classifier is confident of the predic-
tion [215]. In [195], the authors showed that the performance of a self-training
approach and supervised approach is comparable by applying self-training using a
tree based classifier to a natural language classification problem. This motivates
the investigation of a self-training approach that incorporates a random forest
to learn from the labelled and unlabelled data. Unfortunately, the self-training
approach requires a sufficient number of initial labelled data, as classifiers per-
form poorly when trained on a small set of data [55], and an incorrect initial
model will get interactively worse. When the size of the initial labelled data is
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small, a semi-supervised clustering algorithm may be more appropriate as a small
number of labels can be used to aid clustering by adding bias [7]. Therefore, in
this Section, two semi-supervised algorithms are presented to signal ADRs using
labelled and unlabelled data corresponding to one drug; a self-training random
forest and a semi-supervised k-means clustering.
The framework for Semi-Supervised ADR Predictor (SSAP), that contains
both the self-training algorithm and the semi-supervised clustering, is presented in
Figure 5.4. The value crit∗ represents the critical value that is used to determine
whether the self-training or semi-supervised clustering is applied during the SSAP
framework, based on the fraction of total data that is labelled. This value will be
determined by investigating the performance of both semi-supervised techniques
when applied to data with a range of labelled data sizes.
5.3.2.1 Self Training Random Forest
The self training random forest iteratively trains a random forest on the labelled
data for drug α, (XαL , Y
α) = {(xαβ, Y αiβ)|β ∈ RMEα, Y αβ 6= 0}, but after
each random forest is built, it is applied to the unlabelled data XαU = {x
αβ|β ∈
RMEα, Y αβ = 0} and any unlabelled data point assigned a predicted class with
a confidence greater than 0.9 is removed from the unlabelled set and added to
the labelled set. The self training stops when the stopping criteria is met, either
all the originally unlabelled data-points are moved into the labelled set or the
iteration has run for twenty times. In detail, the self train process is:
Once the final random forest is trained, the final iteration model sˆ : X → Y ,
is applied to the unlabelled data XαU . The algorithm returns the predicted class
of the unlabelled data, sˆ(x),x ∈ XαU , or the confidence of the data point being in
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Ω
Input drug α
Determine S =
{(α, β)|β ∈ RMEα}
Extract data:
(XαL , Y
α) =
{(xαβ, Y αβ)|(α, β) ∈
S, Y αβ 6= 0}
and XαU ,=
{(xαβ|(α, β) ∈
S, Y αβ = 0}
Is crit ≥ crit∗?
Yes
Train Random
Forest Classifier
using (XαL , Y
α)
Apply trained Ran-
dom Forest to XαU
Add unlabelled
data-points with
confidence ≥
0.9 to labelled
Is stopping
point reached?
Apply final Random
Forest to XαU and
return probability
of class ADR
No
Apply Metric
Learning to output
M : X → X
Apply Semi-
supervised k-means
to (M(XαL), Y
α)
and M(XαU)
Return distance
from ADR
cluster centre
Self Training Classifier
Figure 5.4: The framework for the Semi-Supervised ADR Predictor algorithm.
This algorithm uses labelled and unlabelled data for the drug of interest only
during training. The technique applied depends on the percentage of labelled
data.
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Input : Labelled data: (XαL , Y
α), Unlabelled data: XαU and Iteration
limit: n}
Output: Final random forest applied to unlabelled data, si(XαU)
Initialization: L1 = ∅, U1 = XαU
for i = 1, 2, 3, ... do
Train random forest, si : X → Y , on labelled data (XαL , Y
α)
⋃
Li.
Apply to unlabelled data si(U i), Set:
Li+1 = Li
⋃
{(xαβ, si(xαβ))|xαβ ∈ U i, confidence of prediction ≥ 0.9}
U i+1 = {xαβ|xαβ ∈ U i, confidence of prediction < 0.9}
if i ≥ n or U i+1 = ∅ then break
end
Algorithm 3: The self train random forest algorithm
the ADR class.
5.3.2.2 Semi-supervised Clustering
The semi-supervised clustering technique is proposed for replacing the self-training
random forest when there is insufficient number of labelled data. The semi-
supervised clustering method has two steps, the first step applies metric learning
[211] using the labelled data, XαL , to learn a mapping, M : X → X , of the at-
tribute space that minimises the distance between data-points in the same class
while adding a constraint to keep data-points from different classes sufficiently far
apart. The second step is the application of the seed-constrained k-means clus-
tering algorithm [7] to determine the clusters using the mapped data, M(Xα),
where Xα = XαU ∪ X
α
L . The k-means algorithm uses the labelled data to deter-
mine the initial centres of the clusters and fixes the labelled data to a cluster, the
unlabelled data-points are then iteratively assigned to the cluster with the clos-
est centre until convergence. Both the metric learning and the semi-supervised
k-means algorithm are described in Chapter 2.2.2.1. In detail, the process is:
151
5. Developing The ADR Learning Framework
1. Apply metric learning with µ = 10−5, tol = 1−−5 and αt = 0.02, where:
• X = XαL
⋃
XαU
• S = {(i, j)|(xi, yi), (xj, yj) ∈ (X
α
L , Y
α), yi = yj}
• D = {(i, j)|(xi, yi), (xj, yj) ∈ (X
α
L , Y
α), yi 6= yj}
To output the metric space mapping M : X → X
2. Apply seed-constrained k-means to M(X), where:
• K = 2
• S1 = {M(xi)|(xi, yi) ∈ (X
α
L , Y
α), yi = 1}
• S2 = {M(xi)|(xi, yi) ∈ (X
α
L , Y
α), yi = −1}
To output the final cluster or the distance from the final ADR centre,
||M(xi)− µ1||, where µ1 is the centre of the ADR cluster.
The algorithm returns the predicted cluster of the unlabelled data-points or
the distance between the data point and the ADR cluster centre.
5.3.2.3 Results and Analysis
The self-training random forest algorithm and semi-supervised clustering algo-
rithm implemented the SSAP framework were both applied to the drugs Nifedip-
ine, Ciprofloxacin and Ibuprofen to analyse the results. For each drug, αi, the
labelled data was extracted, (Xαi , Y αi) = {(xαiβ, Y αiβ)|β ∈ RMEαi , Y αiβ 6=
0}, and randomly partitioned into disjoint training, (XαiL , Y
αi
L ), and validation,
(XαiU , Y
αi
U ), sets.
(Xαi , Y αi) = (XαiL , Y
αi
L )
⋃
(XαiU , Y
αi
U )
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(XαiL , Y
αi
L )
⋂
(XαiU , Y
αi
U ) = ∅
The data input into the algorithms as labelled data was (XαiL , Y
αi
L ) and the data
input into the algorithms as unlabelled data was XαiU . The algorithms were anal-
ysed by investigating the ROC plots determined by comparing their predictions
on the validation data sˆ(x),x ∈ XαiU with the truth Y
αi
U . Both algorithms were
applied for varying values of crit = |XαiL |/|X
αi |, to investigate if there is an obvi-
ous threshold value of crit that can be used to determine which semi-supervised
algorithm to apply when the SSAP framework is implemented (i.e., does the
self-training algorithm always outperform the semi-supervised clustering when
crit ≥ crit∗?).
Figure 5.8 displays the AUC of the ROC plots obtained by applying the semi-
supervised clustering or self-train classifier to the drugs Nifedipine, Ciprofloxacin,
and Ibuprofen. The AUCs varied between 0.55−0.88 and 0.53−0.84 for the semi-
supervised clustering and self-train classifier respectively. For Nifedipine, both
algorithms performed their respective best, with AUCs of 0.80 and 0.88 for the
clustering and self-train respectively, when 90% of the data was labelled, whereas
for Ibuprofen, both algorithms performed their respective best when only 5% of
the data was labelled. This shows that the semi-supervised techniques did not
always improve in performance when the value of crit was increased, this is further
evident in Figures 5.5-5.6. Futhermore, this suggests that the SSAP framework
does not require a large number of labelled data, as, in general, the performance
seems to be similar for low and high values of crit, but the performance depends
on the quality of labelled data.
To investigate how much the initial labels affect the performance, both semi-
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Figure 5.5: The ROC curves for the SSAP framework at 6 different values of crit
when applied to the different drugs. The black, blue, red, orange, yellow and
green curve correspond to crit values of 0.9, 0.7,0.5,0.3,0.1 and 0.05 respectively.
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Figure 5.6: The ROC curves for the SSAP framework at 6 different values of crit
when applied to Ibuprofen. The black, blue, red, orange, yellow and green curve
correspond to crit values of 0.9, 0.7,0.5,0.3,0.1 and 0.05 respectively. Left Plot:
Self Training, Right Plot: Clustering.
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Figure 5.7: The ROC curves for the SSAP framework repeated multiple times
for the drug Ibuprofen at a crit value of 0.1 to investigate consistency. Left Plot:
Self Training, Right Plot: Clustering.
supervised techniques were applied multiple times with a crit value of 0.1, but
the initial labels were varied. The results are displayed in Figure 5.7. It can
be seen that the performance varied each time, and although the semi-supervise
clustering produced good results four out of the five times, one time it performed
very poorly, worse than random guessing when considering a high specificity.
This is probably due to bad initial labels resulting in a poor model that then gets
worse as the unlabelled data are incorporated. This is not ideal, as there is no
control on the labelled data available, and applying one of the semi-supervised
techniques may yield poor results for certain labelled data.
There does not appear to be an optimal value for crit∗ so, rather than only ap-
plying one of the algorithms, it may be optimal to apply both the semi-supervised
clustering and self-trained classifier, and generate signals based on both values.
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Figure 5.8: The AUC for the ROC plots obtained by applying the semi-supervised
clustering and the self training classification within the SSAP framework to the
different drugs at varied crit values.
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5.3.2.4 Summary
The results show that a semi-supervised approach that only uses data for the
drug of interest generally performs well but the performance can be affected by
initial errors in the self training or metric learning. The consequence is that the
SSAP framework is not as consistent as the SAP framework, and although it
may occasionally produce better results (depending on the initial labelled data),
it may also perform very poorly. It was observed that the SAP algorithm, with
the random forest classifier, had a greater AUC than either of the semi-supervised
algorithms for all the crit values investigated for all three drugs.
Overall, the SAP algorithm produced better and more consistent results. It
also has the additional benefit of not requiring knowledge of existing labels for
the drug being investigated, unlike the SSAP algorithm.
5.4 Summary
In this chapter two different frameworks were proposed to signal ADRs. The
frameworks were then applied to data, where the truth was known, and mea-
sures were calculated to determine the suitability of each framework. The first
framework implemented a supervised algorithm and was trained using labelled
data corresponding to a selection of drugs not being investigated. The second
framework used a semi-supervised approach and was train using the labelled and
unlabelled data for the drug of interest.
The ROC plots show that the SAP framework, using a random forest classi-
fier, consistently generates superior results. Interestingly, using the labelled data
for the drug of interest generally leads to a worse performance. Therefore, the
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conclusion of this chapter is that a general model, that uses Bradford-Hill causal-
ity consideration attributes and THIN specific attributes, trained on independent
drugs yields the optimal solution. The tentative results suggest such a framework
is capable of signalling ADRs with a low false positive rate. It is now of inter-
est to determine how this general model compares with existing ADR signalling
algorithms and investigate if it is robust.
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Chapter 6
Evaluating The ADR Learning
Framework
‘As there is no true gold standard, prospective evaluation of
signal detection methods remains a challenge.’
P. M. Coloma[33]
6.1 Introduction
In the previous chapters, a novel idea of automating the application of the
Bradford-Hill causality considerations for mass signalling of ADRs was developed.
In Chapter 4 the attributes derived from the Bradford-Hill causality considera-
tions were presented, and used as inputs into a learning algorithm in Chapter 5.
The tentative results of the novel learning algorithm, named the SAP framework,
suggest that training a general classifier using knowledge of existing ADRs on
attributes based on the Bradford-Hill causality considerations and THIN specific
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attributes may present the opportunity to signal ADRs with a high precision and
sufficiently high specificity. In this chapter, the SAP framework is evaluated by
applying the specific comparison used in Chapter 3 and also by determining the
frameworks ability on the HOI-DOI reference standard, as this enables a general
comparison with previous and future work.
As it was hypothesised that the SAP framework will be able to generate
new signals that can not be generated by existing methods, the framework will
also be applied to the drug-medical event pairs for a selection of drugs that are
not definitively known as ADRs or non-ADRs. The signals generated will be
presented as this offers another perspective into the effectiveness of the SAP
framework and may highlight new ADRs.
6.2 Motivation
The existing methods are known to suffer from the high false positive rate [156]
and this means that further investigation needs to be applied to the signals that
are generated. If the SAP framework has a low false positive rate, then this
additional investigation will not be required, increasing the efficiency of ADR
signalling. As the high false positive rate is due to signalling strong associations
that are non-causal but occur due to confounding effects, the SAP framework
should be more resilient to a high false positive rate as the Bradford-Hill causality
considerations should help distinguish between associations due to confounding,
and associations due to causation [19].
Evaluating the SAP framework on the standard reference [80] will enable
other researchers to readily compare their methods with the SAP framework
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and the SAP framework can be compared with previous results. However, this
standard reference may be biased due to only considering a selection of HOIs.
Therefore, the specific comparison is also applied to evaluate the SAP framework
and determine the false positive rate when a larger number of drug-medical event
pairs are analysed. If the SAP framework is shown to have a low false positive
rate, but this does not inhibit its general ability, then this would be a step forward
for pharmacovigilance.
6.3 Evaluation using the Standard Reference
A recent standard reference set has been introduced to enable a fair comparison
between methods applied to different databases. The standard reference con-
tains ten DOIs and nine HOIs (discussed in Chapter 2.1.5), and consists of 53
definitively known ADR or non-ADR drug-medical event pairs (9 ADRs and 44
non-ADRs). The SAP framework was applied for each of the 53 drug-medical
event pairs on the THIN database and the signals generated by the framework
were compared with the known truth.
Previously, the benchmark measures over all the methods and a variety of
databases are an AUC of 0.77 and an AP of 0.49, the method obtaining these
values had a sensitivity of 0.56, a specificity of 0.82 and a positive predictive
value of 0.38 [156]. The previous comparisons have all concluded that existing
methods have a high false positive rate (≥ 0.18 [156]). On the THIN database the
benchmark values were a sensitivity of 0.67, a specificity of 0.68 and a precision
of 0.33 [214].
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6.3.1 Method
The SAP framework was evaluated by generating signals for each DOI after train-
ing the SAP framework on the other nine DOIs. As some of the DOIs have drugs
in common, the drugs used during training were always excluded from the vali-
dation to prevent bias. Due to the limited number of drug-medical event pairs
available for training, the random forest classifier was found to perform poorly
on the reference standard, so the SAP framework with a support vector machine
classifier embedded was used instead. It was also found, due to the limited train-
ing size, that feature selection was required to reduce the number of attributes
used by the SAP framework. The attributes not used were the TPD filter 1
(xαβ15 ) and TPD filter 2 (x
αβ
16 ), LEOPARD (x
αβ
17 ), experimentation (x
αβ
26 ) and the
risk different (xαβ4 -x
αβ
5 ), risk ratio (x
αβ
7 -x
αβ
8 ) and odds ratio (x
αβ
10 -x
αβ
11 ) when only
considering the first time the drug is prescribed in 13 months or the first time
any drug in the same family is prescribed in 13 months.
6.3.2 Results
Table 6.1 presents the results of the signals generated using the SAP framework
for the standard reference. The number of TPs was 6, the number of FPs was
7, the number of FNs (excluding the pair antibiotics and acute liver failure as
that was not experienced by any patients in the subsection of the THIN database
used) was 2 and the number of TNs was 37. Therefore, at its natural threshold,
the SAP framework had a sensitivity of 0.75, a specificity of 0.84, a precision of
0.46 and a false positive rate of 0.16.
The general raking ability measures were a MAP (average AP) score of 0.490,
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Table 6.1: The results of the SAP framework with the support vector machine
classifier on the 53 standard reference set of DOIs and HOIs.
Angi-
odema
Aplastic
anemia
Acute
liver
injury
Bleed-
ing
GI Hip
frac-
ture
MI Death
after
MI
Renal
Fail-
ure
ACE inhibitors TP TN FP TN
Ampotericin TN TN TN TN TN TP
Antibiotics TN NO 1 TN TN FP TN
Antiepileptics TN FN TN TN TN
Benzodiazapine FP TN TN FP TP FP FP
Beta Blockers TN TN TN TN TN TN
Bisphosphonates TN TN FN TN TN
Tricyclic An-
tidepressants
TN TN TN TP TN
Typical An-
tipsycotics
TN TP FP
Warfarin TN TN TP TN TN TN
an average AUC of 0.703 and an average P(10) of 0.2875. The DOIs antibiotics
and betablockers were not used in the previous calculation due to them having
no positive drug-medical event pairs, so the measures are undefined.
6.3.3 Discussion
Previous benchmarks for existing methods using the common data model on the
standard reference set were an AP ranging between 0.25− 0.49 an AUC ranging
between 0.59−0.77 and a false positive rate ranging between 0.18−0.89 [156]. The
false positive rate of 0.16 returned by the SAP framework was lower than existing
methods obtained in previous studies, but the general ranking measures were
comparable with the optimal existing methods. Therefore, the results of the SAP
framework using the THIN database for the standard reference set show that the
1This DOI-HOI pair was Not Observable (NO) using the THIN database
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SAP framework is able to generate signals as well as the existing methods applied
to the common data model but it has a lower false positive rate. This provides
evidence to support the hypothesis that generating methods for specific database
rather than the common data model may enable new signals to be generated and
supports the hypothesis that incorporating knowledge of existing methods and
attributes based on causation will reduce the number of false positives generated
by the method.
The SAP framework was limited in this evaluation due to the small number
of DOIs and HOIs resulting in a small training set. This shows that the SAP
framework has even more potential, as when the training size increases, the ability
of the classifier will increase and the SAP framework is likely to perform better.
As the SAP framework’s performance was as good, or maybe better, than existing
methods when the training set was small, it is likely to significantly outperform
the methods when more DOIs and HOIs are used to train the classifier. The
evaluation also highlighted how adaptable the framework it, as it can use any
classifier within it, so the most suitable classifier can be chosen based on the
situation. Furthermore, the SAP framework only requires the classifier to be
tuned and feature selection to be applied, so the number of parameters is relatively
low compared to many of the existing methods, making its application more
efficient.
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Method Signal Criteria Ranking Criteria
SAP Framework Class with most votes Confidence of class ADR
ROR05 ROR05 > 1 ROR05
MUTARA180 unexlev > 0 unexlev
HUNT180 (unexlev rank)/(lev rank) > 1 (unexlev rank)/(lev rank)
TPD IC∆05 > 0 IC∆05
Table 6.2: The signalling and ranking criteria of the methods.
6.4 Specific Comparison
6.4.1 Method
The specific comparison, as conducted in Chapter 3.7, was repeated for the drugs
Nifedipine, Ciprofloxacin, Ibuprofen, Budesonide and Naproxen and including
the SAP framework as an additional method. The different criteria used by each
method to generate signals or rank the pairs are described in Table 6.2. The
specific comparison was chosen to be implemented in addition to evaluating the
SAP on the standard reference as this enables a more rigorous evaluation of the
SAP’s ability to generate signals with a low false positive rate.
An additional investigating is implemented by applying the SAP framework to
the ‘risk’ drug-medical event pairs that are not definitively known as non-ADRs
or listed as ADRs on the drug packaging (i.e., the unlabelled drug-medical event
pairs). This will enable potentially new ADRs to be discovered.
6.4.2 Results
6.4.2.1 Nifedipine
Natural Thresholds
Table 6.3 displays the ADR signalling methods abilities at their natural thresh-
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Table 6.3: The results of the signals generated by the different ADR signalling
methods applied to Nifedipine at their natural thresholds.
Method TP FN FP TN Sensitivity Specificity Presicion F-Score
SAP 22 41 8 604 0.349 0.987 0.733 0.473
ROR05 44 36 164 448 0.550 0.732 0.212 0.306
MUTARA180 54 9 267 345 0.857 0.564 0.168 0.281
HUNT180 42 21 248 364 0.667 0.595 0.145 0.238
TPD 1 5 58 11 601 0.079 0.982 0.313 0.127
Table 6.4: The general ranking, Area Under the Curve (AUC), partial AUC
(AUC[0.9,1]) and Average Precision (AP), results of the different ADR signalling
methods applied to Nifedipine.
Method AUC AUC[0.9,1] AP
SAP 0.889 0.054 0.596
ROR05 0.691 0.010 0.129
MUTARA180 0.833 0.053 0.562
HUNT180 0.743 0.031 0.326
TPD 0.716 0.012 0.170
old. The existing methods MUTARA180, SRS and HUNT180 signalled the greatest
number of known ADRs, 54, 44 and 42 respectively. However, these methods also
incorrectly signalled many non-ADR and had low presicion values (0.145−0.212).
The SAP framework had the highest presicion, 0.733, specificity, 0.987 and F-
score, 0.473. This was due to the low number of false positives.
General Ranking
Table 6.4 displays the AUC, AUC[0.9,1] and AP values for the five ADR signalling
methods. The SAP framework had the highest AUC, AUC[0.9,1] and AP, with
values 0.889, 0.054 and 0.596 respectively. The AUC of the SAP framework was
not significantly greater than the AUC for MUTARA180 (p-value 0.093), neither
1The TPD result presented was the optimal result when both the TPD1 and TPD2 were
applied.
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Table 6.5: The results of the signals generated by the different ADR signalling
methods applied to Ciprofloxacin at there natural thresholds.
Method TP FN FP TN Sensitivity Specificity Presicion F-Score
SAP 13 42 0 385 0.236 1.000 1.000 0.382
ROR05 19 36 71 314 0.345 0.816 0.211 0.262
MUTARA180 55 0 327 58 1.000 0.151 0.144 0.252
HUNT180 49 6 257 128 0.891 0.332 0.160 0.271
TPD 4 51 14 371 0.073 0.964 0.222 0.110
was the AUC[0.9,1] (p-value 0.471). The ROC plots are presented in Figure 6.1.
The worse performing method was the ROR05, with an AUC of 0.691 and an AP
of 0.129.
Unlabelled Data Signals
Out 6489 unlabelled drug-medical event pairs containing Nifedipine, 233 were
signalled as ADRs by the SAP framework and are displayed in Appendix D.
The signals (and the number of patients experiencing them 30 days after the
drug) included itching/pruritus (≥1976), psoriasis (579), rash (≥ 836), olecranon
bursitis (483), depression (≥ 3082), joint pain/arthralgia (≥ 3023), appetite loss
(203), tiredness (1848), excessive thirst (36), torticollis (71), dizziness (2585)
and benign essential tremor (91). There were also heart related signals such as
unstable angina (120) and acute myocardial infarction (114).
6.4.2.2 Ciprofloxacin
Natural Thresholds
The methods had variable sensitivities, ranging from 0.073 for HUNT180 to 1
for MUTARA180 and specificities, ranging from 0.0151 for MUTARA180 to 1
for the SAP framework. This suggests their natural thresholds act at varying
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Table 6.6: The general ranking, Area Under the Curve (AUC), partial AUC
(AUC[0.9,1]) and Average Precision (AP), results of the different ADR signalling
methods applied to Ciprofloxacin.
Method AUC AUC[0.9,1] AP
SAP 0.812 0.048 0.614
ROR05 0.713 0.007 0.190
MUTARA180 0.851 0.042 0.547
HUNT180 0.716 0.033 0.406
TPD 0.713 0.011 0.140
stringencies. The SAP framework was able to signal approximately 25% of the
known ADRs and did not signal any non-ADRs. MUTARA180 signalled all the 55
known ADRs but also signalled 327 non-ADRs. The TPD performed the worse
for Ciprofloxacin, with the lowest F-score of 0.110 compared to the others that
ranged from 0.252− 0.382.
General Ranking
For the drug Ciprofloxacin, MUTARA180 had the greatest AUC, 0.851 but the
SAP framework performed better when only considering a low specificity, with
a AUC[0.9,1] of 0.048. The SAP framework also had the greatest AP value,
0.614 compared to the APs of the other methods (0.140 − 0.547). The AUC
of MUTARA180s ROC curve was not significantly greater than the AUC of the
SAP framework ROC curve (p-values 0.241), neither was the AUC[0.9,1] of the
ROC curve for the SAP framework compared to the AUC[0.9,1] of MUTARA180s
ROC curve (p-value 0.235. The ROC plots for the methods applied to signalled
ADRs of Ciprofloxacin can be seen in Figure 6.1.
Unlabelled Data Signals
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Table 6.7: The results of the signals generated by the different ADR signalling
methods applied to Ibuprofen at there natural thresholds.
Method TP FN FP TN Sensitivity Specificity Presicion F-Score
SAP 23 52 3 783 0.307 0.996 0.885 0.455
ROR05 16 59 242 544 0.213 0.692 0.062 0.096
MUTARA180 69 6 538 248 0.92 0.316 0.114 0.202
HUNT180 51 24 522 264 0.68 0.336 0.089 0.157
TPD 3 72 41 745 0.04 0.948 0.068 0.050
Table 6.8: The general ranking, Area Under the Curve (AUC), partial AUC
(AUC[0.9,1]) and Average Precision (AP), results of the different ADR signalling
methods applied to Ibuprofen.
Method AUC AUC[0.9,1] AP
SAP 0.903 0.057 0.654
ROR05 0.473 0 0.076
MUTARA180 0.845 0.045 0.498
HUNT180 0.595 0.020 0.196
TPD 0.654 0.002 0.102
The signals generated by the SAP framework applied to the drug Ciprofloxacin
are listed in Appendix D. Out of 3574 unlabelled drug-medical event pairs con-
taining Ciprofloxacin, 125 pairs were signalled as corresponding to ADRs. Some of
the interesting signals include hypothyroidism (324), depressed mood (625), oral
aphthae (285), muscle injury/strain (46), congestive heart failure (542), Incoordi-
nation symptom (807), canidial balanitis (67), confused (434), achilles tendinitis
(130), left ventricular failure (318) and panic disorder (192).
6.4.2.3 Ibuprofen
Natural Thresholds
The results of the methods applied to Ibuprofen at their natural threshold are
presented in Table 6.7. It can be seen that MUTARA180 was able to signal the
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majority of known ADRs (69/75) at its natural threshold but it also signalled
538 non-ADRs. The SAP framework signalled less, approximately 30% of the
known ADRs (23/75), but managed to only signal 3 non-ADRs, this resulted in
the SAP framework obtaining the greatest presicion, 0.885 and F-score, 0.455.
General Ranking
The SAP framework had the greatest AUC, 0.903, and AUC[0.9,1], 0.057, and these
were significantly greater than the AUC and AUC[0.9,1] corresponding to the sec-
ond best method MUTARA180, with an AUC value of 0.845 and a AUC[0.9,1] of
0.045 (p-values 0.037 and 0.044 respectively). The SAP framework also had the
greatest AP value, 0.654 compared with 0.498, 0.196, 0.102 and 0.076 correspond-
ing to MUTARA180, HUNT180, TPD and the ROR05 respectively. These general
ranking measures are contained in Table 6.8. The ROR05 actually performed
worse than random guessing, with an AUC value under 0.5 and was unable to
signal any known ADRs at a high specificity as its AUC[0.9,1] was 0.
Unlabelled Data Signals
When the SAP framework was applied to unlabelled data corresponding to Ibupro-
fen, there was a total of 200 signals out of a possible 7700. The signalled pairs
included the medical events Nausea (3084), rash (≥ 6155), tiredness symptom
(2937), Gout (3709), essential hypertension (7883), Candidiasis (3488), Cough
(1180), palpitations (1860), shortness of breath (2489), vomiting (170), patient’s
condition improved (22539) and myalgia (2246). A complete list of signals is
contained in Appendix D.
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Table 6.9: The results of the signals generated by the different ADR signalling
methods applied to Budesonide at there natural thresholds.
Method TP FN FP TN Sensitivity Specificity Presicion F-Score
SAP 26 26 0 535 0.5 1 1 0.667
ROR05 23 29 360 175 0.442 0.327 0.060 0.106
MUTARA180 49 3 308 227 0.942 0.424 0.137 0.240
HUNT180 38 14 258 277 0.731 0.518 0.128 0.218
TPD 1 51 12 523 0.019 0.978 0.077 0.031
Table 6.10: The general ranking, Area Under the Curve (AUC), partial AUC
(AUC[0.9,1]) and Average Precision (AP), results of the different ADR signalling
methods applied to Budesonide.
Method AUC AUC[0.9,1] AP
SAP 0.937 0.070 0.767
ROR05 0.705 0.002 0.059
MUTARA180 0.855 0.052 0.544
HUNT180 0.707 0.025 0.232
TPD 0.696 0.003 0.105
6.4.2.4 Budesonide
Natural Thresholds
Table 6.9 displays the results of the signals generated for Budesonide by the meth-
ods at their natural threshold. The SAP framework did not signal the most known
ADRs, MUTARA180 signalled 49 out of 52 known ADRs, but it was able to signal
50% and all the signals were correct (0 false positives). MUTARA180 signalled
308 false positives, so only 49 out of the 357 signals generated by MUTARA180
correspond to known ADRs. The TPD generated the least number of signals,
13 in total, and only 1 corresponded to a known ADRs, making it the wore per-
forming method. The F-score of the SAP framework, 0.667, was over double the
other methods’ F-scores, in the range [0.031, 0.240].
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General Ranking
The SAP framework performed excellently on the drug Budesonide with an AUC
of 0.937, a AUC[0.9,1] of 0.070 and a AP of 0.767. Both the AUC and the AUC[0.9,1]
of the SAP framework was significantly greater than the AUC and the AUC[0.9,1]
of MUTARA180 (p-values 0.0126 and 0.022 respectively), the second best perform-
ing method with an AUC of 0.855 and a AUC[0.9,1] of 0.0524. The results for all
the methods are presented in Table 6.10. The methods that obtained the lowest
ranking performance were the TPD and ROR05, although their AUC values were
approximately 0.7, suggesting all the methods performed well for Budesonide.
Unlabelled Data Signals
There were a total of 206 signals out of a possible 5219 generated by the SAP
framework when applied to unlabelled drug-medical events pairs containing Budes-
onide. A selection of the interesting medical events signalled as ADRs to Budes-
onide are micturition frequency (892), constipation (2650), pain/backache (2397),
accidental falls (1513), incoordination symptom (1407), dermatitis (≥ 1739), dead
(125), heartburn (634), impotence (607), essential hypertension (2258), appetite
loss (82), bloating (71), drug and other substances-adverse effects in therapeu-
tic use (281), alopecia unspecified (100), tremor (201) and patient’s condition
worsened (927). For a list of all the signalled medical events see Appendix D.
6.4.2.5 Naproxen
Natural Thresholds
The SAP framework was able to signal approximately 40% of the known ADRs
and out of the signals generated, 89% corresponded to known ADRs and only 11%
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Table 6.11: The results of the signals generated by the different ADR signalling
methods applied to Naproxen at there natural thresholds.
Method TP FN FP TN Sensitivity Specificity presicion F-Score
SAP 31 49 4 446 0.388 0.991 0.886 0.539
ROR05 25 55 182 268 0.313 0.596 0.121 0.174
MUTARA180 72 8 293 157 0.9 0.349 0.197 0.324
HUNT180 54 26 274 176 0.675 0.391 0.165 0.265
TPD 6 74 15 435 0.075 0.967 0.286 0.119
Table 6.12: The general ranking, Area Under the Curve (AUC), partial AUC
(AUC[0.9,1]) and Average Precision (AP), results of the different ADR signalling
methods applied to Naproxen.
Method AUC AUC[0.9,1] AP
SAP 0.883 0.055 0.700
ROR05 0.510 0.000 0.136
MUTARA180 0.793 0.036 0.503
HUNT180 0.628 0.020 0.325
TPD 0.706 0.008 0.209
corresponded to non-ADRs. MUTARA180 was able to signal 90% of the known
ADRs, but only 20% of the total signals corresponded to ADRs, the remain-
ing 80% were non-ADRs. The SAP framework had the greatest F-score, 0.539,
with the other methods obtaining 0.324, 0.265, 0.174 and 0.119 for MUTARA180,
HUNT180, the ROR05 and TPD respectively. These results are presented in Table
6.11 and the ROC plots are displayed in Figure 6.1.
General Ranking
The general ranking performance of the methods varied when applied to Naproxen,
this can be seen in Table 6.12. The SAP framework and MUTARA180 performed
well, obtaining AUC values of 0.883 and 0.793 respectively and AUC[0.9,1] values of
0.055 and 0.036 repsectively. The SAP framework’s AUC was significantly greater
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than MUTARA180’s AUC (p-value 0.012), as was its AUC[0.9,1] (p-value 0.007).
The SAP frameworks’ AP was greater than the other methods, 0.7, compared
with the other methods ranging from 0.136 (ROR05) to 0.503 (MUTARA180).
The ROR05 performed poorly, with an AUC of 0.51, not much improvement on
random guessing, and a AUC[0.9,1] of 0, showing it was not able to signal any
known ADRs when the specificity if high.
Unlabelled Data Signals
When the SAP framework was applied to the 4540 unlabelled drug-medical event
pairs containing the drug Naproxen, a total of 302 pairs were signalled as cor-
responding to ADRs. For a list of all the medical events contained in these
drug-medical event pairs see Appendix D. The medical events of interest are de-
pression (1677), abdominal pain (1077), acquired hypothyroidism (588), anxiety
states (707), breathlessness (873), hoarse (172), nausea present (232), constipa-
tion (308), unstable angina (24), vomiting (38), left ventricular failure (230),
obstructive jaundice (13), acute retention of urine (13), acute non-ST segment
elevation myocardial infarction (27), ocular hypertension (147), drug stopped-
medical advice (529), spasms (14), congestive heart failure (368) and atria flutter
(20).
6.4.3 Discussion
The SAP framework had a greater AUC value for four out of the five drugs
investigated and a greater AUC[0.9,1] for all five drugs, compared to the existing
methods. The AUC and AUC[0.9,1] was significantly greater, at a 5% significance
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(a) Nifedipine
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(b) Ciprofloxcin
Figure 6.1: The ROC plots for the SAP algorithm, implementing a random forest
(black) and the existing methods MUTARA180 (orange), HUNT180 (red), TPD
(green) and ROR05 (blue).
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(d) Budesonide
Figure 6.1: The ROC plots for the SAP algorithm, implementing a random forest
(black) and the existing methods MUTARA180 (orange), HUNT180 (red), TPD
(green) and ROR05 (blue).
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(e) Naproxen
Figure 6.1: The ROC plots for the SAP algorithm, implementing a random forest
(black) and the existing methods MUTARA180 (orange), HUNT180 (red), TPD
(green) and ROR05 (blue).
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level, for three of the five drugs (Ibuprofen, Budesonide and Naproxen). This
suggests that the SAP framework is overall better at ranking ADRs. As the SAP
framework’s AUC[0.9,1], the AUC when the specificity is high and the false positive
rate is low, was always greater than the existing methods, this shows that the
SAP framework is able to signal ADRs more precisely. This is also evident by
the AP score of the SAP framework being greater than the existing methods for
all five drugs, resulting in an overall Mean Average Precision (MAP) score of
0.667 compared to 0.531, 0.297, 0.145 and 0.118 corresponding to MUTARA180,
HUNT180, TPD and ROR05 respectively.
The SAP framework was able to signal a high percentage of ADRs while main-
taining a low number of false positives. Although MUTARA180 signalled more
ADRs, it also signalled many false positives. Over all five drugs, the number of
SAP and MUTARA180 signals that were true positives were 115 and 299 respec-
tively, but the number of false positives were 15 and 1733 respectively. Therefore,
88.5% of the SAP framework signals are likely to correspond to ADRs, while only
14.7% of MUTARA180’s signals are likely to be ADRs. This means MUTARA180’s
natural threshold signals probably need additional filtering, whereas this is not
necessary when the SAP framework is implemented.
Overall, the SAP framework managed to signal 115 out of the 325 ADRs. This
corresponds to a minimum of 35.4% of the ADRs being identified, as READ code
redundancy may mean that some of the 64.6% remaining non-signalled ADRs
READ codes may correspond to the same medical event as the signalled READ
codes. This value may be further improved by training the SAP framework on
more drugs, or by adding additional attributes based on the remaining Bradford-
Hill causality considerations (consistency, plausibility and coherence). The SAP
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framework was also able to signal medical events that had a low frequency during
the 30 day period after the drug, and medical events with a high background rate
such as depression and myocardial infarction. These medical events are often
difficult to signal by the existing SRS methods [70] as the association strength is
often very weak.
The TPD, HUNT180 and ROR05 performed worse than the SAP framework
and MUTARA180. The methods were unable in general to signal ADRs without
being swamped by false positives and obtained MAP scores of less than 0.5,
suggesting their general ranking ability was poor on the drug-medical event pairs
investigated. The TPD method may have been inhibited as it only analyses
patients that have a long medical history, due to it investigating the 27 months
to 21 month time period prior to the prescription. Therefore, the amount of data
available for the TPD algorithm may have been smaller relative to other methods.
The natural threshold of HUNT180> 1 appeared to act at a similar stringency as
MUTARA180 suggesting this is a good threshold to apply.
It is clear that the SAP framework was consistent over the drugs investigated
and did not perform poorly on any instance. MUTARA180 also returned consis-
tent results, however, the other three existing methods returned mixed results.
They performed poorly for Naproxen and Ibuprofen, with the ROR05 being worse
than random guessing and TDP performing little better.
When the SAP framework was applied to the unlabelled data corresponding
to the five drugs it was able to signal many suspected ADRs and highlighted
some potentially new ADRs. The results obtained from the unlabelled data were
very promising but require further evaluation to confirm causality. The SAP
framework successfully signalled known ADRs with obscure descriptions, and
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this is additional evidence to support its ability.
6.5 Summary
The results of the SAP framework applied on the standard reference set of 53
drug-medical event pairs provide evidence that the SAP framework is able to
signal ADRs with a low false positive rate. The results of applying the SAP
framework on a subset of the THIN database and the results of applying ex-
isting method to the common data model are comparable. This is impressive
as the common data model contains more data than the subset of the THIN
database used through this research. The results provide evidence to support
the argument that methods should be developed for specific databases to utilise
the whole data, as it is known that information can be lost when transforming
LODs into the common data model [214]. It is also clear that single databases
in their raw form are useful sources for pharmacovigilance. The results also show
that introducing attributes based on the Bradford-Hill causality considerations
to tackle the problem of confounding can reduce the number of false positives
signals.
The results of the specific comparison show that the novel SAP framework out-
performs the existing methods evaluated in this thesis (MUTARA180, HUNT180,
ROR05 and TPD) and signalled ADRs with a low false positive rate. The SAP
framework appears to be the first ADR signalling technique that has manage
to signal a sufficient number of ADRs using LODs while obtaining a low false
positive rate. This is an improvement over current pharmacovigilance techniques
applied to LODs and may increase the efficiency in discovering ADRs. Possible
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reasons for the SAP framework’s performance are the inclusion of Bradford-Hill
causality consideration attributes and attributes specific to the THIN database
or its ability to learn from known ADRs.
The SAP framework was able to generate new ADR signals, but further anal-
yse needs to be performed before the the signals can be confirmed as true or not.
The benefit of the SAP framework is that prior results can be used to update the
framework as the signals it generates are confirmed as ADRs or non-ADRs. The
SAP framework’s performance should increase over time as the number of known
definitive ADRs or non-ADRs increases.
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Chapter 7
Conclusions
This thesis has focused on developing an ADR signalling framework, specifically
for the THIN database, that can identify ADRs with a low false positive rate.
It was determined that the current ADR signalling techniques, applied to the
THIN database, had a high false positive rate and the majority of signals were
non-ADRs. The plausible reasons for this were that the existing methods cannot
distinguish between causation and association and they do not take into account
the hierarchal structures embedded within the THIN database.
To overcome this issue of the methods signalling ADRs based on the strength
of association rather than causation, a generalisation of the technique of consider-
ing the Bradford-Hill causality considerations to determine signals was proposed.
The technique was generalised by calculating attributes based on five of the
Bradford-Hill causality considerations (association strength, temporality, biologi-
cal gradient, specificity and experimentation), using the THIN database, and then
using knowledge of existing ADRs to find patterns embedded within the attribute
values that could be used to signal ADRs. By applying a learning technique, a
sixth Bradford-Hill factor, analogy, is also indirectly incorporated. Furthermore,
attributes that incorporated knowledge of the THIN hierarchal structures were
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also proposed and used as attributes into the learning algorithm. These attributes
helped identify medical events that occurred before the drug was taken but then
progressed or were recorded inconsistently.
It was shown that the SAP framework, a classifier trained using data consist-
ing of Bradford-Hill causality considerations and THIN specific attributes corre-
sponding to drug-medical event pairs that are known ADRs or non-ADRs, can
be applied to a different drug-medical event pair to determine if the pair is an
ADR or not with an specificity of 0.75 and a sensitivity of 0.84. The natural
threshold false positive rate was lower than existing methods, showing that the
SAP framework overcomes the current limitation of a high false positive rate that
plagues the existing ADR signalling methods for LODs.
In the continuation of this chapter the contributions of this work are sum-
marised, and suggestions are made for future directions of work to follow on from
this research. The dissemination of this research is reported in the conclusion of
this chapter.
7.1 Contributions
This thesis has made the following contributions:
• Determined the benchmark for the existing methods on the THIN
database
There is no golden standard for signalling ADRs [179] due to the lack of
definitive knowledge of existing ADRs for each drug. In [214], the authors
applied a selection of ADRs signalling techniques to the raw THIN database
and a mapped version of the database to determine if signals are lost during
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the mapping. This was the first example of the THIN database being inves-
tigated for ADR signal detection. Benchmarks for the standard reference
using the raw THIN database were determined, but the authors did not
apply an extensive analysis and the standard reference may contain bias.
In Chapter 3, an extensive analysis was conducted by applying a selection
of existing ADR signalling methods (Reporting Odds Ratio, Temporal Pat-
tern Discovery, Mining Unexpected Temporal Association Rules given the
Antecedent and Highlighting Unexpected temporal association rules Negat-
ing Temporal association rules) to the THIN database and analysing the
signals with two different perspectives. The ROR and TPD had been com-
pared with other methods in numerous studies [156] [80] and the authors
concluded that the methods performed similarly, so rather than applying all
the existing methods, only these two were chosen. MUTARA and HUNT
had not be incorporated in any previous comparison, so they were also
added to the investigation. The previous comparisons had concluded that
the methods had a high false positive rate [156] and this limited there abil-
ity.
The comparisons conducted in this research showed, consistent with previ-
ous results, that the four existing method had a high false positive rate. An
interesting result was that their performance deteriorated when the num-
ber of drug-medical event pairs being investigated increased, although this
may be partially due to the effect of unknown ADRs causing their results
to seem worse than they are. When considering a smaller subset the drug-
medical event pairs, where only definitively known ADRs or non-ADRs are
185
included, the benchmark AUC, AUC[09,1], AP, were 0.770, 0.032, 0.315 re-
spectively. The sensitivity and specificity ranged between 0.061−0.894 and
0.0366− 0.959 respectively.
The comparison suggested that the existing ADR signalling methods are
unsuitable for signalling ADRs using the THIN database due to the large
number of false positive signal generated. It would be difficult to extensively
investigate each signal generated and the majority of them would be false.
• Proposed suitable attributes to distinguish association from cau-
sation
The THIN database is a LOD containing prescription and medical histo-
ries for millions of patients. It offers the potential to infer temporal causal
relationships between drugs and medical events, but no ADR signalling
technique had been developed specifically for the THIN database. Exist-
ing methods, developed for alternative databases, determine the association
strength between a drug-medical pair and signal the pairs with the great-
est association. This causes a high false positive rate, as many medical
events can be highly associated to a drug due to non-causal reasons. When
investigating a single drug-medical event pair, researchers have often con-
sidered the Bradford-Hill causality considerations to draw conclusions [164].
As the THIN database contains data that can be used in consideration of
many Bradford-Hill causality considerations, in this work, a generalisation
and automatisation of this idea was proposed by extracting Bradford-Hill
causality considerations based attributes from the THIN database. The
attributes were then used as inputs into a learning algorithm. This is the
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first attempt of such an approach.
The attributes proposed in Chapter 4 are a mixture of existing and novel cal-
culations to cover five of the Bradford-Hill causality considerations, namely,
association strength, temporality, specificity, biological gradient and exper-
imentation. The association strength based attributes and the majority of
the temporality attributes were extracted from existing pharmacovigilance
methods. The specificity, biological gradient, experimentation and tempo-
rality BA ratios are all novel attributes that were developed in this work. As
this work was focussing on a ADR signalling technique, specifically for the
THIN database, novel attributes were also presented in Chapter 4 to deal
with the hierarchal structure within the THIN data. It was concluded in
Chapter 3 that the existing methods struggle with illness progressions or re-
dundancy within the THIN database. By using the THIN medical event hi-
erarchy, attributes were proposed that identify medical events that are more
detailed or similar to medical events that were reported before the drug.
Different attributes may be required for different healthcare databases, de-
pending on any database specific issues that are identified.
• Developed a novel supervised/semi-supervised technique for causal
inference using THIN
After proposing the novel learning algorithm for signalling ADRs, the fo-
cus fell on what would be better, to develop a supervised classifier that is
trained on labelled data corresponding to a collection drugs or to apply a
semi-supervised algorithm that is trained on both labelled and unlabelled
data for the drug being investigated?
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In previous work, [5] and [113], researchers have trained classifiers to signal
ADRs using chemical data and known ADRs. It was shown that these tech-
niques attained a high recall and precision and the results provided evidence
that incorporating knowledge of ADRs into models improves performance.
The existing methods for signalling ADRs using LODs are unsupervised
and do not incorporate knowledge of existing ADRs.
In Chapter 5, two learning algorithm frameworks, that use the attributes
derived from the THIN data (described Chapter 4), were presented. The su-
pervised technique, the SAP framework, applied a classifier that is trained
on labelled data corresponding to various drugs. The semi-supervised tech-
nique, the SSAP framework, applied either a self-train random forest or
a semi-supervised clustering technique to both the unlabelled and labelled
data of a single drug. It was concluded that the SAP framework outper-
formed the SSAP self-train and semi-supervised approach and the SAP
framework returned consistent results. This was the first attempted of im-
plementing supervised or semi-supervised techniques to infer ADRs using a
LOD.
The SAP framework consistently returned a low false positive rate, even
when the training set was small. As the consuming element of the SAP
framework is the training aspect, the SAP framework is highly efficient
once trained and training rarely needs to occur. The SAP framework was
also shown to be robust, as it was consistently able to signal ADRs with a
low false positive rate over a range of drugs.
• Evaluated the SAP framework on the THIN database
188
In Chapter 6 the SAP framework was compared with the TPD, ROR, MU-
TARA and HUNT methods for a range of drugs using the THIN database.
The results confirmed that the SAP framework, using Bradford-Hill causal-
ity considerations and THIN specific attributes and learning from known
ADRs, was able to signalled ADRs with a low false positive rate, unlike
the existing methods. The SAP framework obtained a greater Average
Precision and AUC[09,1] for all the drugs investigated. The current bench-
marks, set by the SAP framework, for ADR signalling methods using the
THIN database are a MAP of 0.667, a sensitivity of 0.354 and a precision
of 0.885. These results provided evidence to confirm the second hypothesis,
that novel ADR signalling algorithms applied to the THIN database will
outperform existing methods if they deal with the hierarchal structures in
the THIN database, incorporate causality based attributes and learn from
existing ADRs.
The SAP framework was able to generate new ADRs signals when it was
applied to unlabelled drug-medical event pairs. This supports the third
hypothesis. Unfortunately, additional analysis is require to confirm if the
signals are true or false.
The SAP frameworks ability on the OMOP DOI-HOI standard reference
containing ten DOIs and nine HOIs was limited by the training size avail-
able. However, the SAP framework’s ability to generate ADR signals using
the THIN database was comparable to the existing methods ability us-
ing the common data model. This is an impressive result as the common
data model contains more data, and the SAP framework obtained a lower
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false positive rate than existing methods. The performance of the SAP
framework is likely to improve as the training size increases, so the SAP
framework is likely to outcompete the existing methods when a larger stan-
dard reference set is developed. Therefore, the fourth hypothesis, that the
SAP framework will outcompete the existing methods when considering
the standard reference, cannot be currently confirmed but the results do
provide limited evidence to support it.
7.2 Future Work
The areas of research that follow on from this research are now presented.
• Generating attributes for the remaining Bradford-Hill causality
considerations
In Chapter 4, attributes were developed that cover five of the nine Bradford-
Hill causality considerations. The sixth, analogy, was indirectly incorpo-
rated due to using a supervised technique that looks for patterns within
ADRs. The remaining considerations are consistency, plausibility and co-
herence. Future work could aim to generate new attributes to cover these
remaining considerations. Possible suggestions for suitable attributes are,
to calculate the strength of association in different databases, such as SRS
databases, for the consistency factor or to incorporate attributes relating
to chemical structure knowledge, such as in [113], for the coherence factor.
There are two possible ideas to determine attributes for plausibility. The
first idea is to mine the web, such as medical forums, and identify if the
drug-medical event pair have been frequently mentioned as corresponding
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to a possible ADR. In [202], the authors have used text mining techniques
to identify ADRs and this idea could be adapted. The second idea is to
indirectly tackle plausibility by ruling out other possibilities, this could be
done by applying sequential pattern mining and filtering the explainable
medical events (medical events that have progress from a prior illness).
• Combining the SAP and SSAP frameworks using an ensemble
In this research a supervised framework and a semi-supervised framework
were proposed in Chapter 5. Four classifiers, support vector machine, ran-
dom forest, naive Bayes and logistic regression and two semi-supervised
algorithms, self-trained random forest and semi-supervised k-means were
applied to the data and analysed. The results showed that the random for-
est classifier performed the best, so this was selected and used in Chapter
6, although when the training set was small, the support vector machine
classifier performed better. Future would could involved investigating an
ensemble technique that uses the prediction of all the learning algorithms
developed in Chapter 5 to get a final aggregated prediction.
• Quantifying the ADRs
This research has produced a framework that can efficiently and precisely
signal ADRs. Using this framework to signal the ADRs, the signalled ADRs
could then be investigated and the additional risk of having the medical
event due to taking the drug could be determined. This follow up work
would add accurate quantitative information to ADRs, something that is
currently lacking [171].
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• Identifying risk factors corresponding to the ADRs
In addition to quantifying the ADRs, the signals could also be investigated
to determine risk factors. Possible methods of achieving this would be to
apply association rule mining [213] to the patients’ sets of medical history
for all the patients taking the drug and all the patients taking the drug
and experiencing the ADRs, and then identify the rules that occur more
frequently in the patients experiencing the ADR.
• Make the SAP framework run in realtime
The causal based attributes for each drug-medical event pair could be stored
such that when new therapy and medical records are added to the database
the attributes are updated. The SAP framework could then be applied to
determine if the signal status of any drug-medical event pair has changed.
The learning model used within the SAP framework could also be re-trained
after a sufficient amount of new data is added, and could incorporate new
labels as addition ADR knowledge is gained.
• Removing the redundancy in the READ codes
The READ code structure has redundancy and there are multiple READ
codes for the same medical event. This causes issues when trying to aggre-
gate how frequently a medical event occurs after the drug of interest for the
same population as the redundancy partitions the medical event and these
partitions have smaller frequencies than if they were all grouped together.
If future worked aimed to develop an algorithm that could group the READ
codes that correspond to the same medical event together, the results of the
ADR signalling algorithms on the THIN database would improve.
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• Adapting the framework to identify drug-drug interactions
Many researchers have identified the requirement of identifying drug-drug
interactions ADRs. The THIN databases contains data that may be used
to signal drug-drug interaction ADRs and the SAP framework can readily
be adapted. Future work could aim to identify when a patient is taking
two drugs within a similar time interval and then, for drug A, drug B and
medical event 1, generate the attributes developed in Chapter 4 for three
different prescription situations, the first would be patients only taking
drug A, the second would be for patients only taking drug B and the third
would be patients taking both drugs. The three sets of attributes could
be combined into one data-point corresponding to drug A, drug B and the
medical event 1.
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Appendix A
The THIN Database
Introduction
The THIN database is a longitudinal resource containing temporal medical data
corresponding to over 3.5 million active patients and 11.5 million total patients.
The data are anonymously extracted from each individual general practice’s Vi-
sion clinical system, validated and combined to generate the THIN database. The
current database is 326Gb and covered 6.05% of the UK in 2012, with over 0.6
billion medical records (i.e., entries detailing an instance of a medical event such
as an illness, observation or laboratory event) and approximately 1 billion ther-
apy records (i.e., entries detailing an instance of a drug prescription). There is
a slightly higher relative proportion of female patients than male patients in the
database, with 47.7% of a patients being male and 52.3% being female, whereas
the 2011 census suggests the UK population is 49.1% male and 50.9% female.
The number of general practices included within the database is expanding over
time, with 12 new practices recruited during the first three quarters of 2013.
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Figure A.1: An entity relationship diagram of the THIN database.
The database is also expanding due to recently occurring records from registered
practices being added over time.
Structure
The structure of the main THIN database is illustrated in Figure A.1, there are
additional tables not included into the diagram due to them not being incor-
porated within this research. The three main tables are the patient table, the
therapy table and the medical table, see Figures A.2-A.4. Each patient within
the THIN database is represented by a unique anonymous patient id, named the
combid, and the patient table contains the attributes of each patient (e.g., their
year of birth, their body mass index, their smoking habits, the year they reg-
istered and the date of death if they have died). The medical table stores the
temporal data regarding the patients’ medical events. Each entry in the medical
table contains a combid that refers to the patient experiencing the medical event,
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a READ code that corresponds to a medical event and the date that the medical
event occurred. The READ codes are there due to database normalisation, but
one advantage of using the READ codes rather than string descriptions to repre-
sent a medical event is that they have a hierarchical structure that may be useful
when applying data analysis. The READ codes and their structure are discussed
in greater detail further in thin Chapter. The therapy table contains records
regarding drug prescriptions. Each therapy record contains the combid referring
to the patient being prescribed the drug, a drugcode corresponding to the drug
being prescribed and the prescription date. The drugcode is also introduced due
to database normalisation. The drugcode does not have an obvious structure but
each drugcode is linked to up to three British National Formulary (BNF) codes
corresponding to the main chemical components that make up the drug. The
BNF codes do have a hierarchical structure and can be used to identify similar
groups of drugs. The BNF codes are also discussed in greater detail in the latter
section of this Chapter.
READ Codes
The READ codes are a clinical terminology thesaurus used for recording medical
events within General Practice databases. Each medical event is encoded into
a READ code, and the READ code consists of five elements from the alphabet
{1−9, a−z, A−Z, •}. The READ codes have a hierarchal tree structure with five
levels. The medical events become more specific as the level increases, so the child
READ codes correspond to the same medical event as their parent READ code
but are more specific. The level of a READ code x = x1x2x3x4x5 is calculated
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Figure A.2: A screen shot of the patient table contained within the THIN
database.
Figure A.3: A screen shot of the therapy table contained within the THIN
database.
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Figure A.4: A screen shot of the medical table contained within the THIN
database.
Figure A.5: An example of the branch of the THIN READ code tree.
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as,
Lv(x) =


argmini{(i− 1)|xi = •} if ∃i s.t. xi = •
5 otherwise.
(A.1)
An example of a branch in the READ codes is,
A• • •• Infectious and parasitic diseases (level 1)
A1• • • Tuberculosis (level 2)
A12•• Other respiratory tuberculosis (level 3)
A120• Tuberculosis pleurisy (level 4)
A1201 Tuberculosis of pleura (level 5)
where it can be seen that all the READ codes above are infections and the infec-
tion represented by the READ code becomes more detailed as the level increases.
A graphical illustration of this section of the READ code tree can be seen in
Figure A.5.
Unfortunately, the READ codes have redundancies and a single medical event
may have multiple corresponding READ codes found in widely varying branches
of the READ code tree. This can lead to issues during data analysis as it is
difficult to aggregate the data for the READ codes corresponding to the same
medical event, and the partitioning can result in a lower confidence in the results
that are obtained. There are also problems with inconsistent READ code usage
by medical staff. For example, some staff may frequently enter high level specific
READ codes while others may have a tendency to enter low level READ codes
that are less specific. Furthermore, it is common to find ‘temporal READ code
progressions’, where a low level READ code is initially recorded and shortly in
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Figure A.6: An example of the branch of the British National Formulary (BNF)
tree.
time afterwards a child or grand-child READ code is recorded due to additional
knowledge being obtained.
BNF Codes
The BNF codes are based on BNF sections. They have a hierarchal tree structure
linking drugs that are prescribed for the similar indication (i.e., the reason for
being given the drug), and drugs with the same BNF code are from the same
drug family. Figure A.6 illustrates a branch of the BNF code tree. If we consider
each BNF code to be represented by yi = yi1.yi2.yi3.yi4, where each element is in
the alphabet {1 − 15, 00}, then yi1 is the primary category, yi2 is the secondary
category, yi3 is the tertiary category and yi4 is the quaternary category. There are
15 different primary categories, these primary categories relate to the the most
general description of the drug indication. The similarity between two BNF codes
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yi1 Category
1 Gastro-intestinal system
2 Cardiovascualar system
3 Respiratory system
4 Central nervous system
5 Infections
6 Endocrine system
7 Obstetrics, gynaecology, and urinary-tract disorders
8 Malignant disease and immunosuppression
9 Nutrition and blood
10 Musculoskeletal and joint diseases
11 Eye
12 Ear, nose, and oropharynx
13 Skin
14 Immunological products and vaccines
15 Anaesthesia
can be calculated as,
S(yi,yj) =
|{yik|yik = yjk}|
max(|{k|yik 6= 00}|, |{k|yjk 6= 00}|)
(A.2)
where the similarity measure is 1 if and only if the two BNF codes are the same,
and greater than zero if and only if the BNF codes correspond to drugs prescribed
for a similar indication.
Issues & Validation
There are known issues with the database including concept drift and problems
with the level of time stamp detail. In general, the data is validated during
extraction and additional fields are added into the tables to indicate the integrety
of each record, so problematic records can be excluded from the study.
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Data Collection Issues
One of the main limitations of the THIN data is changes in the way data is
collected or the type of data collected over time may lead to concept drift. Over
time the READ codes that are actively used may change, new READ codes may
get added and old READ codes may be removed. For example, it is common for
old records to contain the READ code ’ZZZZZ’ corresponding to an unmappable
medical event. The drug prescription rate is unlikely to stay constant over time,
as new knoweldge of suspected ADRs or new studies detailing the effectiveness
of a drug can impact a General Practioneers decision to prescribed a drug. It is
also common for new drugs to be introduced.
Time Stamps
Each record in the medical and therapy table contains a time stamp. These time
stamps are the day that the doctors entered the event of prescription into the
database. As the time stamp is only in days, it is not possible to determine the
order for the medical events and prescriptions within one day. When a medical
event and prescription are recordered for the same paient on the same day it may
be possible that the patient was prescribed the medication due to the medical
event or that the medical event is an adverse drug reaction of the medication.
To address the uncertainty of the order of events with the same timestamp
for the same patient, the medical events recorded on the day a drug is prescribed
are often ignorred from the calculation of assocation between a drug and medical
event.
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Appendix B
Drugs
Drugs Investigated
NSAIDs
The drugs Ibuprofen, Ketoprofen, Fenoprofen and Celecoxib used in this study
are all from the same drug family known as non-steroidal anti-inflammatory drugs
(NSAIDs). These drugs are typically prescribed for continuous pain associated
with inflammation and have a variety of common side effects including gastroin-
testinal disturbances, hypersensitivity reactions and depression. Rarer side ef-
fects include congestive heart failure, renal failure and hepatic failure. Elderly
patients are more prone to side effects associated with NSAIDs. In this study the
the drugs tended to be prescribed sightly more to females with the male propor-
tion ranging from 0.335 − 0.405 and to older patients, although Ibuprofen was
prescribed to younger patients more than the other NSAID drugs. The NSAID
drug prescribed the most was Ibuprofen with over a million first in 13 month
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Table B.1: Information about the NSAID drugs investigated in this paper. Total
is the number of times the drug is prescribed for the first time in 13 months, age
is the average age of the patients who are prescribed the drug for the first time in
13 months and male proportion is the number of patients that are male divided
by the total number of patients who are prescribed the drug for the first time in
13 months.
Drug Total TPD MUTARA ROR Age male proportion
celecoxib 68036 62946 62100 63416 62.49 0.335
ibuprofen 1178163 1012555 858819 903415 45.56 0.405
ketoprofen 72946 65718 61710 63536 58.17 0.375
fenoprofen 1255 1008 975 1036 56.29 0.404
prescriptions, whereas Fenoprofen was only prescribed 1225 times for the first
time in 13 months, see Table B.1.
Quinolones
The quinolones are a class of drugs used to treat bacterial infections such as res-
piratory track infections and urinary-track infections. Ciprofloxacin, levofloxacin,
moxifloxacin, nalidixic acid and norfloxacin are drugs from the quinolone family
that are investigated in this paper. The quinolones have many side effects, includ-
ing tendon rupture. The average age of the patients prescribed the quinolones
for the first time in 13 months was similar between all the drugs, around the
late fifties. The male proportion shows that females are prescribed quinolones
more than males, but this was more obvious for norfloxacin and nalidixic acid.
Ciprofloxacin was the most prescribed quinolone and moxifloxacin was the least
common, with only 1465 prescriptions. Table B.2 shows the information on the
drugs from the THIN database.
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Table B.2: Information about the Quinolone drugs investigated in this paper.
Total is the number of times the drug is prescribed for the first time in 13 months,
age is the average age of the patients who are prescribed the drug for the first
time in 13 months and male proportion is the number of patients that are male
divided by the total number of patients who are prescribed the drug for the first
time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
ciprofloxacin 280011 250158 227739 235420 55.64 0.440
levofloxacin 7662 7028 6775 6928 60.55 0.43
norfloxacin 14876 13224 12220 12625 56.83 0.262
moxifloxacin 1465 1347 1343 1371 62.09 0.419
nalidixic acid 4273 3646 3620 3787 55.63 0.127
Table B.3: Information about the tricyclic drugs investigated in this paper. Total
is the number of times the drug is prescribed for the first time in 13 months, age
is the average age of the patients who are prescribed the drug for the first time in
13 months and male proportion is the number of patients that are male divided
by the total number of patients who are prescribed the drug for the first time in
13 months.
Drug Total TPD MUTARA ROR Age male proportion
doxepin 6752 6029 5908 6104 56.69 0.316
lofepramine 45532 38565 37642 39517 51.39 0.285
nortriptyline 11775 10519 10307 10650 54.43 0.286
Tricyclic Antidepressants
Tricyclic antidepressant drugs are a family of drugs used to treat depression and
are known to cause, among others, cardiovascular and central nervous system side
effects. The three drugs, doxepin, lofepramine and nortriptyline where selected in
this paper. The tricyclic antidepressants investigated are prescribed to patients
with similar ages and genders and tend to be prescribed more often to older
females. The main difference between the drugs is that doxepin is only prescribed
to 6752 patients whereas the other two drugs are prescribed to more than 10000
patients, see Table B.3.
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Table B.4: Information about the calcium channel blocker drugs investigated in
this paper. Total is the number of times the drug is prescribed for the first time
in 13 months, age is the average age of the patients who are prescribed the drug
for the first time in 13 months and male proportion is the number of patients that
are male divided by the total number of patients who are prescribed the drug for
the first time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
nifedipine 125491 112715 112499 115823 65.29 0.453
verapamil 24334 22000 21896 22513 65.01 0.405
felodipine 69534 65093 64036 65202 67.46 0.454
amlodipine 270918 251316 249972 254876 66.68 0.494
nicardipine 2796 2510 2511 2593 65.91 0.481
Calcium Channel Blockers
The drugs nifedipine, nicardipine, amlodipine, felodipine and verapamil are all
calcium channel blocker that are used to treat high blood pressure and raynaud’s
phenomenon. It is common for the calcium channel blockers to be prescribed
with other drugs and applying the existing algorithms to detect side effects on
the calcium channel blockers will investigate the effect of confounding due to
multiple prescriptions. The drug nifidipine was previously used to investigate
the TPD applied to the UK IMA Disease Analyzer, so investigating the calcium
channel blockers will also give insight into how robust the TPD is when applied
to different electronic healthcare databases. The calcium channel blockers are
generally prescribed for the first time in 13 months to patients around 65 years
old. Amlodipine and nicardipine are prescribed only slightly more to females than
males, whereas the other calcium channel blockers investigated are prescribed
even more often to females. Amlodipine and nifedipine have been prescribed
over 100000 times for the first time in 13 months in the THIN database, but
nicardipine has only been prescribed 2796 times, see Table B.4.
208
Table B.5: Information about the sulphonylurea drugs investigated in this paper.
Total is the number of times the drug is prescribed for the first time in 13 months,
age is the average age of the patients who are prescribed the drug for the first
time in 13 months and male proportion is the number of patients that are male
divided by the total number of patients who are prescribed the drug for the first
time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
glibenclamide 11874 10356 10377 10768 65.12 0.540
gliclazide 45824 41626 40537 41612 65.02 0.546
glimepiride 10957 10156 9882 10081 64.20 0.534
glipizide 5315 4856 4614 4731 66.50 0.535
tolbutamide 3113 2758 2793 2894 69.40 0.487
Sulphonylureas
The sulphonylurea drug family includes tolbutamide, glibenclamide, gliclazide,
glimepiride and glipizide. They are a class of antidiabetic drugs used for the
management of type 2 diabetes mellitus. The sulphonylureas are prescribed for
the first time in 13 months to older patients will an average age around 65 years
old and all the sulphoylureas investigated except tolbutamide are prescribed more
often to males, with approximately equal male proportions. Glipizide and tolbu-
tamide are the less frequently prescribed sulphonylurea drugs. The general infor-
mation about each of the sulphonylurea drugs can be seen in Table B.5.
Penicillins
The last drug family is the Penicillin drugs amoxicillin, ampicillin, flucloxacillin,
benzylpenicillin and phenoxymethlypenicillin. These drugs are used to treat bac-
terial infections. The number of times the drugs are recorded as being prescribed
in the THIN database varies between 2000 to over two million. There is also a
divergence between the average age of the patients prescribed each of the drugs,
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Table B.6: Information about the penicillin drugs investigated in this paper.
Total is the number of times the drug is prescribed for the first time in 13 months,
age is the average age of the patients who are prescribed the drug for the first
time in 13 months and male proportion is the number of patients that are male
divided by the total number of patients who are prescribed the drug for the first
time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
amoxicillin 2795759 2321098 1593874 1718875 38.84 0.427
benzylpenicillin 2071 1610 1840 1972 31.79 0.471
flucloxacillin 971174 834017 729967 765428 41.42 0.456
phenoxymethly 55397 45941 45679 48142 29.67 0.396
ampicillin 80655 63458 64827 69381 39.18 0.423
with the penicillins generally being prescribed to younger patients than many of
the other drugs families investigated in this paper. The male proportion is fairly
similar between the different penicillin drugs, with females being prescribed the
drug more often than males, see Table B.6.
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Appendix C
Software Details and Preliminary
Work
C.1 Software Details
The data were stored in MS SQL server and the data manipulation (generation of
the Bradford Hill causality consideration attributes) was performed using SQL.
The classification was performed using the function ‘train’ and the feature se-
lection used to pre-process the data prior to classification for all the classifiers
expect random forest was the function ‘rfe’ within the ‘caret’ package [97] in the
open source software R. The ‘rfe’ function found the subset of attributes that
maximised the accuracy of the classification. The ‘train’ function trained the
various classifiers based on maximising the AUC performance measure using a
parameter grid search.
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C.2 Wrapper Feature Selection
Table C.1: The features selected and their rank of importance based on applying
naive Bayes wrapper for the analysis performed in Chapter 5.
Attribute Nifedipine Ciprofloxacin Ibuprofen
Subset Size 25 30 30
TPD IC delta (x1) 4(17) 4(14) 4(7)
TPD IC delta 95% CI (x2) 4(22) 4(2) 4(18)
RD all (x3) 5 4(1) 4(3)
RD first drug (x4) 4(19) 4(3) 4(1)
RD first BNF (x5) 5 4(6) 4(2)
RR all (x6) 4(21) 4(29) 4(10)
RR first drug (x7) 4(10) 4(27) 4(5)
RR first BNF (x8) 4(5) 4(24) 4(12)
OR all (x9) 4(25) 4(30) 4(9)
OR first drug (x10) 4(9) 4(28) 4(6)
OR first BNF (x11) 4(4) 4(25) 4(11)
AB month all (x12) 4(16) 4(23) 4(19)
AB month first drug (x13) 4(7) 4(16) 4(25)
AB month first BNF (x14) 4(3) 4(20) 4(27)
TPD filter 1 (x15) 4(15) 5 4(29)
TPD filter 2 (x16) 5 5 5
LEOPARD (x17) 5 4(18) 4(26)
Read code Lv 5 (x18) 4(18) 4(21) 4(28)
Age all (x19) 4(8) 4(7) 4(15)
Age first drug (x20) 4(2) 4(5) 4(8)
Age first BNF (x21) 4(1) 4(4) 4(4)
Gender all (x22) 5 4(11) 5
Gender first drug (x23) 4(11) 4(12) 4(17)
Gender first BNF (x24) 4(6) 4(13) 4(21)
Dosage (x25) 4(13) 4(26) 4(20)
Experimentation (x26) 5 4(17) 4(13)
Noise (x27) 4(24) 4(19) 4(14)
Illness progression (x28) 5 4(15) 4(24)
AB month Lv 3 (x29) 4(23) 4(9) 4(16)
AB month Lv 4 (x30) 4(14) 4(22) 4(23)
Read code Lv 4 (x31) 4(12) 4(10) 5
Read code Lv 3 (x32) 4(20) 4(8) 4(22)
Read code Lv 2 (x33) 5 5 4(30)
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C.3 Preliminary Work
The following is extracted from my conference paper title ‘Attributes for causal
inference in longitudinal observational databases’:
Feature Selection
In this study we apply a multivariate filter, the Correlation-based Feature Se-
lection (CFS) algorithm [69], as this algorithm is not dependent on a specific
classifier. The CFS algorithm finds the optimal feature subset based on the
trade-off between how correlated the class labels are to the feature subset and
how intercorrelated the features of the subset are.
The feature selection was applied to the attributes descirbed in Tables C.2-C.3.
The data used in this study are extracted from The Health Improvement Network
database (www.thin-uk.com) and can be found at: http://www.ima.ac.uk/reps.
Results
Table C.4 shows that the optimal attribute subset to use for ADR discovery is
LEOPARD, RD13BNF , ABratio Level 3, Gender Ratio and Read Code Level.
The temporal and strength attributes had the greatest correlation with the class
labels, whereas 75% of the dosage attributes has a zero correlation measure.
Discussion
The results show that the temporal and strength attributes are key for signalling
ADRs as these had the highest correlation with the class labels but the specificity
attributes Gender Ratio and Read Code level offered potentially new in sight than
213
Table C.2: Attribute Summary Table
Feature Criterion Description
RR, RD, OR Strength The Risk Ratio, Risk Difference and
Odds Ratio for all prescriptions.
RR13d,RD13d,OR13d Strength The Risk Ratio, Risk Difference and
Odds Ratio for drugs prescribed for the
first time in 13 months.
RR13BNF ,RD13BNF
,OR13BNF
Strength The Risk Ratio, Risk Difference and
Odds Ratio for drugs corresponding to a
bnf that has not been prescribed in the
last 13 months.
IC∆ Strength The TPD Information Component as
calculated in [128]
lowerIC∆ Strength The lower 95% interval of the Informa-
tion Component as calculated in [128]
Age STDEV Specificity Standard deviation of patient’s age who
experience medical event after drug di-
vided by standard deviation of the ages
for all the patients.
Gender Ratio Specificity Male proportion of patients experiencing
the medical event within 30 days of the
drug divided by male proportion of pa-
tients prescribed the drug.
RR drug / RR bnf Specificity The RR of the drug divided by the RR
for all the drugs in the same family.
Read Code Level Specificity The specificity level of the medical event:
general (level 1)- specific (level 5).
ABratio Level 2 Temporality How often the level 2 version of the med-
ical event is recorded after the prescrip-
tion compared to before.
ABratio Level 3 Temporality How often the level 3 version of the med-
ical event is recorded after the prescrip-
tion compared to before.
LEOPARD [161] Temporality 1 if the drug is prescribed significantly
more after the medical event than before,
0 otherwise.
OEfilt1 [128] Temporality 1 if the IC∆ is greater the month before
the drug than the month after, 0 other-
wise.
OEfilt2 [128] Temporality 1 if the IC∆ is greater on the day of pre-
scription compared to the month after, 0
otherwise.
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Table C.3: Attribute Summary Table
Feature Criterion Description
Dosage Ratio Dosage Average dosage of patients experiencing
the medical event within 30 days of the
drug divided by average dosage of pa-
tients prescribed the drug.
High Low Ratio Dosage Proportion of patients given the high-
est dosage that experience the medical
event (within 30 days) divided by the
proportion of patients given the lowest
dosage that experience the medical event
(within 30 days).
Spearman’s rank Dosage The Spearman’s rank correlation coef-
ficient between the patient dosage and
{0, 1} indicating if the patient experi-
enced the medical event within 30 days.
Pearson
product-
moment
Dosage The Pearson product-moment correla-
tion coefficient between the patient
dosage and {0, 1} indicating if the pa-
tient experienced the medical event
within 30 days.
Repeat1 Experiment Number of patients that have medical
event in at least two distinct hazard peri-
ods and not in their non-hazard periods
divided by the number of patients that
have at least two distinct hazard periods
and have medical event in one hazard pe-
riod.
Repeat2 Experiment Number of patients that have medical
event in two distinct hazard periods and
not in their non-hazard periods divided
by the occurrence in the non-hazard pe-
riods.
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available via the temporal and strength attributes. The experiment and dosage
attributes investigated in this paper did not offer sufficient additional information
than what could be gained from the RD13BNF or the LEOPARD attributes,
although there does appear to be some correlation between the class labels and
both the Pearson’s correlation rank attribute and the Repeats attributes.
The reason the dosage attributes did not have a greater correlation with the
class labels may be due to a limiting factor of comparing different measurement
types. The dosages can be recorded via different measurement types for exam-
ple ‘mg’, ‘%’, ‘mm x cm xcm’ or the measure type may be missing. As it is
difficult to determine if x quantity of ‘mg’ is greater than y quantity of ’%’, the
dosage attributes were calculated only considering prescriptions measured in ‘mg’
(as this was the most popular). Unfortunately this resulted in occasional issues
due to ‘mg’ measured prescriptions of some drugs investigated always being the
same quantity or many prescriptions of a drug not being included in the dosage
attribute calculations. The experiment attributes were also limited if the drug
investigated was rarely repeated. Furthermore, the experiment attributes may
have been biased in this study due to using known ADRs, as if an ADR is known
and a patient experiences the ADR after the drug then the doctor is likely to no-
tice this and not prescribed the drug to that patient in the future. One possible
way to overcome this issue would be to use only newly discovered ADRs in the
data as the medical records may be more likely to have patients, who at the time
unknowingly experienced the ADRs, having a repeat prescription.
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Table C.4: The results of the CFS algorithm ordered by the measure of correlation
with the class labels. Attributes not selected by the CFS algorithm have the
attribute they are most correlated to listed in the CFS rank column.
Attribute Class Correlation CFS Rank
LEOPARD 0.3238 1
OEfilt1 0.2637 LEOPARD
OEfilt2 0.2618 LEOPARD
RD13BNF 0.2347 2
RD13d 0.2248 LEOPARD
RD 0.2231 RD13BNF
ABratio Lv3 0.2231 3
ABratio Lv2 0.1755 ABratio Lv3
RR13d 0.1593 RD13BNF
OR13d 0.1593 RD13BNF
RR13BNF 0.1514 RD13BNF
OR13BNF 0.1514 RD13BNF
RR 0.1408 RD13BNF
OR 0.1408 RD13BNF
lowerIC∆ 0.135 RD13BNF
Pearson rank 0.1029 RD13BNF
Gender Ratio 0.0663 4
Repeats1 0.0651 LEOPARD
Repeats2 0.0651 LEOPARD
IC∆ 0.0608 RD13BNF
Read Code Lv 0.0279 5
RRDrug/RRBNF 0 -
Dosage Ratio 0 -
High Low Ratio 0 -
Age STDEV 0 -
Spearman’s’ rank 0 -
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Conclusion
In this paper we have applied feature selection to attributes we generated based on
the Bradford Hill causality criteria to determine suitable attributes to be used by
a general learning algorithm to identify side effects in LODs. This is the first time
suitable attributes for identifying causal relations between prescribed drugs and
medical events have been explored and the results now present the opportunity to
develop novel learning algorithms. We have found that the specificity attributes
offer additional information for ADR signalling and it would be advantageous to
include them into ADR signalling algorithms. Unfortunately the experiment and
dosage attributes were not very correlated with the class labels but this is likely
to be due to current limitations.
Possible future work could focus on developing a way to compare prescriptions
with different measurement types so all the prescription data can be used for
calculating the dosage attributes or involve developing attributes that cover the
remaining Bradford Hill causality criteria (plausibility, coherence, consistency and
analogy).
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Appendix D
SAP Result Tables
ADR Signalling Framework Results
The signals generated by the SAP framework on the unlabelled data for the drugs
Nifedipine, Ciprofloxacin, Ibuprofen, Budesonide and Naproxen.
Nifedipine
Read Code Medical Event Frequency
N131. Cervicalgia - pain in neck 3659
D00.. Iron deficiency anaemias 1281
81H.. Dressing of wound 7674
K15.. Cystitis 3156
461.. Urine exam. - general 1482
R090. [D]Abdominal pain 2520
H00.. Acute nasopharyngitis 1037
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1C9.. Sore throat symptom 2749
1D13. C/O: a pain 5013
16C2. Backache 2527
M18z. Pruritus NOS 1976
413.. Laboratory test requested 6064
H05z. Upper respiratory infection NOS 6865
M0z.. Skin and subcut tissue infection NOS 454
G84.. Haemorrhoids 1494
1972. Epigastric pain 1537
1M10. Knee pain 2690
M2yz. Other skin and subcutaneous tissue disease NOS 2102
A53.. Herpes zoster 1549
M01.. Furuncle - boil 342
K190z Urinary tract infection, site not specified NOS 5167
M12z1 Eczema NOS 2785
16C6. Back pain without radiation NOS 2385
2.... Examination / Signs 2845
R021z [D]Rash and other nonspecific skin eruption NOS 2875
H33.. Asthma 2792
N142. Pain in lumbar spine 4225
8HQ1. Refer for X-Ray 2421
H06z0 Chest infection NOS 14291
H27z. Influenza NOS 678
1C14. Blocked ear 994
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2D82. O/E - wax in auditory canal 1939
892.. Informed consent for procedure 1976
M03z0 Cellulitis NOS 2326
856.. Acupuncture 597
1625. Abnormal weight loss 581
M101. Seborrhoeic dermatitis 803
M2z0. Skin lesion 931
ZV583 [V]Attention to surgical dressings or sutures 347
ZV681 [V]Issue of repeat prescription 2994
8BMC. Prescription collected by pharmacy 1206
1922. Sore mouth 476
H02.. Acute pharyngitis 1055
8C1B. Nursing care blood sample taken 10786
2516. Abdomen examined - NAD 902
AB0.. Dermatophytosis including tinea or ringworm 1051
8H5B. Referred to urologist 975
M0... Skin and subcutaneous tissue infections 963
8CA.. Patient given advice 5746
E2B.. Depressive disorder NEC 3082
N094K Arthralgia of hip 2466
1A... Genitourinary symptoms 1313
41B1. Blood test due 2474
8H77. Refer to physiotherapist 1952
F587. Otalgia 1047
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K190. Urinary tract infection, site not specified 3347
8E... Physiotherapy/remedial therapy 2474
2F13. O/E - dry skin 2055
Z4A.. Discussion 4065
AB2.. Candidiasis 1156
TC... Accidental falls 4253
SP255 Postoperative wound infection, unspecified 568
25Q.. O/E - rectal examination done 484
22L.. O/E - wound healing 325
H26.. Pneumonia due to unspecified organism 382
M180. Pruritus ani 568
D21z. Anaemia unspecified 1690
M21z1 Skin tag 474
N2471 Leg cramps 1915
8BAA. Pain relief 1455
F502z Otitis externa NOS 1962
1J4.. Suspected UTI 1551
1.... History / symptoms 1610
1C... Ear/nose/throat symptoms 287
58D.. Ultrasound scan 259
AB01. Dermatophytosis of nail 939
M07z. Local infection skin/subcut tissue NOS 986
J43.. Other non-infective inflammatory gastroenteritis
and colitis
719
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67I.. Advice 1789
22J.. O/E - dead 231
F501. Infective otitis externa 1395
8B3A1 Medication increased 3450
N094. Pain in joint - arthralgia 1243
M161z Psoriasis NOS 599
R062. [D]Cough 959
176.. C/O - catarrh 370
8B314 Medication review 15307
M111. Atopic dermatitis/eczema 1320
1C3.. Earache symptoms 383
1CA2. Hoarse 430
1C12. Hearing difficulty 704
J520z Constipation NOS 965
2128. Patient’s condition the same 5198
F1310 Benign essential tremor 91
2227. O/E - rash present 836
8C9.. Reassurance given 671
A781. Viral warts 420
J50zz Intestinal obstruction NOS 134
C2621 Vitamin B12 deficiency 323
8H9.. Planned telephone contact 809
1D14. C/O: a rash 3294
N143. Sciatica 2510
223
M12z0 Dermatitis NOS 1143
K28y6 Epididymal cyst 185
M262. Sebaceous cyst - wen 659
67E.. Foreign travel advice 1570
73050 Irrigation of external auditory canal for removal
of wax
9722
8B21. Drug prescription 637
2315. Resp. system examined - NAD 1622
1D15. C/O: itching 715
4K... General pathology 1119
85D.. Injection given 737
F51.. Nonsuppurative otitis media + eustachian tube
disorders
94
8B3H. Medication requested 16644
16C5. C/O - low back pain 1507
H060. Acute bronchitis 2569
19EA. Change in bowel habit 812
8P... Removal of surgical material and sutures 230
M230. Ingrowing nail 521
E112. Single major depressive episode 328
R0300 [D]Appetite loss 203
R0040 [D]Dizziness 2585
7G223 Removal of suture from skin NEC 809
J082. Oral aphthae 645
224
1C8.. Nasal symptoms OS 301
6896. Depression screening using questions 12687
16C.. Backache symptom 451
M244. Folliculitis 402
R021. [D]Rash and other nonspecific skin eruption 520
7NB16 [SO]Toe NEC 20
19FZ. Diarrhoea symptom NOS 374
ZV49z [V]Unspecified limb or other problem 1398
1739. Shortness of breath 1856
F4E51 Xanthelasma 31
1832. Ankle swelling 1681
8BAD. Chemotherapy 236
1982. Nausea present 440
H17.. Allergic rhinitis 504
M12.. Contact dermatitis and other eczemas 316
2D... Ear, nose + throat examination 610
5882. Spirometry 386
M036z Cellulitis and abscess of leg NOS 534
8H21. Admit medical emergency unsp. 470
68M.. Spirometry screening 381
70560 Carpal tunnel release 346
8HP2. Refer for microbiological test 285
Eu32z [X]Depressive episode, unspecified 832
1AG.. Recurrent urinary tract infections 294
225
J1544 Helicobacter gastritis 15
ZGB62 Advice about side effects of drug treatment 55
M05.. Impetigo 242
2G5.. O/E - foot 5012
ZGB64 Advice to start drug treatment 112
8B35. Drug Rx stopped-medical advice 1671
J530. Anal fissure 173
C3541 Hypercalcaemia NEC 113
N2133 Olecranon bursitis 483
R1057 [D]Glucose, blood level abnormal 318
F4Kz1 Eye pain NOS 522
Z1B13 Change of dressing 348
6A... Patient reviewed 37926
Eu410 [X]Panic disorder [episodic paroxysmal anxiety] 13
F4D0. Blepharitis 1266
7K6WS Arthroscopic acromioplasty 23
165.. Temperature symptoms 217
2FD.. O/E - skin cyst 360
G3111 Unstable angina 120
73130 Myringotomy and insertion of short term grom-
met
26
1BK.. Worried 329
8B41. Repeated prescription 6599
N30z8 Bone infection NOS, of other specified site 70
226
8B3A2 Medication decreased 1337
N0946 Arthralgia of the lower leg 3023
F52z. Otitis media NOS 624
E2003 Anxiety with depression 790
G57y9 Supraventricular tachycardia NOS 99
M03z1 Abscess NOS 157
G581. Left ventricular failure 1154
M01z. Boil NOS 182
8C1.. Nursing care 2782
G57y7 Sinus tachycardia 57
J5730 Rectal haemorrhage 1424
R0350 [D]Excessive thirst 36
ZV700 [V]Routine health checkup 152
8C15. Nursing care - dressing 1557
G30.. Acute myocardial infarction 1145
R0734 [D]Bloating 107
H041. Acute tracheitis 541
1BE1. Problem situation 238
E2C01 Anger reaction 10
168.. Tiredness symptom 1848
J521. Irritable colon - Irritable bowel syndrome 848
5.... Radiology/physics in medicine 706
F504. Impacted cerumen (wax in ear) 4067
7N511 [SO]Prostate 57
227
8HQ2. Refer for ultrasound investign 403
8B24. Prescription given no examination of patient 907
SD... Superficial injury 446
7L143 Intravenous blood transfusion NEC 303
ZV411 [V]Other eye problems 420
AB200 Candidiasis of mouth 445
1B1X. Behavioural problem 3
ZGB17 Advice to stop treatment 18
8B316 Medication changed 2761
ZGB67 Advice about drug dosage 208
4JK21 High vaginal swab culture negative 7
H170. Allergic rhinitis due to pollens 768
7L172 Blood withdrawal for testing 12960
7H2B0 Paracentesis abdominis for ascites 6
ZV6D5 [V]Person consulting for explanatn of investiga-
tion findings
232
22Q.. Wound observation 237
N2179 Plantar fasciitis 789
R090B [D]Groin pain 651
M07yz Other spec local skin/subc infection NOS 646
ZV720 [V]Examination of eyes and vision 114
R1320 [D]Echocardiogram abnormal 28
G83.. Varicose veins of the legs 752
7K6Z2 Injection of therapeutic substance into joint 372
228
1B5.. Incoordination symptom 2893
AB20. Candidiasis of mouth and oesophagus 368
79294 Insertion of coronary artery stent 64
A7811 Verruca plantaris 123
A7814 Plain wart 151
F4Kz4 Redness of eye NOS 282
Z1823 Chaperone refused 44
N135z Torticollis NOS 71
195.. Indigestion symptoms 365
1M... Pain 634
M12z2 Infected eczema 186
7G2E3 Dressing of skin NEC 731
1BT.. Depressed mood 908
S64.. Intracranial injury NOS 290
196.. Type of GIT pain 437
Table D.1: The medical events signalled by the SAP framework with the random
forest classifier for the drug Nifedipine. The medical events are ranked by the
confidence returned by the classifier for the medical event belonging to the ADR
class.
Ciprofloxacin
Read Code Medical Event Frequency
1BT.. Depressed mood 625
2227. O/E - rash present 329
E2B.. Depressive disorder NEC 779
229
A53.. Herpes zoster 364
892.. Informed consent for procedure 513
Z4A.. Discussion 2861
66R5. Rep.presc. treatment changed 515
C04.. Acquired hypothyroidism 324
32... Electrocardiography 363
D00.. Iron deficiency anaemias 468
R021z [D]Rash and other nonspecific skin eruption NOS 658
168.. Tiredness symptom 1006
8E... Physiotherapy/remedial therapy 686
D00y1 Microcytic hypochromic anaemia 164
J082. Oral aphthae 285
Eu32. [X]Depressive episode 139
1D14. C/O: a rash 1310
F4430 Anterior uveitis 9
8C1B. Nursing care blood sample taken 3263
E2741 Transient insomnia 164
81H.. Dressing of wound 4336
J520z Constipation NOS 433
R0720 [D]Difficulty in swallowing 90
E200. Anxiety states 573
R090B [D]Groin pain 468
J5730 Rectal haemorrhage 465
R0608 [D]Shortness of breath 1143
230
7L172 Blood withdrawal for testing 3209
R021. [D]Rash and other nonspecific skin eruption 176
ZV57C [V]Palliative care 260
ZV682 [V]Expert advice request 43
G5y34 Ventricular hypertrophy 22
G5yy9 Left ventricular systolic dysfunction 11
S5yz1 Muscle injury / strain 46
2127. Patient’s condition worsened 1099
8B311 Medication given 2556
1D13. C/O: a pain 1931
8H77. Refer to physiotherapist 602
G580. Congestive heart failure 542
8B313 Medication commenced 929
Z1B13 Change of dressing 247
Z1K13 Removal of suture from skin 15
Z4G1B Giving encouragement to continue treatment 7
M18z. Pruritus NOS 576
8H9.. Planned telephone contact 581
E112. Single major depressive episode 87
Eu32z [X]Depressive episode, unspecified 356
ZV681 [V]Issue of repeat prescription 806
8H21. Admit medical emergency unsp. 340
K2710 Balanitis 77
22C2. O/E - oedema of ankles 383
231
R060A [D]Dyspnoea 397
70652 Nerve conduction studies 18
8BAA. Pain relief 782
R0300 [D]Appetite loss 88
8C15. Nursing care - dressing 981
681.. Screening - general 905
771Qz Diagnostic rigid sigmoidoscopic exam of sigmoid
colon NOS
134
ZV583 [V]Attention to surgical dressings or sutures 121
N145. Backache, unspecified 387
7G2E3 Dressing of skin NEC 351
Ryu8A [X]Hyperglycaemia, unspecified 22
G84.. Haemorrhoids 487
R0700 [D]Nausea 59
2315. Resp. system examined - NAD 988
N2470 Swelling of limb 328
AB200 Candidiasis of mouth 501
1B13. Anxiousness 700
313B. Audiogram 86
ZZZZZ converted code 4445
1982. Nausea present 428
1M10. Knee pain 685
7C032 Unilateral total orchidectomy - unspecified 39
8C1.. Nursing care 1124
232
173.. Breathlessness 2023
677B. Advice about treatment given 1826
M1535 Perioral dermatitis 17
761Fz Diagnostic fibreoptic endoscopic exam upper GI
tract NOS
158
7L17. Blood withdrawal 2638
70560 Carpal tunnel release 77
8H8.. Follow-up arranged 1439
C3652 Dehydration NEC 90
1B5.. Incoordination symptom 807
423.. Haemoglobin estimation 70
AB220 Candidal balanitis 67
2841. Confused 434
8B3A3 New medication commenced 293
R0420 [D]Swelling in head or neck 45
7L171 Venesection 610
ZV680 [V]Issue of medical certificate 1019
E2001 Panic disorder 192
ZL233 Under care of district nurse 55
H17.. Allergic rhinitis 158
8B316 Medication changed 727
G581. Left ventricular failure 318
E2003 Anxiety with depression 254
41D0. Blood sample taken 1984
233
R0073 [D]Lethargy 157
8HB2. Medical follow-up 533
21262 Asthma resolved 106
ZV6D6 [V]Alcohol abuse counselling and surveillance 4
N2174 Achilles tendinitis 130
7L185 Intramuscular injection of vitamin B12 724
7G2A6 Insertion of hormone implant 54
J4101 Ulcerative colitis 103
C3661 Fluid retention 94
S6460 Minor head injury 6
A3B11 Meticillin resistant staphylococcus aureus 73
M1616 Guttate psoriasis 17
7N522 [SO]Epididymis 31
8H4B. Referred to rheumatologist 132
68... Screening 724
8H76. Refer to dietician 150
ZV700 [V]Routine health checkup 48
R1057 [D]Glucose, blood level abnormal 82
H51y7 Malignant pleural effusion 15
R1100 [D]Albuminuria 27
Z174L Skin care 36
J50zz Intestinal obstruction NOS 102
C11y3 Impaired fasting glycaemia 45
44120 Urea and electrolytes normal 24
234
Eu410 [X]Panic disorder [episodic paroxysmal anxiety] 7
F4C71 Subconjunctival haemorrhage 90
A3A0. Gas gangrene 13
7G2EA Two layer compression bandage for skin ulcer 31
Table D.2: The medical events signalled by the SAP framework with the random
forest classifier for the drug Ciprofloxacin. The medical events are ranked by the
confidence returned by the classifier for the medical event belonging to the ADR
class.
Ibuprofen
Read Code Medical Event Frequency
D00.. Iron deficiency anaemias 1876
198.. Nausea 3084
K190z Urinary tract infection, site not specified NOS 5945
461.. Urine exam. - general 1842
M28.. Urticaria 1268
81H.. Dressing of wound 10761
2227. O/E - rash present 1717
D21z. Anaemia unspecified 2089
16E.. Feels unwell 2129
8H9.. Planned telephone contact 1386
H33.. Asthma 3253
M0z.. Skin and subcut tissue infection NOS 599
K190. Urinary tract infection, site not specified 4806
H06z0 Chest infection NOS 17499
235
22L.. O/E - wound healing 600
1B5.. Incoordination symptom 3824
R021z [D]Rash and other nonspecific skin eruption NOS 3253
SP255 Postoperative wound infection, unspecified 887
Z4A.. Discussion 8370
1D14. C/O: a rash 6155
1982. Nausea present 987
168.. Tiredness symptom 2937
535.. Standard chest X-ray 1465
R090. [D]Abdominal pain 4220
67I.. Advice 3408
1922. Sore mouth 794
7G2E3 Dressing of skin NEC 817
8HB2. Medical follow-up 2143
J5730 Rectal haemorrhage 1473
66R5. Rep.presc. treatment changed 2890
H1y1z Nasal cavity and sinus disease NOS 907
M0... Skin and subcutaneous tissue infections 1766
AB2.. Candidiasis 3488
1J4.. Suspected UTI 2814
1A... Genitourinary symptoms 1976
2315. Resp. system examined - NAD 2992
C34.. Gout 3709
66R.. Repeat prescription monitoring 3230
236
H30.. Bronchitis unspecified 1682
G20.. Essential hypertension 7883
4131. Blood test requested 2484
1C14. Blocked ear 1257
2F13. O/E - dry skin 2790
8B314 Medication review 13074
AB200 Candidiasis of mouth 681
E2B.. Depressive disorder NEC 5162
R062. [D]Cough 1180
J520z Constipation NOS 1422
M230. Ingrowing nail 1016
1BT.. Depressed mood 2678
F4D0. Blepharitis 1298
M07z. Local infection skin/subcut tissue NOS 1685
Eu32z [X]Depressive episode, unspecified 2044
G66.. Stroke and cerebrovascular accident unspecified 919
ZV720 [V]Examination of eyes and vision 147
8C1.. Nursing care 4083
8C15. Nursing care - dressing 2028
1AG.. Recurrent urinary tract infections 500
196.. Type of GIT pain 984
1737. Wheezing 1553
181.. Palpitations 1860
67E.. Foreign travel advice 3206
237
182.. Chest pain 10791
413.. Laboratory test requested 7598
1B321 Weakness of leg 177
8C1L. Wound care 884
23... Examn. of respiratory system 1535
ZV681 [V]Issue of repeat prescription 3691
81H5. Change of dressing 635
8B41. Repeated prescription 6877
R021. [D]Rash and other nonspecific skin eruption 894
F51y0 Eustachian tube dysfunction 742
F502z Otitis externa NOS 2593
E112. Single major depressive episode 569
1Y... Patient feels well 2684
AB20. Candidiasis of mouth and oesophagus 513
K28y8 Pain in testis 258
2841. Confused 1066
D00y1 Microcytic hypochromic anaemia 618
1.... History / symptoms 2793
M05.. Impetigo 1098
6A... Patient reviewed 70321
7G2E. Dressing of skin or wound 1255
1739. Shortness of breath 2489
8CA.. Patient given advice 9574
N2133 Olecranon bursitis 919
238
73050 Irrigation of external auditory canal for removal
of wax
9848
A07y0 Viral gastroenteritis 355
8HQ2. Refer for ultrasound investign 857
1D13. C/O: a pain 12907
8C1B. Nursing care blood sample taken 12573
H02.. Acute pharyngitis 2993
E200. Anxiety states 2845
AD30. Scabies 554
8H76. Refer to dietician 698
N20.. Polymyalgia rheumatica 2441
Z1B13 Change of dressing 498
M03z. Cellulitis and abscess NOS 1473
G65.. Transient cerebral ischaemia 1212
662.. Cardiac disease monitoring 17235
J0250 Dental abscess 909
1B8.. Eye symptoms 1863
7M0G1 Aspiration of other lesion of organ NOC 65
8H8.. Follow-up arranged 4686
8H5B. Referred to urologist 1159
J64.. Cholelithiasis 544
7NB00 [SO]Shoulder NEC 60
81HZ. Wound dressing NOS 1866
R012z [D]Gait abnormality NOS 155
239
2D82. O/E - wax in auditory canal 2078
ZV680 [V]Issue of medical certificate 4916
M18z. Pruritus NOS 2310
892.. Informed consent for procedure 3444
TGyz3 Accidental injury NOS 70
D41yz Other specified disease of blood or blood forming
organ NOS
148
1D131 C/O - pain in hallux 256
S2420 Fracture of scaphoid 83
R0701 [D]Vomiting 170
H060. Acute bronchitis 3311
G33.. Angina pectoris 3241
R0222 [D]Lump, localized and superficial 517
212.. Patient examined 3042
7G2B1 Injection of therapeutic substance into skin 183
41D0. Blood sample taken 8004
2128. Patient’s condition the same 14124
N30z8 Bone infection NOS, of other specified site 275
G30.. Acute myocardial infarction 629
4K... General pathology 1181
8BAA. Pain relief 4430
7G22. Removal of repair material from skin 1713
F501. Infective otitis externa 2790
AB0.. Dermatophytosis including tinea or ringworm 1382
240
173B. Nocturnal cough / wheeze 492
1C9.. Sore throat symptom 8963
N2243 Ganglion unspecified 216
8C9.. Reassurance given 1597
2126. Patient’s condition improved 22539
M15y1 Intertrigo 1556
M0203 Paronychia of finger 249
Z1B.. Dressing of skin or wound 677
7L172 Blood withdrawal for testing 13906
AB220 Candidal balanitis 102
A53.. Herpes zoster 2338
C3652 Dehydration NEC 117
8H7R. Refer to chiropodist 941
7G251 Drainage of lesion of skin NEC 189
H00.. Acute nasopharyngitis 1627
ZV49z [V]Unspecified limb or other problem 3605
F1382 Spasmodic torticollis 118
ZL146 Under care of deputising GP 245
R0052 [D]Insomnia NOS 2374
246.. O/E - blood pressure reading 7872
7G0C1 Biopsy of lesion of skin NEC 35
N2410 Myalgia unspecified 2246
SN52. Drug hypersensitivity NOS 251
M03z0 Cellulitis NOS 3272
241
8HQ1. Refer for X-Ray 7376
F4Kz4 Redness of eye NOS 282
ZV583 [V]Attention to surgical dressings or sutures 550
R0400 [D]Facial pain 568
7L171 Venesection 1946
7L11y Other specified injection of therapeutic sub-
stance
66
173.. Breathlessness 3310
M101. Seborrhoeic dermatitis 1018
R065z [D]Chest pain NOS 195
H26.. Pneumonia due to unspecified organism 489
19FZ. Diarrhoea symptom NOS 728
677B. Advice about treatment given 6676
8B311 Medication given 8307
19B.. Flatulence/wind 629
32... Electrocardiography 2209
SN530 Allergic reaction 110
ZV6D5 [V]Person consulting for explanatn of investiga-
tion findings
283
7L17. Blood withdrawal 11641
1B320 Weakness of arm 68
M244. Folliculitis 773
R0608 [D]Shortness of breath 2053
F4G01 Orbital cellulitis 56
242
N23y4 Spasm of muscle 597
E2001 Panic disorder 933
1954. Indigestion 1326
4617. MSU = abnormal 173
ZGB62 Advice about side effects of drug treatment 75
SP2y2 Postoperative pain 289
1D15. C/O: itching 1097
D00zz Iron deficiency anaemia NOS 52
N2241 Ganglion of joint 115
R082. [D]Retention of urine 440
N2457 Shoulder pain 1446
R0043 [D]Vertigo NOS 1898
C2943 Iron deficiency 130
ZZZZZ Converted code 21209
1A7.. Vaginal discharge symptom 1047
585.. Other diagnostic ultrasound 412
4618. Urine dipstick test 1090
704A0 Therapeutic lumbar epidural injection 121
M12.. Contact dermatitis and other eczemas 580
F586. Otorrhoea 286
7G090 Cauterisation of lesion of skin NEC 230
M200z Corns NOS 127
243
Table D.3: The medical events signalled by the SAP framework with the random
forest classifier for the drug Ibuprofen. The medical events are ranked by the
confidence returned by the classifier for the medical event belonging to the ADR
class.
244
Budesonide
Read Code Medical Event Frequency
R090. [D]Abdominal pain 1436
K190z Urinary tract infection, site not specified NOS 1626
N245. Pain in limb 5360
1A1.. Micturition frequency 892
892.. Informed consent for procedure 1286
D00.. Iron deficiency anaemias 670
413.. Laboratory test requested 3881
8C9.. Reassurance given 540
19C.. Constipation 2650
A53.. Herpes zoster 703
1D14. C/O: a rash 2553
2227. O/E - rash present 601
N142. Pain in lumbar spine 2397
1B8.. Eye symptoms 875
1B8Z. Eye symptom NOS 352
1M10. Knee pain 1999
N131. Cervicalgia - pain in neck 2365
Z4A.. Discussion 3827
K190. Urinary tract infection, site not specified 1513
TC... Accidental falls 1528
R021z [D]Rash and other nonspecific skin eruption NOS 1396
16C2. Backache 1185
245
M244. Folliculitis 394
1A... Genitourinary symptoms 760
AB0.. Dermatophytosis including tinea or ringworm 645
M03z0 Cellulitis NOS 1236
16C5. C/O - low back pain 1189
461.. Urine exam. - general 518
K15.. Cystitis 1687
2F13. O/E - dry skin 1066
F501. Infective otitis externa 1082
M0z.. Skin and subcut tissue infection NOS 272
1B5.. Incoordination symptom 1407
8H77. Refer to physiotherapist 1176
8B24. Prescription given no examination of patient 524
ZV583 [V]Attention to surgical dressings or sutures 233
M12z0 Dermatitis NOS 514
16C6. Back pain without radiation NOS 1831
81H.. Dressing of wound 3827
M07z. Local infection skin/subcut tissue NOS 736
1BT.. Depressed mood 1238
1J4.. Suspected UTI 1133
41D0. Blood sample taken 3193
8B4.. Previous treatment continue 5212
D21z. Anaemia unspecified 561
1D15. C/O: itching 494
246
2D82. O/E - wax in auditory canal 762
8H9.. Planned telephone contact 664
E2001 Panic disorder 432
7L172 Blood withdrawal for testing 6199
8C1B. Nursing care blood sample taken 4453
M101. Seborrhoeic dermatitis 438
N143. Sciatica 1198
7L17. Blood withdrawal 4396
M02z. Cellulitis and abscess of digit NOS 254
6A5.. Ongoing review 273
8B41. Repeated prescription 3431
22J.. O/E - dead 125
N0946 Arthralgia of the lower leg 1112
J155. Gastritis unspecified 324
8CA.. Patient given advice 4064
N094K Arthralgia of hip 1182
66R.. Repeat prescription monitoring 1212
E2B.. Depressive disorder NEC 1434
AB01. Dermatophytosis of nail 574
16E.. Feels unwell 789
16C.. Backache symptom 314
M2yz. Other skin and subcutaneous tissue disease NOS 986
E200. Anxiety states 1170
J520z Constipation NOS 471
247
6A... Patient reviewed 28334
2516. Abdomen examined - NAD 557
677B. Advice about treatment given 2990
2126. Patient’s condition improved 8208
H06z0 Chest infection NOS 20537
1955. Heartburn 634
8C1.. Nursing care 1349
7G22. Removal of repair material from skin 668
F59.. Hearing loss 653
E2273 Impotence 607
F502z Otitis externa NOS 783
M0... Skin and subcutaneous tissue infections 634
G20.. Essential hypertension 2258
N0945 Arthralgia of the pelvic region and thigh 519
M12.. Contact dermatitis and other eczemas 223
1C3.. Earache symptoms 556
4618. Urine dipstick test 355
R0300 [D]Appetite loss 82
M111. Atopic dermatitis/eczema 1739
R090B [D]Groin pain 358
2.... Examination / Signs 3388
M12z1 Eczema NOS 2033
424.. Full blood count - FBC 451
1C9.. Sore throat symptom 3604
248
8C15. Nursing care - dressing 771
7.... Operations, procedures, sites 259
ZV725 [V]Radiological examination NEC 63
22L.. O/E - wound healing 182
8E... Physiotherapy/remedial therapy 1413
58D.. Ultrasound scan 205
8BAA. Pain relief 890
1.... History / symptoms 1628
8BI.. Other medication review 448
M2z0. Skin lesion 454
22C2. O/E - oedema of ankles 577
M12z2 Infected eczema 276
J0931 Coated tongue 33
R0734 [D]Bloating 71
16Z3. Recurrence of problem 499
Z1B.. Dressing of skin or wound 252
N2132 Lateral epicondylitis of the elbow 570
J5730 Rectal haemorrhage 516
J521. Irritable colon - Irritable bowel syndrome 787
4131. Blood test requested 1374
73050 Irrigation of external auditory canal for removal
of wax
3217
F301z Trigeminal neuralgia NOS 65
2128. Patient’s condition the same 3380
249
662.. Cardiac disease monitoring 6147
K3110 Gynaecomastia 40
SP255 Postoperative wound infection, unspecified 244
M161z Psoriasis NOS 265
1C14. Blocked ear 523
1AA.. Prostatism 298
N145. Backache, unspecified 682
6896. Depression screening using questions 5625
6A2.. Coronary heart disease annual review 758
K20.. Benign prostatic hypertrophy 390
N094. Pain in joint - arthralgia 764
R0902 [D]Colic NOS 37
M01.. Furuncle - boil 244
C34.. Gout 741
M03z1 Abscess NOS 161
M03z. Cellulitis and abscess NOS 339
N2470 Swelling of limb 362
TJ... Drugs and other substances-adverse effects in
theraputic use
281
N135z Torticollis NOS 78
19FZ. Diarrhoea symptom NOS 250
1A53. Lumbar ache - renal 405
F4Kz1 Eye pain NOS 207
7K36. Diagnostic arthroscopy of knee 129
250
8B21. Drug prescription 309
K271. Balanoposthitis 98
J0854 Angular stomatitis and cheilitis 170
8B314 Medication review 6558
G65.. Transient cerebral ischaemia 325
2G5.. O/E - foot 1275
196.. Type of GIT pain 369
R0081 [D]Excessive sweating 80
36150 Gastroscopy abnormal 22
AB200 Candidiasis of mouth 1042
33C.. Circulatory function tests 274
67E.. Foreign travel advice 1578
32... Electrocardiography 789
4.... Laboratory procedures 521
M180. Pruritus ani 308
F51y0 Eustachian tube dysfunction 388
R021. [D]Rash and other nonspecific skin eruption 364
M2400 Alopecia unspecified 100
246.. O/E - blood pressure reading 1966
J64.. Cholelithiasis 249
16ZZ. General symptom NOS 377
F340. Carpal tunnel syndrome 399
2D... Ear, nose + throat examination 659
41B1. Blood test due 1127
251
7M07z Cryotherapy to organ NOC NOS 184
46... Urine examination 294
R0103 [D]Tremor NOS 201
SE... Contusion (bruise) with intact skin 223
K4211 Vulvitis unspecified 88
1D131 C/O - pain in hallux 70
N2133 Olecranon bursitis 256
E2003 Anxiety with depression 528
212.. Patient examined 1243
N2410 Myalgia unspecified 527
AD30. Scabies 197
1B321 Weakness of leg 44
J573. Haemorrhage of rectum and anus 231
J0250 Dental abscess 322
1M11. Foot pain 349
8H4B. Referred to rheumatologist 239
8H5B. Referred to urologist 430
K28y8 Pain in testis 70
K10y0 Pyelonephritis unspecified 23
N0940 Arthralgia of unspecified site 255
15C.. Vaginal irritation 135
F504. Impacted cerumen (wax in ear) 1240
M05.. Impetigo 452
C2943 Iron deficiency 76
252
ZV700 [V]Routine health checkup 64
8H8.. Follow-up arranged 1847
C3652 Dehydration NEC 28
F52z. Otitis media NOS 1426
8CAK. Patient given telephone advice out of hours 570
R0904 [D]Abdominal cramps 43
893.. Post operative monitoring 130
J10y4 Oesopheal reflux without mention of oesophagi-
tis
1108
535.. Standard chest X-ray 914
1J... Suspected condition 651
Z1B13 Change of dressing 191
ZV411 [V]Other eye problems 204
D00y1 Microcytic hypochromic anaemia 233
F4D0. Blepharitis 499
G3... Ischaemic heart disease 781
8A... Monitoring of patient 199
2127. Patient’s condition worsened 927
N2452 Pain in leg 656
Table D.4: The medical events signalled by the SAP framework with the random
forest classifier for the drug Budesonide. The medical events are ranked by the
confidence returned by the classifier for the medical event belonging to the ADR
class.
253
Naproxen
Read Code Medical Event Frequency
E2B.. Depressive disorder NEC 1677
R090. [D]Abdominal pain 1077
D00.. Iron deficiency anaemias 627
K190z Urinary tract infection, site not specified NOS 1507
1C9.. Sore throat symptom 1707
R021z [D]Rash and other nonspecific skin eruption NOS 1034
1BT.. Depressed mood 858
535.. Standard chest X-ray 402
H06z0 Chest infection NOS 4417
G84.. Haemorrhoids 541
C04.. Acquired hypothyroidism 588
H02.. Acute pharyngitis 640
8H9.. Planned telephone contact 392
D21z. Anaemia unspecified 797
413.. Laboratory test requested 3664
461.. Urine exam. - general 445
892.. Informed consent for procedure 1173
Z4A.. Discussion 2371
H05z. Upper respiratory infection NOS 2634
1A... Genitourinary symptoms 530
81H.. Dressing of wound 2969
M230. Ingrowing nail 372
254
1D14. C/O: a rash 1456
66R.. Repeat prescription monitoring 797
H00.. Acute nasopharyngitis 380
2315. Resp. system examined - NAD 547
H30.. Bronchitis unspecified 514
K190. Urinary tract infection, site not specified 902
M07z. Local infection skin/subcut tissue NOS 574
H060. Acute bronchitis 823
AB2.. Candidiasis 801
E200. Anxiety states 707
173.. Breathlessness 873
66R5. Rep.presc. treatment changed 911
M18z. Pruritus NOS 638
M244. Folliculitis 247
2F13. O/E - dry skin 590
2227. O/E - rash present 337
7L17. Blood withdrawal 4328
H1y1z Nasal cavity and sinus disease NOS 286
1Z... History/symptom NOS 632
1CA2. Hoarse 172
16E.. Feels unwell 411
7G22. Removal of repair material from skin 497
8B4.. Previous treatment continue 2945
662.. Cardiac disease monitoring 5045
255
R0608 [D]Shortness of breath 556
G20.. Essential hypertension 2348
8H76. Refer to dietician 199
G66.. Stroke and cerebrovascular accident unspecified 232
H06z1 Lower resp tract infection 867
SP255 Postoperative wound infection, unspecified 278
1982. Nausea present 232
761Fz Diagnostic fibreoptic endoscopic exam upper GI
tract NOS
146
1B5.. Incoordination symptom 902
8B41. Repeated prescription 1709
J10y4 Oesopheal reflux without mention of oesophagi-
tis
466
7L172 Blood withdrawal for testing 5052
1737. Wheezing 395
1922. Sore mouth 196
8C1.. Nursing care 721
8C17. Nursing care - injections 388
M05.. Impetigo 226
196.. Type of GIT pain 184
F4D0. Blepharitis 318
19EA. Change in bowel habit 234
E2273 Impotence 628
M180. Pruritus ani 243
256
1739. Shortness of breath 571
22L.. O/E - wound healing 147
2516. Abdomen examined - NAD 326
J1011 Reflux oesophagitis 189
4618. Urine dipstick test 296
AD30. Scabies 106
8B314 Medication review 3576
M2300 Ingrowing great toe nail 166
J520z Constipation NOS 308
ZV681 [V]Issue of repeat prescription 1485
E2001 Panic disorder 231
E2003 Anxiety with depression 440
N2133 Olecranon bursitis 361
7L18. Intramuscular injection 1066
M12z1 Eczema NOS 764
Z174N Wound care 63
8C15. Nursing care - dressing 539
M0... Skin and subcutaneous tissue infections 488
F4Kz1 Eye pain NOS 160
G3111 Unstable angina 24
R060A [D]Dyspnoea 233
M2yz. Other skin and subcutaneous tissue disease NOS 645
6A... Patient reviewed 21724
D00y1 Microcytic hypochromic anaemia 197
257
8B3R. Drug therapy discontinued 534
36140 Gastroscopy normal 21
1J4.. Suspected UTI 702
K28y6 Epididymal cyst 75
23... Examn. of respiratory system 272
7G2E3 Dressing of skin NEC 263
8BI.. Other medication review 301
1972. Epigastric pain 800
4.... Laboratory procedures 342
R0701 [D]Vomiting 38
41D0. Blood sample taken 3007
7C242 Standard circumcision 33
8CA.. Patient given advice 2562
4142. Blood sample -¿ Haematol Lab 426
1Y... Patient feels well 765
E112. Single major depressive episode 107
ZV583 [V]Attention to surgical dressings or sutures 149
G5y34 Ventricular hypertrophy 19
73050 Irrigation of external auditory canal for removal
of wax
2577
7L064 Amputation below knee 4
J3030 Unilateral inguinal hernia - simple 56
G30.. Acute myocardial infarction 162
J5747 Anal pain 65
258
R0700 [D]Nausea 35
K2414 Acute epididymitis 54
8H5B. Referred to urologist 319
677B. Advice about treatment given 1684
Eu431 [X]Post - traumatic stress disorder 31
7P051 Ultrasound of abdomen 31
2126. Patient’s condition improved 6857
8CAL. Smoking cessation advice 1621
ZZZZZ Converted code 4290
7G2A9 Subcutaneous injection of hormone antagonist 87
G581. Left ventricular failure 230
M15y1 Intertrigo 441
7H220 Exploratory laparotomy 35
8B311 Medication given 2296
J66y6 Obstructive jaundice NOS 13
8H21. Admit medical emergency unsp. 115
F587. Otalgia 510
44121 Urea and electrolytes abnormal 48
R090F [D]Acute abdomen 12
8B42. Previous treatment repeat 1333
8B24. Prescription given no examination of patient 293
1B8Z. Eye symptom NOS 274
7701z Other excision of appendix NOS 26
SK160 Other hip injuries 31
259
M111. Atopic dermatitis/eczema 444
ZL233 Under care of district nurse 20
2841. Confused 203
7G2E. Dressing of skin or wound 324
R062. [D]Cough 284
G3... Ischaemic heart disease 641
AB0.. Dermatophytosis including tinea or ringworm 421
Z1779 Outpatient care 30
M161z Psoriasis NOS 244
32... Electrocardiography 579
R047. [D]Epistaxis 226
M271. Non-pressure ulcer lower limb 980
4131. Blood test requested 969
R0822 [D]Acute retention of urine 13
G65.. Transient cerebral ischaemia 282
79360 Implantation of intravenous cardiac pacemaker
system
15
8H7R. Refer to chiropodist 260
1968. Abdominal discomfort 185
ZV680 [V]Issue of medical certificate 1629
R0905 [D]Epigastric pain 52
E2900 Grief reaction 65
22C2. O/E - oedema of ankles 434
2G5.. O/E - foot 920
260
1B321 Weakness of leg 33
M270. Decubitus (pressure) ulcer 161
7L185 Intramuscular injection of vitamin B12 686
R0733 [D]Abdominal distension, gaseous 19
Z1B13 Change of dressing 166
173B. Nocturnal cough / wheeze 94
7NB13 [SO]Lower leg NEC 98
7G2EA Two layer compression bandage for skin ulcer 14
R021. [D]Rash and other nonspecific skin eruption 172
M0z.. Skin and subcut tissue infection NOS 149
7G251 Drainage of lesion of skin NEC 58
G3071 Acute non-ST segment elevation myocardial in-
farction
27
8BAA. Pain relief 1332
F4504 Ocular hypertension 147
22Q.. Wound observation 164
7B2A. Diagnostic cystoscopy 293
A3Ay2 Clostridium difficile infection 17
K3110 Gynaecomastia 30
8C1L. Wound care 190
2128. Patient’s condition the same 3954
7G2E1 Dressing of burnt skin NEC 44
H03.. Acute tonsillitis 544
8HB2. Medical follow-up 851
261
J50zz Intestinal obstruction NOS 46
7L1H0 Direct current cardioversion 10
7L123 Myocardial perfusion scan 13
J5031 Faecal impaction 16
N2243 Ganglion unspecified 74
8HQ1. Refer for X-Ray 2396
7G033 Excision of lesion of skin NEC 146
Eu32z [X]Depressive episode, unspecified 488
N094M Arthralgia of knee 322
81HZ. Wound dressing NOS 497
M1610 Psoriasis unspecified 416
7B2Az Diagnostic cystoscopy NOS 115
F4E51 Xanthelasma 28
ZGB66 Advice to stop drug treatment 35
A0745 Helicobacter pylori gastrointestinal tract infec-
tion
10
7G2B1 Injection of therapeutic substance into skin 17
K10y0 Pyelonephritis unspecified 14
G831. Varicose veins of the leg with eczema 315
1.... History / symptoms 695
761F1 Diagnostic gastroscopy NEC 74
44120 Urea and electrolytes normal 68
7G223 Removal of suture from skin NEC 363
262
782Gz Diagnostic endosc retrograde exam
bile+pancreatic ducts NOS
15
77352 Injection of sclerosing substance into haemor-
rhoid
29
8B35. Drug Rx stopped-medical advice 529
M07z1 Infection toe 95
F5611 Benign paroxysmal positional vertigo or nystag-
mus
232
8CA40 Pt advised re wt reducing diet 171
SK150 Other finger injuries, unspecified 89
Ryu8A [X]Hyperglycaemia, unspecified 7
Eu411 [X]Generalized anxiety disorder 15
C3540 Hypocalcaemia NEC 16
R0102 [D]Spasms NOS 14
F4005 Eye infection 11
1C14. Blocked ear 325
R082. [D]Retention of urine 103
R0400 [D]Facial pain 141
R1100 [D]Albuminuria 14
G2... Hypertensive disease 1284
F4200 Background diabetic retinopathy 78
C11y3 Impaired fasting glycaemia 96
C2621 Vitamin B12 deficiency 103
G57y7 Sinus tachycardia 12
263
8C9.. Reassurance given 291
761Fy Diagnostic fibreoptic endoscopic exam upper GI
tract OS
15
R0043 [D]Vertigo NOS 534
Z4G1B Giving encouragement to continue treatment 23
7M05z Laser therapy to organ NOC NOS 11
8B3A1 Medication increased 956
Z1K13 Removal of suture from skin 22
ZV57C [V]Palliative care 84
SD... Superficial injury 202
TE640 Insect bite NOS 130
246.. O/E - blood pressure reading 2878
M0212 Paronychia of toe 62
8BAB. Pain control 461
78105 Endoscopic cholecystectomy 63
42QE0 INR - international normal ratio normal 3
7M371 Radiotherapy NEC 145
SN52. Drug hypersensitivity NOS 78
19FZ. Diarrhoea symptom NOS 140
2D82. O/E - wax in auditory canal 472
K253. Phimosis 37
G73z0 Intermittent claudication 209
4K1.. Histology 149
8A... Monitoring of patient 91
264
1AG.. Recurrent urinary tract infections 107
2127. Patient’s condition worsened 861
R090z [D]Abdominal pain NOS 39
ZL146 Under care of deputising GP 34
R0904 [D]Abdominal cramps 27
68... Screening 1200
N2470 Swelling of limb 342
ZV49z [V]Unspecified limb or other problem 1085
ZV654 [V]Other counselling NEC 93
M03z0 Cellulitis NOS 828
7B2B5 Insertion of urethral catheter 4
R1431 [D]Electrocardiogram (ECG) abnormal 12
K20.. Benign prostatic hypertrophy 390
31340 Audiogram bilateral abnormality 7
1B13. Anxiousness 582
1C8.. Nasal symptoms OS 166
77282 Examination of rectum under anaesthetic 11
R0901 [D]Abdominal colic 79
72550 Trabeculectomy 29
F563. Labyrinthitis 193
TJ... Drugs and other substances-adverse effects in
theraputic use
422
H33zz Asthma NOS 26
R0720 [D]Difficulty in swallowing 63
265
6791. Health ed. - smoking 2170
M2y45 Epidermal cyst 35
F501. Infective otitis externa 600
7NB16 [SO]Toe NEC 20
NyuBC [X]Osteopenia 132
G5730 Atrial fibrillation 283
G580. Congestive heart failure 368
7M0G1 Aspiration of other lesion of organ NOC 20
Z1745 Ear care 19
M01.. Furuncle - boil 225
679.. Health education - subject 188
F4Ey4 Cyst of eyelid NOS 20
7717z Other excision of colon NOS 8
Z174O Post-surgical wound care 16
N0810 Loose body in joint, unspecified joint 19
K272z Other penile inflammatory disorder NOS 5
M1271 Sunburn 39
8HB20 Medical follow-up - normal 69
G20z. Essential hypertension NOS 201
ZV6D5 [V]Person consulting for explanatn of investiga-
tion findings
149
7G2AC Insertion of gonadorelin analogue implant 21
G5731 Atrial flutter 20
7M340 Local anaesthetic nerve block 36
266
R012z [D]Gait abnormality NOS 26
AB200 Candidiasis of mouth 181
R1103 [D]Microalbuminuria 41
8BA.. Other misc. therapy 174
7920y Saphenous vein graft replacement of coronary
artery OS
7
Table D.5: The medical events signalled by the SAP framework with the random
forest classifier for the drug Naproxen. The medical events are ranked by the
confidence returned by the classifier for the medical event belonging to the ADR
class.
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